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Frontispiece
Electron m icrograph of an insect cell infected with wild type Autographa 
californica multiple nuclear polyhedrosis virus .
fj
The black arrows indicate viral particles containing multiple nucleocapsids. The 
particles are of two types: occluded particles are encased in polyhedral crystals - 
made of the protein polyhedrin; non-occluded particles are free in the cytoplasm. 
The fibrillar material (white arrow) is believed to be accumulations of the viral plO 
protein.
The baculovirus expression sytem is based upon the replacement of the viral gene 
encoding for the polyhedrin protein with a foreign gene of interest.
Photograph kindly supplied by Dr Helen Laird, Electron Microscopy Unit, 
Department of Veterinary Pathology, University of Glasgow.
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Summary
Feline leukaemia virus (FeLV) is a major cause of degenerative and proliferative 
diseases of myeloid, lymphoid and erythroid origin in domestic cats. The envelope 
of FeLV, which is a typical retrovirus, is studded with a transmembrane protein 
(TM) that anchors an external surface glycoprotein (SU). The FeLV SU (gp70) 
carries both neutralising epitopes and subgroup phenotypic determinants. FeLV 
occurs naturally in 3 subgroups, which are defined by a superinfection interference 
assay, suggesting that three FeLV cellular receptors exist, one for each subgroup. 
The regions of SU which determine the A/C phenotype have been defined as lying 
in a small variable region towards the amino terminus of the protein.
The aims of this project were to produce recombinant SU's from FeLV subgroups A 
and C (and two A/C chimeras) and to use them in studies of virus/host interactions. 
The first interaction that was investigated was that which occurs between FeLV and 
naturally occuring neutralising antibodies. The second interaction that was 
examined was that which occurs between FeLV and the surface of the host cell. A 
subsidiary aim was to use the FeLV-A recombinant SU in vaccine studies.
Recombinant baculovirus vectors containing the coding sequences of the entire 
FeLV SU together with N terminal components of TM from FeLV-A/Glasgow 1 
and FeLV-C/Sarma were constructed. The vectors were co-transfected with 
baculovirus DNA into insect cells and the resulting recombinant baculoviruses were 
plaque purified. The recombinant baculoviruses were used to produce 
glycoproteins, called Bgp70-A and Bgp70-C respectively, which were concentrated 
by ultrafiltration. The proteins were further concentrated and partially purified by 
lentil lectin affinity chromatography. Two chimeric FeLV-A/C recombinant 
proteins (Bgp70-215 and Bgp70-VC) were also produced using the baculovirus 
expression system. The coding sequences used to produce these proteins were 
derived from chimeric FeLVs that are classified in superinfection interference 
assays as belonging to subgroup C. The recombinant viruses were demonstrated to 
contain the correct coding sequences for the subgroup determining region by a 
mixture of PCR and restriction enzyme digest analysis.
Several investigations were performed into the biological properties of the proteins. 
All the Bgp70's have an approximate relative molecular mass of 80 kDa. The 
proteins are aberrantly glycosylated and are not cleaved. In accordance with the 
recently published findings of other workers, only small quantities of the proteins 
are produced. An anti-FeLV SU monoclonal antibody bound to the proteins in both 
ELISAs and western blots. Furthermore, a recovered cat serum which had been 
derived from a natural infection with FeLV-A contained antibodies that bound to 
proteins in western blots. However, this serum did not contain antibodies which 
bound to Bgp70-C in ELISAs. Studies with subgroup-specific monoclonal
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antibodies demonstrated that Bgp70-A, -VC and -215 were indistinguishable. In 
similar ELISAs both a monoclonal antibody and a recovered cat serum, which were 
specific for FeLV-C/Sarma, only bound to Bgp70-C.
On the basis of these results, the ability of the recombinant proteins to block the 
action of neutralising antibodies was examined. It was demonstrated that Bgp70-A, 
-VC and -215 interfered with the action of neutralising antibodies from recovered 
cat sera which had been derived from a natural infection with FeLV-A, whereas 
Bgp70-C did not. These results suggest that the major neutralising epitope(s) of 
FeLV lies outside the subgroup determining region.
Infection interference assays were performed to investigate the ability of the 
recombinant proteins to serve as ligands for the FeLV cell surface receptors. It was 
demonstrated that Bgp70-A interfered with infection by FeLV-A of a susceptible 
cell line, whereas Bgp70-C, -VC and -215 did not. Conversely, Bgp70-C, -VC and 
-215 interfered with the infection by FeLV-C/FA27C of a susceptible cell line, but 
Bgp70-A did not. These data suggest that the Bgp70’s may be sufficiently similar to 
the wild type proteins to serve as ligands with which to identify the FeLV cell 
surface receptors. Co-immunoprecipitation studies were performed using surface 
labelled cells. All the proteins bound to several cell surface proteins from both 
permissive and non-permissive cell lines. There were no differences in the spectrum 
of cell proteins precipitated between the subgroups.
The potential use of Bgp70-A as an FeLV vaccine was also examined. The protein 
did not induce detectable prechallenge gp70 antibodies in any of the five 
vaccinates. This was possibly due to the small quantities used. One of the 
vaccinates showed a delayed onset of viraemia when given a severe challenge and 
another vaccinate never became viraemic. In another group, which contained cats 
vaccinated with a commercial vaccine (Leucogen, Virbac), four out of five cats 
rapidly became persistently viraemic. The fifth cat became p27 antigenaemic, but 
never became viraemic. In contrast, all of the unvaccinated controls rapidly became 
viraemic. One of the controls subsequently recovered from the infection. This result 
suggests that neither vaccine protected the cats against the challenge.
The experiments described in this thesis demonstrate that recombinant surface 
glycoproteins of FeLV produced in the baculovirus expression system can be used 
to study initial virus/host interactions. It is suggested that the ease with which these 
proteins can be produced, and their isolated coding sequences manipulated, 
represent a significant improvement on previously reported methods.
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Chapter 1. Introduction
This thesis describes studies on feline leukaemia virus (FeLV) and, in particular, on 
FeLV recombinant surface glycoproteins produced in a baculovirus expression 
system. The aim of the project was to produce the recombinant glycoproteins and to 
assess their functional properties in a variety of systems. In particular, the ability of 
the proteins to act as ligands for virus neutralising antibodies and FeLV cell surface 
receptors was investigated. A subsidiary aim of the project was to use one of the 
recombinant glycoproteins in vaccine studies.
FeLV surface glycoproteins are the target of virus neutralising antibodies and the 
site of the initial virus / host cell interaction (Jarrett et al, 1972; Sarma and Log, 
1973; Russell and Jarrett, 1978a; Salerno et al, 1978; Lutz et al, 1980). This 
chapter contains an introduction to FeLV biology, followed by an overview of 
recent advances in the analysis of initial virus / host cell interactions. Finally, a 
description of basic baculoviral biology is presented to facilitate the understanding 
of the baculovirus expression system.
1.1 Feline Retroviruses
Cats are afflicted with a number of retroviruses, of which two are of considerable 
importance to clinical veterinary science: FeLV and feline immunodeficiency virus 
(FTV). Three other feline retroviruses are also known; RD-114 virus, feline 
syncytium forming virus and endogenous feline leukaemia virus.
1.1.1 Feline Leukaemia Virus
FeLV was discovered in a multi-cat household in Glasgow in which a cluster of 
lymphomas had occurred (Jarrett et al, 1964a; Jarrett et al, 1964b). The authors of 
these papers demonstrated that the virus caused disease in experimentally infected 
cats and, in appearance, resembled murine leukaemia viruses (MuLVs) which were 
later classified as retroviruses. This breakthrough established that retroviruses, 
which many researchers had previously believed only caused disease in certain 
inbred strains of mice and fowl, were pathogenic in outbred mammalian 
populations. Later it was demonstrated that the virus was horizontally transmitted 
(Hardy et al, 1973), caused non-neoplastic disease (Anderson et al, 1971; 
Anderson and Jarrett, 1971) and the virus-transformed cells were the targets of 
immune surveillance (Essex et al, 1975). These findings caused a resurgence of 
interest in the study of retroviral biology in outbred populations and ultimately 
paved the way for the identification of the human retroviruses.
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1.1.2 Feline Immunodeficiency Virus
FIV was discovered in 1986 in a multi-cat household with a cluster of unusual 
infections in California (Pedersen et al., 1987). It has since been shown to be a 
lentivirus with a worldwide distribution, associated with a variety of chronic 
infections and T cell depletion (Pedersen et al., 1989; Torten et al., 1991). It is an 
important model for human immunodeficiency virus (HIV) infection (Neil, 1990; 
Jarrett et al., 1991). There is thought to be no epidemiological association between 
FIV and FeLV infection (Hosie et al., 1989). Cats which are already infected with 
FeLV do, however, show more signs during the initial viraemic phase of 
experimental FIV infection (Pedersen et al., 1990). Several reviews of clinical 
aspects of FIV infection and the molecular biology of FIV have been published 
(Hosie et al., 1989; Sparger et al, 1989).
1.1.3 Other Feline Retroviruses
(1)RD 114
RD-114 is an endogenous feline retrovirus which is related to the baboon 
endogenous virus (Livingston and Todaro, 1973; Sen et al., 1978). RD-114 was 
initially identified in human tumour cells which had been injected into a foetal cat 
and was originally thought to be of human origin (McAllister et al., 1972). The 
virus is described as xenotropic as it can replicate in the cell lines of several 
heterologous species, but only in a few feline cell lines (Livingston and Todaro, 
1973). It has recently been suggested that the host range restriction of RD-114 is 
determined by altered cellular receptors and aberrant glycosylation of the env gene 
product in non-permissive cell lines (Dunn et al, 1993).
(2) Feline syncytium forming virus
Feline syncytium forming virus (FeSFV) is a member of the genus of retroviruses 
called spumaviruses (Riggs et al, 1969). FeSFV is widespread amongst cats but is 
thought to be non-pathogenic (Jarrett et al., 1974). It acts as an important 
contaminant in some retroviral assays.
(3) Endogenous feline leukaemia virus
Endogenous feline leukaemia viruses (enFeLVs) were first identified as FeLV- 
related DNA sequences in cells from an FeLV-free cat colony (Okabe et al, 1976). 
They are a group (7-20) of defective, mostly full length, FeLV-like proviruses 
contained within the feline cell. A number of enFeLV sequences have been 
molecularly cloned (Soe et al, 1983; Soe et al., 1985). They differ from FeLV 
principally in the U3 region and in a portion of the env gene (Stewart et al., 1986).
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They are thought to represent an historical record of defective FeLV infection of 
germ line cells. They are inherited in a Mendelian fashion.
1.2 Feline Leukaemia Virus
1.2.1 Virology
(1) Classification
FeLV is a member of the family Retroviridae, which are RNA-containing 
enveloped viruses. The taxonomic features of the Retroviridae are given in Table 
1.1, which was derived from comprehensive reviews of the subject (Teich, 1985; 
Coffin, 1992). FeLV was formerly classified as an oncovirus (Teich, 1985), but is 
now regarded as being a member of the mammalian type C retrovirus group 
(Coffin, 1992). FeLV is believed to have originated several millions of years ago 
from an ancestral rodent retrovirus (Benveniste et al., 1975).
(2) Viral Structure
FeLV contains two copies of a single stranded, RNA genome, which is 
approximately 8000 base pairs (bp) long. The genome encodes 3 polyproteins 
which undergo post-translational modification by endogenous proteolysis. The 
nucleic acid, with its associated reverse transcriptase (RT) and integrase (IN) 
enzymes, is contained in a protein core. The protein core is formed by 4 proteins; 
matrix protein (MA), capsid protein (CA), nucleocapsid protein (NC) and a fourth 
protein, pl2, which is of unknown function. This core is surrounded by a lipid 
based envelope studded with a transmembrane viral-encoded protein (TM) to which 
is attached by disulphide bridges the external surface glycoprotein (SU) (Pinter and 
Fleissner, 1979). TM and SU are also referred to as pl5(E) and gp70 respectively.
(a) Replication of FeLV
The replication cycle of FeLV has not been studied in detail, but it is generally 
assumed to follow the same sequence as other retroviruses. On entering each cell 
the viral RNA is uncoated and reverse transcribed to form a single stranded DNA 
molecule, which is then converted into a double stranded form, the provirus 
(Varmus and Swanstrom, 1985). At each end of the RNA genome are found short 
terminal repeats, called r, which contain unique regions called U3 and U5 
respectively. The short terminal repeats are important for the synthesis of the 
proviral DNA. During this process the unique sequences of r, U3 and U5, are 
duplicated at both ends, resulting in the formation of the proviral long terminal 
repeats (LTRs) which contain both U3 and U5 (Temin, 1981). The double stranded 
DNA provirus migrates to the nucleus where a proportion becomes circular
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Table 1.1 Taxonomy of Retroviridae 
a) Taxonomic features
Morphological properties Spherical enveloped virions with surface 
projections and containing an icosahedral 
capsid.
Nucleic Acid Two identical subunits of linear, positive 
sense, single-stranded RNA. Capped at 5’ 
end, polyadenylated at 3f end.
Protein About 60% by weight.
Lipid About 35% by weight. Derived from host 
cell membrane.
Carbohydrate About 4% by weight. Associated with env 
gene products.
Physico-chemical properties Density 1.16-1.18g /ml in sucrose.
Sensitive to lipid solvents, detergents and 
heat inactivation.
Resistant to UV and X irradiation
b) Classification of retroviruses
— Mammalian type B group
RETROVIRUSES -
e.g Mouse m am mary  
tumour virus
e.gALVAvian type C group
-Mammalian type C group
—Mammalian type C group e.g FeLV, MuLV
—Reptilian type C group 
—Reticuloendotheliosis group
c.g Viper retrovirus
-HTLV-BLV group 
Type D group
Lentiviruses 
■ Spumaviruses
e.g reticuloendotheliosis 
virus
e.g HTLV-1
e.g Mason-Pfizer 
monkey virus
e.g FIV, HIV 
e.g FeSFV
(Panganiban, 1985). The integrase protein (IN), which may possess an 
endonuclease activity to cut the circular forms, removes 2 bases from the 3'- 
hydroxyl termini and mediates the integration of the nicked linear precursor into the 
host cell genome (Grandgenett and Mumm, 1990). Following integration the 
provirus is transcribed into positive sense RNA which is then translated or 
incorporated into budding virions. A spliced messenger RNA is also produced 
which encodes for the envelope proteins (Papenhausen and Overbaugh, 1992).
The transcriptional products of the provirus and structure of the mature virion are 
diagrammatically represented in Figure 1.1 which was adapted from published 
reviews (Hardy, 1980b; Dickson et al. 1985).
(3) Natural Infection
FeLV is transmitted in saliva by the oronasal route, presumably by mutual 
grooming between cats (Hardy et al., 1973). After the virus has entered the host, it 
replicates first in the lymphocytes of the tonsils and pharyngeal lymph nodes, 
which then spread the infection to the systemic lymphoid tissues, including the 
bone marrow. During these early stages gut-associated lymphoid tissue is also 
infected (Rojko et al., 1979b).
At this stage the cat may eliminate the infection, perhaps due to the production of 
low titres of virus neutralising antibodies or by other mechanisms not yet elucidated 
(see below). Alternatively, due to the large numbers of bone marrow cells that are 
infected the virus may disseminate widely throughout the body. Virus can be found 
in the plasma or in infected neutrophils and platelets (Rojko et al., 1979b). The 
appearance of such infected cells in the blood is considered to be the hallmark of 
persistent viraemia.
As a third alternative, the cat may contain the infection within the bone marrow in a 
latent state for a variable period of time. Occasionally such latently infected cats 
may revert to the viraemic state, particularly when given immunosuppressive doses 
of steroids (Rojko et al., 1982), or enduring physiological stresses such as lactation 
(Pacitti et al, 1986). In most cats, however, the latent infection appears to be 
eventually eliminated (Pacitti, 1987).
(4) Subgroups o f FeLV
Three subgroups of FeLV (A, B and C) have been defined on the basis of 
interference with superinfection (Sarma and Log, 1973). These authors 
demonstrated that cells infected with one isolate of FeLV could not be 
superinfected with isolates of the same subgroup. Subsequently, subgroup-specific
18
Figure 1.1 The products and basic structure of the FeLV provirus
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differences in the host range in vitro were demonstrated (Jarrett et al., 1973; Sarnia 
et al, 1975). The existence of three FeLV subgroups with different host ranges has 
traditionally been taken as evidence of the presence of three cellular receptors, one 
for each subgroup (Sarma and Log, 1973; Jarrett, 1984; Riedel et al, 1986; 
Donahue et al, 1988; Rigby et al, 1992). Recently however, some doubt has been 
cast on this assumption (Reinhart et al, 1993).
The evidence for three subgroups was originally augmented by neutralisation data 
(Sarma and Log, 1973). Subsequently, others (Russell and Jarrett, 1978b) found 
that a degree of cross-neutralisation occurred between the subgroups.
FeLV subgroup A (FeLV-A) is found in all cases of FeLV infection (Jarrett et al, 
1978). It is antigenically monotypic (Russell and Jarrett, 1978b) and is believed to 
be responsible for inter-host transmission. FeLV-A infects only feline cells (Jarrett 
et al, 1973; Sarma et al, 1975). A high degree of sequence conservation has been 
observed between several isolates of FeLV-A that were originally isolated in 
different countries and several years apart (Donahue et al, 1988). This study 
suggested that stringent selection against antigenic changes is occurring at the level 
of inter-host transmission.
FeLV-B is found in approximately 33% of FeLV positive cats that are otherwise 
healthy: this proportion rises to about 58% when viraemic cats with lymphoma are 
examined (Jarrett et al, 1978). This result suggested that FeLV-B may be 
associated with an increased risk of developing neoplastic disease. FeLV-B 
replicates in wide range of cell lines derived from heterologous species, including 
human cells (Jarrett et al, 1973), but not guinea pig cells (Sarma et al, 1975). 
Available sequence data and experimental evidence suggests that FeLV-B arises by 
recombination with enFeLV (Nunberg et al, 1984b; Stewart et al, 1986; 
Overbaugh et al, 1988b; Neil et al, 1991). The minimal requirement of enFeLV 
sequences required to transform FeLV-A into FeLV-B has not been determined. It 
has been demonstrated that the in vitro properties of FeLV can be altered by 
recombination with enFeLV and that the enFeLVs which encode a full length env 
gene can provide most of the envelope sequences necessary for a replication 
competent provirus (Pandey et al, 1991). From these studies it is also clear that 
FeLV-B may continuously evolve in vivo by means of novel mutations and 
recombinations.
FeLV-C isolates are rare; only 2% of all FeLV isolations contain this subgroup 
(Jarrett et al, 1978). FeLV-C occurs in association with FeLV-A or FeLV-A and 
FeLV-B (Jarrett et al, 1978). FeLV-C isolates are uniquely associated with the 
development of pure red cell aplasia (Hoover et al, 1974; Mackey et al, 1975;
19
Onions et al., 1982). FeLV-C replicates in several cell lines derived from 
heterologous species, including guinea pig cells (Sarma et al., 1975). Several 
isolates of FeLV-C are indistinguishable from FeLV-A in neutralisation assays 
(Russell and Jarrett, 1978b). The prototypic isolate, FeLV-C/Sarma, can be 
distinguished from FeLV-A. FeLV-C is thought to arise by mutation from FeLV-A 
(Neil et al., 1991), though FeLV-C/Sarma probably contains additional sequences 
derived from enFeLV. Subsequently Rigby (1989) sequenced the env gene of 
several other FeLV-C isolates and demonstrated by site directed mutagenesis that 
the determinants of the superinfection interference phenotype of FeLV-C were 
located within the VR 1 region (Neil et al., 1991). These results have subsequently 
been confirmed by others (Brojatsch et al, 1992). The sequences of VR 1 from 
various FeLV isolates, including two site-directed mutants (Rigby, 1989), are 
illustrated in Figure 1.2. The disease-causing and infectivity phenotypes are, 
however, not completely associated with this small region (Rigby et al., 1992). 
Other sequence differences, possibly near VR 5, may play a role in the generation 
of these phenotypes (Rigby et al., 1992). This possibility has still to be fully 
investigated.
1.2.2 Clinical Aspects
(1) Clinical Disease
The diseases caused by, or associated with, FeLV have been extensively reviewed 
elsewhere (Jarrett, 1985; Hardy, 1980a; Mackey, 1975). The range of clinical 
conditions associated with FeLV is shown in Table 1.2.
Some clinical conditions have been associated with particular isolates of FeLV, for 
example, myeloid leukaemia and FeLV-GM-1 (Testa et al., 1988). Often, these 
isolates are replication defective (Tzavaras et al., 1990). Only one disease, pure red 
cell aplasia, is associated with a particular subgroup of FeLV, subgroup C.
(a) FeLV induced immunodeficiency
Many oncogenic retroviruses are associated with an initial immune dysfunction 
shortly after infection. Immunodeficiency may persist for the remainder of the cat’s 
life. Impairment of the correct functioning of the feline immune system is thought 
to be involved in the pathogenesis of many FeLV associated diseases. 
Immunodeficiency is one of the leading causes of morbidity and mortality in 
persistently viraemic cats (Jarrett, 1985).
Immunodeficiency may be due to non-specific viral induced factors such as tumour 
development or the immunosuppressive properties of certain viral proteins. It has
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Figure 1.2 Sequence of various FeLV isolates around VR 1 region
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The figure shows the predicted amino acid sequences of various isolates of 
FeLV around the subgroup-determining region, VR 1. The numbering 
corresponds to the predicted amino acid residues of the envelope polyprotein 
precursor of FeLV-A/Glasgow 1 (Stewart et al., 1986). The dots indicate 
sequence homology: the dashes indicate spaces introduced to conserve 
alignment. The sequences of the two FeLV-A/C chimeras, FeLV-A/C-Sarma and 
FeLV-A/C-215, used in this project are also shown. The VR 1 and VR 2 regions 
are indicated and are derived from Neil et a l , (1991).
The sequences in this diagram were derived from the following sources; 
FeLV-A/Glasgow-1 (Stewart et al., 1986); FeLV-C/Sarma (Reidel et al, 1986); 
FeLV-B/Gardner-Arnstein (Elder and Mullins, 1983); FeLV-B/Snyder-Theilen 
(Nunberg et al., 1984b); FeLV-C/FA27, FeLV-C/FZ215, FeLV-C/FS246, 
FeLV-A/C-Sarma and FeLV-A/C-215 (Rigby, 1989; Rigby et al, 1992).
Table 1.2 The diseases associated with FeLV infection
Malignant haemopoietic diseases 
Lymphomas
alimentary
multicentric
thymic
lymphatic leukaemia
30% FeLV positive 
60% FeLV positive 
80% FeLV postive 
60% FeLV positive
Leukaemia
Many types including >90% FeLV positive
myeloid leukaemia 
erythroleukaemia 
reticuloendotheliosis
Non-malignant haemopoietic disease 
Anaemia
Haemopoietic aplasias - erythroid or myeloid
Immunosuppression
Medullary osteosclerosis
Myelofibrosis
Others
Glomerulonephritis
Infertility
Neurological Disorders
General malaise, diarrhoea, weight loss etc.
This last category includes a range of disorders found in FeLV infected cats but 
often the causal link has been only circumstantial.
(Derived from Hardy, 1980a; Jarrett, 1984; Jarrett, 1985)
been shown that FeLV TM is immunosuppressive in vitro affecting both 
granulocyte and lymphocyte lineages (Mathes et al, 1978; Lafrado et al., 1987). 
The relevance of these studies in vivo has not been determined.
The generation of proximal pathogens may also be responsible for 
immunodeficiency. A variant replication-defective form of FeLV-A, FeLV-61C, 
has been isolated which causes a fatal immunodeficiency disease in cats (Mullins et 
al, 1986). This isolate is also cytopathic for the feline T cell line, 3201B 
(Overbaugh et al., 1992). FeLV-61C has also been termed FeLV-FAIDS, which has 
caused a degree of confusion since the discovery of FIV and its associated disease 
complex. The helper virus isolate (FeLV-61E) that was obtained from the same cat, 
is also of the subgroup A phenotype.
No other groups have isolated viruses similar to FeLV-61C, which suggests that the 
generation of such viruses may be an uncommon event. Inoculation of 61E does not 
induce immunodeficiency suggesting that immunodeficiency variants do not 
commonly arise from this isolate in vivo (Overbaugh et al., 1988a; Donahue et al., 
1991; Overbaugh et al, 1992).
The mechanism by which FeLV-61C causes immunodeficiency and T cell 
cytopathicity has been extensively investigated. Molecular cloning and subsequent 
sequencing of the 61C isolate revealed differences in the env gene chiefly in the VR 
1 and VR 5 regions. Using a large number of recombinants of 61C and its subgroup 
A helper virus (FeLV-61E), the regions of the envelope gene responsible for T cell 
killing and immunodeficiency have been identified (Donahue et al, 1991). 
Replacement of the gag and pol genes of 61C with those of 61E produces a 
recombinant virus which retains the cytopathic properties of 61C, but is replication 
competent (FeLV-EECC). The nature of the immunodeficiency induced by the 
virus has been shown to be initially due to lymphocyte subset alterations, 
specifically in the CD4+ lineage (Quackenbush et al, 1990). The mechanism by 
which these sequences exert their effects has been suggested to be a failure to 
develop superinfection interference, which results in the accumulation of 
unintegrated viral DNA within the cells (Mullins et al, 1986; Reinhart et al., 
1993). This may lead to the accumulation of envelope proteins within the cell. It is 
known that differences in the envelope protein of 61C result in delayed processing 
and retention of the envelope proteins within the cell (Poss et al, 1989; Poss et al., 
1990). The viral determinants of the failure to establish superinfection interference 
appear to localise to the same regions as those responsible for T cell killing and 
immunodeficiency (Reinhart et al, 1993).
It has recently been shown that subtle differences in the ecotropic murine leukaemia
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virus (E-MuLV) receptor protein, the principal mammalian basic amino acid 
transporter (Albritton et al., 1989; Kim et al, 1991; Wang et al., 1991), can 
effectively block the entry of one strain of E-MuLV into a murine fibroblast cell 
line (Eiden et al., 1993). This result suggests that retroviruses in the same receptor 
group interact in different ways with that receptor and therefore can exhibit 
differences in host range. This result would also suggest that the failure of FeLV- 
61E to establish superinfection interference against the replication competent 
FeLV-61E/61C chimera (FeLV-EECC) (Reinhart et al., 1993) could be due to a 
failure of interference at the level of the VCR/VAS interaction, despite utilisation 
of a common receptor. This is in contrast to the postulated existence of a 
secondary, virus-specific, receptor (Reinhart et al., 1993).
(b) FeLV induced oncogenesis
FeLV may cause neoplastic development by a variety of distinct mechanisms 
including transduction of the myc oncogene, integration of FeLV into the myc gene 
(Neil et al, 1984) and the generation of oncogene-containing feline sarcoma 
viruses (FeSVs) (Snyder and Theilen, 1969). A comprehensive review of this field 
has been published recently (Rezanka et al, 1992).
(c) FeLV induced pure red cell aplasia
Pure red cell aplasia (PRCA) is one of the most acute, degenerative retrovirus 
induced diseases known (Hoover et al, 1974). Newborn kittens infected 
experimentally with biologically or molecularly cloned isolates of FeLV-C rapidly 
become anaemic and die (Onions et al., 1982; Riedel et al, 1986). However, if 8 
week old kittens are infected experimentally with FeLV-C they do not become 
viraemic or develop disease. In contrast control animals of a similar age are 
susceptible to FeLV-A (Jarrett et al, 1984). This age-related restriction can be by­
passed by inoculation of the virus into the bone marrow (Dornsife et al, 1989) or 
using FeLV-A as a helper virus (Jarrett et al, 1984).
From experiments involving in vitro bone marrow cultivation, the anaemia has been 
demonstrated to be due to a failure in the maturation of erythroid progenitors (Testa 
et al, 1983; Abkowitz et al, 1987a). The myeloid compartment of the bone 
marrow is unaffected until the terminal stages of the disease. The exact role of 
FeLV-C in the development of PRCA is not clear. It is not due to the clonal 
expansion of a transformed myeloid cell (Abkowitz et al, 1985) and lacks a 
defined immunological component (McAllister et al, 1972). The early progenitors 
do become more sensitive to heterologous complement, but these changes are not 
seen with cat serum (Abkowitz et al, 1987b). It has been demonstrated that FeLV- 
C, like FeLV-A, replicates in a wide range of haematopoietic cells (Dean et al.,
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1992). These authors failed to demonstrate any significant difference.in the number 
of cells infected by each subgroup. However, early erythroid progenitors are rare 
and so the analysis of whole bone marrow in this fashion may be insufficiently 
sensitive. It has been suggested that PRCA is a model for aplastic anaemia in 
humans (Sen et al., 1978; Riedel et al., 1986). However, although the pathological 
findings are similar, the latter condition is a pan-cell aplasia with a well defined 
immunological basis.
(2) Immunity to FeLV
Innate immunity plays an important role in the epidemiology of FeLV infections. A 
gradual decline in the susceptibility of cats to FeLV infection is seen with 
increasing age (Hoover et al, 1976). If newborn kittens are experimentally infected 
with FeLV then they all become persistently viraemic. If the experiment is repeated 
with 8 week old cats then approximately 85% become persistently viraemic. Cats of 
16 weeks of age are less susceptible to FeLV: about 15% become persistently 
viraemic when experimentally challenged (Hoover et al, 1976). Others (Jarrett et 
al, 1982) have found a similar age-related restriction, though the exact results 
differ from those given above. The marked age-related susceptibility to the 
development of persistent viraemia probably explains why most FeLV viraemic 
cats are under 6 years old (Hosie et al, 1989). In experimental infections, 
immunosuppressive therapy with prednisolone at 10 mg/kg abrogates this age 
related resistance (Rojko et al, 1979a).
Passive immunity, derived from maternal antibodies to FeLV, is known to exist 
(Hoover et al, 1977; Jarrett et al., 1977). Resistance to infection can also be 
experimentally induced by the transfer of hyperimmune neutralising goat anti-FeLV 
serum up to 6 days after challenge with the virus (deNoronha et al, 1978). These 
results suggested that the presence of neutralising antibodies alone were sufficient 
to confer resistance to the development of persistent viraemia.
Virus neutralising antibodies have been demonstrated in the sera of recovered cats 
and have been presumed to be the major method by which cats resist subsequent 
challenges (Sarma et al, 1974; Schaller and Olsen, 1975; Russell and Jarrett, 
1978a). In the absence of experimental challenge, they are the best marker for the 
FeLV-immune cat. Detectable titres do not appear until 6 to 8 weeks post-infection. 
This finding suggests that other, earlier, mechanisms may also play a role in 
preventing the onset of viraemia. These mechanisms may include cytotoxic T cells 
(CTL). As assays for CTL activity in the cat are currently being developed this 
possibility has yet to be investigated fully. A review of the roles of T cells, natural 
killer cells, complement and interferon in the control of FeLV viraemia has been
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published (Rojko and Olsen, 1984).
(3) The Prevention o f FeLV Infection
Approximately 80% of cats that are persistently viraemic with FeLV die within 3 
years of diagnosis (McClelland et al. 1980). In situations where close social contact 
exists between cats, such as closed multiple cat households, FeLV prevalence rates 
of up to 90% are found (Jarrett, 1984). These observations indicate a need for an 
effective method of controlling FeLV in the field. A test and removal scheme 
(Hardy et al., 1976) has been used successfully in many breeding catteries (Weijer 
and Daams, 1978). The continuing success of the scheme is dependent upon the 
isolation of the cats from sources of infection. Where such conditions do not exist, 
vaccination represents the only available method for controlling FeLV.
(4) Vaccination against FeLV
FeLV vaccination should be considered a distinct possibility because many 
naturally exposed cats become immune (Russell and Jarrett, 1978a). Immunization 
with purified envelope glycoprotein is known to be sufficient to induce virus 
neutralising antibodies (Salerno et al., 1978). By analogy with Friend murine 
leukaemia virus it is likely that only very small quantities of pure, non-denatured, 
envelope glycoprotein are required (Hunsmann et al., 1975). It is also known that 
the presence of neutralising antibodies alone is sufficient to protect cats against the 
development of viraemia (Jarrett et al., 1977; Hoover et al., 1977; deNoronha et al,
1978). The inference from these studies is that the ideal FeLV vaccine would 
consist of the purified envelope glycoprotein and would induce virus neutralising 
antibodies prior to challenge. A number of problems in obtaining this ideal have 
been identified and have ensured that no currently available vaccine is universally 
regarded as having achieved this ideal, though most do seem to provide some 
protection against the development of persistent viraemia (Haffer et al, 1987; 
Marciani et al., 1991; Hoover et al., 1991; Hines et al., 1991; Tizard and Bass, 
1991; York and York, 1991).
Early studies did not attempt to purify the envelope glycoprotein but instead 
utilised low doses of live virus, whole killed virus or infected cells (Jarrett et al., 
1975; Pedersen et al., 1979; Salerno et al., 1979). The use of live virus is 
considered to be too dangerous for routine commercial use. However the 
experimental vaccines were effective (Jarrett et al., 1975; Salerno et al, 1979). 
Vaccines containing formaldehyde inactivated virus (Pedersen et al, 1979) or heat 
inactivated virus (Olsen et al, 1976) were not successful. This may reflect the 
denaturing effect of certain methods of fixation on the envelope glycoprotein. A 
subsequent formalin inactivated preparation was more successful (Pedersen et al,
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1986). There are now several inactivated virus vaccines commercially available in 
the USA (Hoover et al, 1991; Tizard and Bass, 1991; Hines et al, 1991; York and 
York, 1991). One of these vaccines is reported to induce pre-challenge virus 
neutralising antibodies (York and York, 1991). However this study was flawed by 
the use of non-SPF cats whose prior exposure to FeLV was not fully ascertained by 
testing for FOCMA antibodies. No whole inactivated FeLV vaccines can therefore 
be regarded as being completely protective. The potential immunosuppressive 
properties of vaccines containing the TM component of the FeLV env gene (Mathes 
et al, 1978) have, to date, not been demonstrated by experimental data.
The use of FeLV-infected cells as FeLV vaccines has produced equivocal results; 
some workers have reported failure (Pedersen et al, 1979), whilst others have 
described more encouraging results (Jarrett et al, 1975). Protection against the 
development of FeSV-induced fibrosarcomas was observed following the 
vaccination of cats with FeLV-infected cells but not against the development of 
viraemia with FeLV (which was present as a helper virus) (Grant et al, 1980).
The low yields of envelope glycoprotein initially precluded the use of this viral 
component as a commercial vaccine. However, the production of envelope 
glycoprotein from virus infected cells can be increased in vitro with the use of 
serum-free culture medium (Lewis et al, 1981). This technique formed the basis of 
the first commercial FeLV vaccine (Leukocell; Norden). This vaccine was 
subjected to extensive trials (Mastro et al, 1986; Sharpee et al., 1986). 
Subsequently the vaccine was refined and is now marketed as Leukocell 2 (Haffer 
et al., 1987). The efficacy of both vaccines has been questioned by other workers 
(Pedersen et al, 1985; Kumar et al. 1989; Hoover et al, 1991; Tizard and Bass, 
1991; Sebring et al., 1991). Furthermore the first commercial FeLV vaccine had a 
relatively high incidence of severe adverse reactions (Pollock and Haffer, 1991).
The next logical step for vaccine researchers was to increase the quantity of 
envelope protein by using recombinant DNA technology. The first recombinant 
FeLV envelope protein was produced using a bacterial expression system (Marciani 
et al, 1991). The product was non-glycosylated and required high concentrations of 
urea for solubilisation. As recombinant soluble proteins are often poorly 
immunogenic, the production of recombinant envelope glycoprotein requires the 
use of highly effective adjuvants. The successful use of native gp70 incorporated 
into immune stimulating complexes (ISCOMs) has been reported (Osterhaus et al., 
1985; Osterhaus et al, 1989). The vaccine induced virus neutralising antibodies in 
cats prior to challenge with FeLV. These studies are the only description of an 
FeLV vaccine which consistently induces prechallenge virus neutralising 
antibodies. However, significant losses of the envelope glycoprotein during the
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purification process may preclude the use of this preparation as a commercial 
vaccine (Akerblom et al., 1989; Osterhaus et al, 1989). Increasing the efficiency of 
antigen incorporation into the ISCOMs by palmitification of the antigen (Reid, 
1992), or a recombinant version thereof, may yet produce a reliable and cost- 
efficient vaccine.
The development of synthetic peptide vaccines corresponding to putative 
neutralising epitopes of the FeLV SU has not yielded much success. Vaccination of 
rabbits with these peptides produced virus neutralising antibodies, but these results 
could not be repeated in cats (Elder et al., 1987; Nick et al, 1990; Kumar et al. 
1989; Weijer et al, 1993). This may reflect a genetic restriction in cats to certain 
epitopes. It is known that minor changes in amino acid sequence outside of the 
antibody binding region affect the binding of neutralising monoclonal antibodies 
(Nicholaisen-Strouss et al, 1987).
There have been several attempts to develop a live recombinant virus vaccine 
vector (Gilbert et al., 1986; Wardley et al, 1992; Tartaglia et al., 1993). These 
vectors rely on infection of the cats own cells to make the FeLV envelope 
glycoprotein. This protein should therefore be identical to the protein that is 
produced during natural FeLV infection. The vector-derived protein may also be 
presented to the immune system in a similar fashion to native FeLV envelope 
protein in a natural challenge. Gilbert et al. (1986) generated a recombinant 
vaccinia virus which contained the env gene of FeLV-B. The protein was expressed 
in vitro but a lack of immunogenicity was observed following inoculation into both 
cats and mice. The reason for this lack of immunogenicity was not determined. 
Subsequently, a recombinant feline herpesvirus containing the FeLV env and gag 
genes was demonstrated to express a product in vitro (Cole et al., 1990). However, 
on testing in cats, detectable anti-gp70 antibodies were only induced when a 
recombinant protein (produced in the baculovirus system) was included with the 
recombinant virus in the vaccination schedule (Wardley et al., 1992).
Recently the use of a recombinant canarypox virus as a vaccine vector has been 
reported (Tartaglia et al, 1993). Inoculation of this virus into five cats did not 
generate any virus neutralising antibodies. However, subsequent challenge of these 
cats with FeLV failed to establish persistent viraemia. In contrast, all the control 
cats became persistently viraemic. To prevent the establishment of persistent 
viraemia without the development of virus neutralising antibodies reinforces the 
concept of T cell effector mechanisms playing an early role in virus elimination. 
However vaccines need to be effective over long periods of time and, in the 
absence of virus neutralising antibody, it is not clear how this is to be assessed.
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Cats are most susceptible to the development of persistent viraemia following a 
challenge with FeLV once maternal antibody has waned but before the 
development of age related resistance, that is between 6 and 16 weeks of age. As 
the age related resistance can be overcome experimentally using corticosteriods 
(Rojko et al., 1979a), it is suggested that in high exposure situations the 
phenomenon may only provide some protection. The existence in the cat population 
of some FeLV positive individuals that are old (Hosie et al., 1989) is probably a 
testimony to this, although long term carrier status cannot be discounted. These 
findings suggest that the most appropriate time to vaccinate a cat is early in life, but 
that vaccination may be considered at any age.
In summary, two major problems confront an aspiring FeLV vaccine manufacturer. 
Firstly, quantity of envelope glycoprotein, and secondly, the availability of an 
effective, non-toxic adjuvant.
1.3 Viral Cellular Receptors
1.3.1 General Introduction
Every virus, in order to replicate, must gain entry to a host cell. Advances in 
molecular biology techniques have permitted the detailed examination of the 
mechanisms by which viruses enter cells. Central to these studies has been the 
concept that a single molecule in the host cell membrane acts as an initial binding 
site for the virus. A variety of terms have been employed to describe these 
molecules and here the term Viral cell surface receptor’ (VCSR) shall be used. The 
adherence of one or several viral surface molecules (receptor binding sites : RBSs) 
to the VCSR is regarded as being a prerequisite for the entrance of the virus. The 
specificity of this reaction and the distribution of its participants represent major 
determinants in the pathogenesis of many viral diseases. It is highly improbable that 
VCSRs were evolved by the host cell for the benefit of the virus; rather they are 
normal components of the cell membrane and serve some useful function for the 
cell. The virus can be regarded as subverting these components for its own 
purposes. This section illustrates some of the concepts associated with viral cell 
surface receptors and describes the methods which have been employed to study 
them.
Following binding to a VCSR, the virus may enter by pH-dependent receptor- 
mediated endocytosis or pH-independent membrane fusion. Comprehensive 
reviews of these two processes and the involvement of the viral envelope proteins 
in them has been published (White et al, 1983; Marsh and Helenius, 1989).
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(1) Definition of a viral cell surface receptor
Viral cell surface receptors can be defined as single, specific cell surface molecules 
that are normal components of the cell membrane but which are directly used by a 
virus as an initial binding site. This definition does not include the units formed at a 
later stage of viral entry by the recruitment of other cell surface molecules; here 
these units are regarded as being part of the entry process and not part of the 
binding process. The term ’viral entry complexes (VECs)' could be employed to 
describe these later units. Not included in this definition either are ’virus receptors’ 
which do not bind specifically to viruses, but rather to molecules such as antibodies 
which themselves have bound to viruses. For example, the infection of 
macrophages by several viruses is enhanced by the presence of anti-virus antibodies 
which bind to the virus and to the macrophage Fc receptor. The antibody-virus 
complex is then endocytosed. Viruses which are known to infect macrophages in 
this manner include dengue virus (Halstead and O'Rouke, 1977), feline infectious 
peritonitis virus (FIPV) (Olsen et al, 1992) and HIV (Takeda et al.t 1988). It has 
been suggested that antibody-dependent enhancement of FeLV infection may occur 
(Nick et al, 1990; Pedersen et al, 1986). In these instances, these viruses do not 
possess a cell surface receptor. Equally, in some circumstances, viruses may be able 
to use several cell surface receptors on a given cell type.
Many viruses have had cell surface receptors assigned to them. Lentz (1990) lists 
25 viruses with their corresponding VCSRs. Most of these VCSRs are only vaguely 
described, for example ’sialoglycoproteins’ for encephalomyocarditis virus. 
Alternatively, several reports may give conflicting information, for example, 
Hepatitis B may use the polymeric IgA or serum albumin receptors on hepatocytes 
(Machida et al, 1984; Neurath et al, 1986). It is possible that both molecules could 
function as receptors. A few VCSRs are well defined and these are listed in Table 
1.3.
The possession of a receptor confers on the cell nothing more than an ability to 
bind the virus. Mere interaction of the RBS and its corresponding cell surface 
receptor is insufficient to ensure active viral penetration or productive infection. 
Murine cells, if transfected with the cDNA encoding for CD4, develop the ability to 
bind HIV but will not allow the virus to replicate (Maddon et al, 1986). These 
interactions are, however, necessary preconditions for both viral penetration and 
productive infection. Even if a cell possesses a receptor, the virus must still obtain 
access to the tissues. The importance of access to susceptible tissues was 
demonstrated a number of years ago when it was shown that vaccinia virus, which 
is normally taken up by the Kupffer cells of the mouse liver and does not infect the 
hepatocytes, can infect hepatocytes if it is injected into the mouse bile duct (Mims,
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Table 13  Viral cell surface receptors
Virus VCR Reference
ENVELOPED
HIV CD4 Dalgleish et al., 1984
Epstein-Barr virus CR2 (C3d receptor) Fingeroth et a l, 1984
Sindbis virus High affinity laminin 
receptor
Wang et a l, 1992
Mouse hepatitis virus Carcinoembryonic
antigen
Williams et a l, 1990 
Williams et a l, 1991
Transmissable gastro­
enteritis virus
Aminopeptidase N Delmas et a l, 1992
Human coronavirus 229E Aminopeptidase N Yeager et a l, 1992
Rabies virus Acetylcholine receptor Lentz et a l, 1982
Ecotropic murine 
leukaemia virus
Basic amino acid 
transporter
Albritton et a l, 1989 
Kim e ta l, 1991 
Wang et a l, 1991
Vaccinia Epidermal growth factor 
receptor
Eppstein et a l, 1985
Gibbon ape leukaemia 
virus
Phosphate transporter 
protein
O’Hara et a l, 1990 
Johann et a l, 1992
NON-ENVELOPED
Echovirus Integrin VLA-2 Bergelson et al., 1992
Poliovirus Novel member of
immunoglobulin
superfamily
Mendelssohn et a l, 1989
Rhinovirus ICAM-1 Greve et a l, 1989 
Staunton et a l, 1989
1960). A VCSR is present, though not normally accessible.
(2) The biochemical nature o f the VCSR
Individual VCSRs have been identified from all 3 major groups of cell structural 
components, namely proteins, lipids and carbohydrates (including 
glycosaminoglycans). Molecules containing sialic acid are used by a number of 
viruses such as influenza, polyoma and encephalomyocarditis viruses (Lentz,
1990).
Proteins which act as VCSRs have aroused the most interest in recent years. In a 
few cases viruses have enabled the identification of previously unidentified cell 
surface proteins, for example the poliovirus cell surface receptor is a novel member 
of the immunoglobulin superfamily (Mendelson et al., 1989). In other cases viruses 
have been found to use previously characterised molecules. For example, the 
receptor for gibbon ape leukaemia virus (GALV) was found to be a phosphate 
permease that had previously been identified in Neurospora crassa (Johann et al, 
1992).
(3) Quantification o f receptors
The choice of which method to use to attempt to identify a viral cell surface 
receptor will, to some extent, depend on the quantity of receptor available. The 
determination of the number of VCSflRs per cell is hampered in many cases by the 
minimum requirement for viral entry being greater than one receptor. The 
difference may be due to the need to form viral entry complexes. HeLa cells, which 
are susceptible to poliovirus, have 1 x 105 binding sites per cell for the poliovirus 
VCSR-specific monoclonal antibody D171. However, as determined by viral assays 
(which rely on viral entry), HeLa cells have only 3000 poliovirus binding sites 
(Mendelson et al., 1989). Experiments involving competition between isolated viral 
glycoprotein and virus for a VCSR, showed that there were approximately 5 x 105 
MuLV gp71 binding sites per cell (DeLarco and Todaro, 1976). It has also been 
demonstrated that HIV requires multiple gpl20 molecules (and by implication 
multiple CD4 molecules) for infection (Layne et al, 1990).
1.3,2 The Importance of Studies on Viral Cell Surface Receptors
(1) Anti-viral treatment
Some viruses, particularly those which exhibit a large degree of antigenic diversity 
or a high rate of antigenic change, may never be readily controlled by vaccination; 
for example, HIV. These viruses may have to be controlled by anti-viral drugs. At 
present most antiviral agents act on the virus once it has penetrated the cell.
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Examples of such drugs include AZT and acyclovir. An ideal antiviral agent would 
prevent viral entry into the cell. Such agents would presumably act either at the 
level of the VCSR/RBS interaction or the subsequent viral penetration. To date, 
although in vitro results have been encouraging, in vivo results have been 
disappointing. A detailed description of agents which might be able to interfere 
with the VCSR/RBS interaction can be found in a recent review (Lentz, 1990).
(2) Viral pathogenesis
The RBS/VCSR interaction of some viruses may help to understand the 
pathogenesis of their diseases. For example, the use of the acetyl-choline receptor 
of synaptic membranes by rabies virus may explain the neurotropism exhibited by 
the virus (Lentz et al, 1982). Similarly the functional consequences of vaccinia 
virus entering the host cell by means of the epidermal growth factor receptor are 
amply demonstrated by the resulting clinical disease (Eppstein et al, 1985). The 
underlying mechanisms of other viral diseases are less amenable to explanation in 
terms of the RBS/VCSR interaction: for instance the employment of the widespread 
intercellular adhesion molecule 1 (ICAM-1) by the human rhinovirus, the causative 
agent of the common cold, does not readily explain the nature of the disease 
produced by the virus (Greve et al., 1989; Staunton et al, 1989).
(3) Autoimmunity.
It has commonly been observed that viruses bind to molecules at sites which are 
themselves sites for natural body ligands. These observations suggest that there may 
be similarities between the RBS and host cell proteins. Some similarities have been 
identified, such as those between Coxsackie B4 virus and myocardial cells, with 
implications in the pathogenesis of autoimmune disease (Oldstone, 1987). By 
similar reasoning it is possible to envisage that this similarity may benefit the virus 
by avoiding the direction of an immune reaction to those portions of its external 
proteins that are involved in host cell binding (Oldstone, 1987).
13.3 Methods of Identifying Receptors
(1) Blockage o f viral infection with other ligands
Conceptually the simplest method to identify a VCSR is to use a ligand with a 
known receptor specificity to block virus infection.
Such an approach, however, is fraught with the potential for misinterpretation. 
Ligands can exert their anti-virus binding effects by a variety of routes other than 
simple blockage. The value of a-bungarotoxin in identifying the rabies virus 
receptor (Lentz et al, 1982) was questioned for several years until conclusive proof
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was later provided (Lentz et al, 1987).
Isolated FeLV-A SU glycoprotein has been used as a ligand for the putative VCSR 
for FeLV-A (Ghosh et al., 1992). This study is discussed further in Chapter 6.
(2) Blockage o f viral infection with monoclonal antibodies
A common way of identifying VCSRs is to block viral infection with an anti-cell 
monoclonal antibody. The process is greatly simplified if the identity of the cell 
surface ligand recognised by the monoclonal antibody is already known.
The identification of the C3d complement receptor (CR2), a membrane-spanning 
glycoprotein, on the surface of B lymphocytes as the Epstein-Barr virus VCSR was 
the first receptor to be identified by this method (Fingeroth et al., 1984). The 
monoclonal antibody used was of known specificity and the cell tropism of the 
virus had suggested that CR2 might well serve as the VCSR. Similarly, the known 
T helper cell tropism of HIV greatly facilitated the identification of CD4 as its 
major receptor (Dalgleish et al., 1984).
As an alternative to this strategy, monoclonal antibodies can be prepared 
specifically for their ability to block viral infection by injection of susceptible cells 
into mice. Having identified such a monoclonal antibody it may be possible to 
identify its ligand directly; for example, integrin VLA-2 was identified as the 
receptor for echo virus 1 in this fashion (Bergelson et al., 1992). Alternatively, the 
ligand can be purified by affinity chromatography and then amino acid sequencing 
can be used to identify a homologue. The identification of ICAM-1 as the major 
human rhinovirus receptor by one group relied on this technique (Greve et al., 
1989), while another group used a monoclonal antibody of known specificity 
(Staunton et al, 1989). ICAM-1 is a member of the immunoglobulin superfamily 
that interacts with the LFA-1 receptor on T cells. An essentially similar technique 
was used to identify aminopeptidase-N as the receptor for two coronaviruses in the 
same serogroup, transmissible gastroenteritis virus (TGEV) (Delmas et al, 1992) 
and human coronavirus 229E (HuCo229E) (Yeager et al, 1992). The receptor for 
mouse hepatitis virus (MHV), a third, unrelated, coronavirus, has been identified as 
a member of the carcinoembryonic antigen family (Williams et al., 1990; Williams 
eta l, 1991).
A disadvantage of this technique is that monoclonal antibodies which block virus 
adsorption do not always bind to the cell surface receptor (Thiry et al., 1983; 
Sommerfelt et al, 1990). A further disadvantage is that a large number of 
hybridomas may have to be screened for the production of monoclonal antibodies 
that not only bind to the receptor, but also block infection. For example, 700
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hybridomas were screened for their ability to produce antibodies that blocked 
rhinovirus infection (Greve et al, 1989).
(3) Anti-idiotype antibodies
It is often easier to determine the identity of the RBS, than the identity of the 
VCSR. By generating antibodies to the RBS and subsequently generating anti­
idiotype antibodies it might be possible to identify the VCSR. This approach has 
been attempted for Sindbis virus (Wang et al, 1991). The anti-idiotypic antibody 
identified a 63 kDa protein which was later demonstrated to be a minor, species- 
specific, Sindbis virus receptor. The major Sindbis virus receptor was identified, 
using an anti-susceptible cell monoclonal antibody, as the high affinity laminin 
receptor (Wang et al, 1992).
A recent study of the recognition of CD4 by antibodies and HIV gpl20 questioned 
the usefulness of antibodies as mimics for RBSs (Davis et al, 1992). These authors 
suggested that there were no reports of anti-idiotype antibodies unambiguously 
identifying a VCSR. The results obtained with the Sindbis virus anti-idiotype 
antibodies are therefore likely to be the exception rather than the rule. Polyclonal 
anti-idiotype antibodies have been prepared using FeLV gp70 which partially block 
the infection of susceptible cells (Tavares et al, 1991).
(4) Transfection o f cDNA
In recent years several VCSRs have been definitively identified by the transfection 
of susceptible cell cDNA into insusceptible cells. These VCSRs include the 
receptors for poliovirus (Mendelson et al, 1989), ecotropic murine leukaemia virus 
(Albritton et al, 1989) and gibbon ape leukaemia virus (O'Hara et al, 1990). It is 
interesting to note that two retroviral cell surface receptors have been identified in 
this fashion.
To identify a receptor using this method, it is first necessary to demonstrate that 
transfection of viral DNA or RNA into an non-susceptible cell is sufficient to 
establish an infection and therefore the VCSR represents the only barrier to 
infection of the cell. Secondly, it is important to have a means of identifying the 
receptor positive cells. Anti-cell monoclonal antibodies that block viral infection, 
but which, for whatever reason, cannot be used to isolate the receptor, are effective 
markers (Mendelson et al, 1989). Retroviral vectors carrying a drug resistance 
gene can be used in the identification of retroviral receptors (Albritton et al, 1989; 
O'Hara eta l, 1990).
Transfection of cDNA avoids the difficulties caused by the lability of receptor
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(Mendelson et al, 1989) but requires the screening of large eukaryotic and 
prokaryotic cell libraries. The cloning of the receptor gene is, however, a distinct 
advantage. Such a clone can be used to examine other host tissues for the 
expression of receptor transcripts by using northern hybridization analyses 
(Mendelson et al., 1989). Another advantage of this technique is that no knowledge 
is required of the functional nature of the receptor. The technique is not applicable 
to those viruses which have specific, post-entry, requirements for productive 
infection.
13.4 Retrovirus Cell Receptors
(1) General Comments
The receptors for several retroviruses have now been conclusively identified. The 
best characterised of these is the interaction of HIV SU with CD4, (McDougal et 
al., 1991) which is discussed below. Using recombinant retroviral vectors the cell 
surface receptors for gibbon ape leukaemia virus (GALV) and ecotropic murine 
leukaemia virus have been identified as being a phosphate permease protein and a 
basic amino acid transporter respectively (Albritton et al, 1989; O'Hara et al., 
1990; Kim et al, 1991; Wang et al., 1991; Johann et al, 1992). Preliminary studies 
have also been performed on a number of other putative retrovirus receptors (Hosie 
et al, 1993; Ghosh et al, 1992).
Early in the study of retroviruses it was noted that cell lines infected with one 
retrovirus were not susceptible to other isolates of the same retrovirus (Rubin, 
1960). This phenomenon, referred to as superinfection interference, is not unique to 
retroviruses but has been extensively used in this field. Since some retroviruses can 
infect cell lines of non-host origin in vitro, superinfection interference can be 
investigated between retroviruses from different species. Retroviruses can therefore 
be grouped according to their receptor usage, without at the same time knowing the 
nature of the receptor. At least 8 receptor groups exist on human cells for 
retroviruses (Sommerfelt and Weiss, 1989). Using the information that FeLV-B and 
GALV interfered with each other on human cells, it was possible to identify the 
receptor on human cells for FeLV-B as the same phosphate permease protein that 
used by GALV (Takeuchi et al, 1993). It remains to be confirmed whether the 
receptor for FeLV-B on feline cells is a homologue of this human protein.
Recently, studies on the identification of the FIV cell surface receptor have been 
described (Hosie et al., 1993, Willett et al, in press). These studies used an anti­
cell monoclonal antibody that blocked FIV infection. It has yet to be demonstrated 
that the monoclonal antibody blocks infection at the level of the VCSR. The cell 
surface component recognised by the monoclonal antibody is not thought to be the
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feline homologue of CD4 (Brown et al, 1991; Hosie et al., 1993) but rather the 
feline homologue of CD9 (Willett et al., in press).
The existence of endogenous retroviruses, such as RD-114, which are unable to 
infect their own host cells but can, experimentally, infect non-host cell lines may 
represent an historical record involving incarceration following VCSR mutation.
(2) H IV  / CD4
Several methods have been used to demonstrate that HIV uses CD4 as its major 
receptor. The original papers (Dalgleish et al, 1984; Klatzmann et al., 1984) 
reported the testing of the susceptibility of different cell types to pseudotypes of 
vesicular stomatitis virus bearing the retroviral envelope antigen. It was also 
demonstrated that the common determinant for rosette formation between virus 
infected and susceptible cells was the expression of the CD4 molecule. 
Furthermore, 155 different monoclonal antibodies were tested for their ability to 
block both the rosette and the pseudotype assay. Each of 14 anti-CD4 antibodies 
blocked both rosette and pseudotype formation. Preincubation of CD4+ cells with 
anti-CD4 monoclonal antibodies also blocked infection by HIV (Klatzmann et al., 
1984).
The ability of HIV to infect CD4+ cells explains the T cell tropism of the virus. It 
also explains the infection by HIV of a wide range of cells that also express CD4 
(Weiss, 1991). The CD4 antigen is a member of the immunoglobulin superfamily 
(Maddon et al, 1986) and has a variety of functions. It is involved in immune 
recognition and stabilises the interaction of the T cell receptor with MHC class 11 
molecules (Janeway, 1988). The binding of gpl20 to CD4 blocks many of its 
immune reactions and the subsequent viral replication is believed to be responsible 
for many of the immunological abnormalities noted in HIV infected individuals 
(Rosenberg and Fauci, 1991). However, certain aspects of the pathogenesis of HIV 
infection are not so readily explained in terms of HIV / CD4 interaction (Weiss,
1991). There is also evidence that CD4 is not the receptor for HIV in the brain 
(Clapham et al, 1989). It is known that HIV-2 and SIV also employ CD4 as a cell 
surface receptor (Sattentau et al, 1988).
The interaction of CD4 and the envelope surface protein of HIV (gpl20) has been 
analysed in great detail. The site of CD4-binding activity on gpl20 has been 
identified as amino acid residues 422-437 and the site of gpl20 binding on CD4 has 
been localised to the VI domain (Habeshaw et al, 1990; McDougal et al, 1991). 
The gpl20-binding site on CD4 is close to the MHC class 11 binding site and a 
region of gpl20 near to the CD4 binding site is partially homologous to MHC class
11. These observations together suggest that the viral attachment site (RBS) of HIV
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may mimic the natural ligand for the VCSR. Furthermore, they suggest that the 
RBS may be not be antigenic in humans (Habeshaw et al., 1990).
After HIV has bound to CD4 the mechanism by which the virus enters the cell is 
not known. A model has been proposed that involves conformational changes by 
both gpl20 and CD4, as well as the transmembrane gp41 protein (Eiden and 
Lifson, 1992). It is known that HIV infection does not require the endocytosis of 
CD4 (Maddon et al, 1988).
1.4 The Baculovirus Expression System
1.4.1 Baculoviruses: an Introduction
The family Baculoviridae contains several viruses of scientific and economic 
importance. They are the only group of viruses whose host range is restricted to the 
phylum Arthropoda, most members infecting the subphylum Insecta, though some 
have been isolated from Crustacea. The best studied and most commonly used 
baculovirus is the Autographa californica multiple nuclear polyhedrosis virus 
(AcMNPV) (Luckow and Summers, 1988). It is the type member of the family 
Baculoviridae and was originally isolated from a larva of the alfalfa looper 
(Autographa californica). Experimentally AcMNPV infects over 30 species of 
Leptopteran insects (moths, butterflies and their allies), chiefly when they are in the 
larval stage (Luckow and Summers, 1988).
AcMNPV is a rod shaped, enveloped virus approximately 350 nm in length 
(Federici, 1986). The 128 kb double stranded DNA genome is circular and is 
encased in a nucleocapsid (Luckow and Summers, 1988). Each virion may contain 
several nucleocapsids inside a single phospholipid based envelope. In the wild state 
several virions are encased in a protein capsule, called a polyhedron, which protects 
the virion against adverse environmental conditions external to its host. This 
capsule is made of a single protein called polyhedrin (Federici, 1986).
The life cycle of AcMNPV is complex, involving two forms of transmission, one 
intra-host and the other inter-host (Grandos and Williams, 1986). Following 
ingestion of the polyhedrin-encased virus, viral particles are released by a host 
enteric protease into the alkaline environment of the insect gut. After the virus has 
infected the epithelial cells of the insect’s midgut, its genome is expressed in 4 
stages (immediate-early, delayed-early, late and very late stages) (Cochran et al. 
1986). The products of the last stage are 2 proteins: one, polyhedrin, with a relative 
molecular mass of 29,000 Da and another, plO, of 10,000 Da. The function of plO 
is unknown, but it may be involved in cell lysis.
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The infected cells release two forms of the virus; non-occluded and occluded. The 
non-occluded forms are released into the body fluids and can infect most of the 
insects cells. This allows the virus to spread rapidly throughout the body. The 
polyhedrin occluded virus cannot infect the host cells and plays little or no part in 
intra-host transmission.
The infection is usually fatal and once the insect is dead the polyhedrin-encased 
virions are released into the environment where they may persist for some time. In 
contrast the non-occluded virions are quickly inactivated in the external 
environment. Therefore the inter-host form of transmission, in contrast to the intra- 
host form, does require the virus to be encased in polyhedrin.
1.4.2 The Application of AcMNPV in the Baculovirus Expression System
Neither of the two late proteins, plO and polyhedrin, are required for intra-host or 
in vitro transmission. The baculovirus expression system is based upon the 
replacement of these two non-essential genes with genes encoding for foreign 
proteins (Smith et al., 1983a; Smith et al, 1983b; King and Possee, 1992).
This is achieved by co-transfection of susceptible cells with wild type AcMNPV 
DNA and a recombinant plasmid which contains the foreign gene, flanked by 
extended polyhedrin gene sequences (Luckow and Summers, 1988). Homologous 
recombination occurs and the cells produce viral particles containing the foreign 
gene (see Figure 1.3). The only difficulty inherent in this system is distinguishing 
cells infected with the recombinant virus before all the cells are overcome with the 
occlusion positive, wild type virus. Several strategies have been developed for facil­
itating the purification of the recombinant, polyhedrin negative, stock away from its 
wild type counterpart. The use of lacZ as a reporter gene has been documented 
(Zuidema et al, 1990; Pennock et al, 1984). This system allows the cells infected 
by recombinant viruses to be visualised by staining with a chromogenic substrate.
The baculovirus expression system has two inherent safety features. As their host 
range is restricted to the phylum Arthropoda, the viruses are not pathogenic to 
vertebrates. The polyhedrin promoter has been demonstrated to be inactive in 
mammalian cells (Carbonell et al, 1985). The system also avoids the use of 
transformed cells or transforming elements. Insect cells are simple to culture, 
requiring easily obtained media, no C02 enrichment, and relatively crude 
temperature control systems. The system can, with the aid of air-lift fermentation 
vats, easily be scaled up for industrial purposes (Luckow and Summers, 1988). The 
foreign protein is glycosylated by the insect cell and is often chemically and 
functionally similar to the wild type protein.
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Figure 1.3 Schematic representation of the baculovirus expression 
system
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The figure shows a schematic representation of the baculovirus expression system 
A transfer vector containing the foreign gene of interest, flanked by sequences 
immediatly up- and downstream of the polyhedrin gene, is co-transfected with wild 
type baculovirus DNA into insect cells. Recombination occurs and a mixture of 
recombinant and wild type viruses are produced which can be separated by plaque 
purificatioa
An ampicillin resistance marker gene is included in the transfer vector to aid 
prokaryotic manipulatioa Additional modifications to the system include a marker 
gene to aid selection of the recombinant viruses.
Many proteins have been produced in the baculovirus expression system. The more 
important examples are summarised in Table 1.4. For further information, Luckow 
and Summers (1988) list some 37 proteins that have been produced using the 
baculovirus expression system. Early vectors introduced the foreign gene 
downstream from the polyhedrin start codon resulting in the production of a fusion 
protein. Subsequently, altering the polyhedrin start codon from ATG to ATT 
allowed the high level production of non-fused proteins (Luckow and Summers, 
1989).
The use of an alternative baculovirus expression system based upon the Bombyx 
mori nuclear polyhedrosis virus has also been described (Maeda, 1989). This 
system, which was originally developed for in vivo expression using silkworm 
larvae (Maeda et al., 1985), may produce larger yields of certain proteins. The use 
of Heliothus virescens larvae and AcMNPV for in vivo expression is also 
documented (Kuroda et a l , 1989). The main advantage of such systems is the total 
quantity of protein that can be produced. The systems are also useful for studying 
the effects of certain foreign proteins on insect mortality.
1.43 Baculoviruses as Biological Control Agents
Baculoviruses are highly pathogenic to a number of commercially important insect 
pests. This has prompted attempts to use them to control insect numbers. Unlike 
many conventional pesticides they will not persist in the environment and cannot 
harm vertebrates. They do, however, suffer from certain drawbacks. They are 
expensive to produce and much of the virus is inactivated before it can infect the 
host. They are also insufficiently pathogenic allowing the insects to survive for up 
to 1 week after infection
In an attempt to overcome this latter obstacle workers at Oxford generated a 
recombinant baculovirus which expressed a scorpion toxin gene instead of its 
polyhedrin gene (Stewart et al, 1991). This modification decreased the survival 
time of the infected individuals at the same time decreasing the LD50 values. The 
particular scorpion toxin chosen has no effect on mammals such as mice.
1.5 Project Aims
The identification of the FeLV cell surface receptor(s) will greatly assist the 
understanding of FeLV pathogenesis. In particular, the characterization of the 
FeLV-C cell surface receptor may help to explain the specific development of pure 
red cell aplasia induced by isolates of this subgroup.
The development of an effective FeLV vaccine will aid the control of this common,
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Table 1.4 Some proteins produced in the baculovirus expression system
Viral proteins Reference
HIV env Rusche et a l, 1987 (and others)
FeLV env Thomsen et a l , 1992
African horse 
sickness virus
VP7 Chuma etal., 1992
Avian leukaemia 
virus
env Notebom et a l , 1990
FIV gag Morikawa et a l , 1991
Hepatitis B Core antigen Hilditch et a l, 1990
Influenza Haemagglutinin Kuroda et a l , 1986
Bacterial proteins
E. coli (3 galactosidase Pennock et a l , 1984
E. coli Chloramphenicol acetyl transferase Carbonell et a l , 1985
Human proteins
Interleukin-2 Smith et a l , 1985
(3 interferon Sm iths a l, 1983
c-myc Miyamoto et al, 1985
Adapted from Luckow and Summers (1988)
serious feline pathogen. When the work for this thesis began there were no 
commercial FeLV vaccines available in the UK. Although subsequently two 
vaccines were released, neither provides complete protection against the 
development of persistent viraemia.
The initial aim of this project was to produce recombinant FeLV SU from all three 
subgroups of FeLV and two FeLV-A/C chimeras in a protein expression system. 
Subsequently, the proteins were to be analysed using a variety of techniques to 
assess their functional characteristics in comparison to the native proteins.
The proteins were then to be used in an attempt to identify the cell surface 
receptor(s) for FeLV. Initially, the ability of the proteins to block FeLV infection 
was to be assessed and then co-precipitation studies with surface labelled cell 
lysates performed.
A subsidiary aim was to use the recombinant FeLV-A SU in vaccine studies.
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Chapter 2. Materials and Methods
2.1 Materials
Details of reagents and methods commonly used are given below. Specific 
materials and methods are described in the relevant chapters.
2.1.1 Equipment
Plasticware was obtained from Costar or Nunc. All centrifuges and rotors used 
were made by Beckman. All other equipment manufacturers are named in the text.
2.1.2 Chemicals
All chemicals used were of Analar quality and, except where indicated, were 
obtained from BDH, NBL, Gibco BRL, Pharmacia or Sigma.
2.1.3 Standard Solutions
Acrylamide (30%) : Purchased from NBL as a solution containing 29 : 1 (w/w) 
acrylamide: methylene-bisacrylamide.
Agarose gel loading buffer : 10% Ficoll, 0.02% bromophenol blue, 0.02% xylene 
cyanol FF, 0.02% Orange G in water. To a given volume of sample was added a 
quarter volume of gel loading buffer.
Alkaline phosphatase (AP) buffer: 200 mM NaCl, 10 mM MgCl2, 100 mM Tris (pH
9.5). Sterilised by autoclaving.
Ammonium persulphate : 10% (w/v) solution in water. Aliquots were stored at 
-20°C
Ampicillin : 100 mg/ml filter sterilised and stored in aliquots at -20°C. Used as a
1,000 x stock.
Blocking solution : TBS +3% (w/v) Marvel (Chivers and Sons Ltd., Dublin). 
Bromo-chloro-indolylphosphate (BCIP) = 0.5 g dissolved in 10 ml of 100% DMF. 
Coupling buffer : 10 mM NaHC03, 1 mM EGTA, pH 9.6. Filter sterilised.
Ethidium bromide : 10 mg/ml water. Stored in a light proof container.
2 x HEPES buffered saline : 280 mM NaCl, 50 mM HEPES, 3 mM Na2HP04 (pH
7.05). Filter sterilised. The pH was checked periodically.
Klenow buffer: 50 mM Tris (pH 7.6), 10 mM MgCl2, filter sterilised and stored in
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aliquots at 4°C.
L Agar : 15 g Bacto-agar added immediately before autoclaving 1 litre of L Broth 
(see below).
L Broth : 1% (w/v) tryptone, 0.5% (w/v) yeast extract in 90 mM NaCl. The 
suspension was sterilised by autoclaving prior to use and then glucose was added to 
a final concentration of 20 mM and MgCl2 to a final concentration of 10 mM.
Lysozyme : 10 mg/ml in water. Made fresh when required.
Nitrobluetetrazolium (NBT): 0.5 g dissolved in 10 ml of 70% DMF.
Phosphate buffered saline (PBS): 140 mM NaCl, 2.7 mM KC1, 10 mM Na2HP0 4 , 
1.5 mM KH2P04 (pH 7.2). Sterilised by autoclaving.
PBS-Tween : PBS + 0.05% (v/v) Tween 20.
PBS-EDTA : PBS + 0.5 mM EDTA (pH 7.2) with 0.005% phenol red as an 
indicator. Sterilised by autoclaving.
Protein gel loading buffer : 10% glycerol, 62.5 mM Tris (8.0), 2% SDS, 5% p- 
mercaptoethanol, 0.01% bromophenol blue in water. This was used as a 4 x stock.
SDS-PAGE stacking gel buffer : 125 mM Tris, 17 mM SDS (pH 6.8).
SDS-PAGE separating gel buffer : 375 mM Tris, 17 mM SDS (pH 8.8).
SDS-PAGE running buffer: 120 mM Tris, 0.5 M Glycine, 17 mM SDS.
STET solution : 1% Triton X100 (v/v), 20% sucrose (w/v), 5% EDTA (w/v) in 50 
mM Tris (pH 8.0).
Streptomycin : 25 mg/ml filter sterilised and stored in aliquots at -20°C. Used as a
1,000 x stock.
TBE : 100 mM Tris, 100 mM orthoboric acid, 2.5 mM EDTA.
TE: 10 mM Tris, 1 mM EDTA.
Tris buffered saline (TBS) : 140 mM NaCl, 2.7 mM KC1, 25 mM Tris (pH 8.0). 
Sterilised by autoclaving.
TBS-Tween : TBS + 0.05% (v/v) Tween 20.
Western buffer : 25 mM Tris, 200 mM glycine in a 20% methanol/water solution. 
X-Gal : 5-bromo 4-chloro 3-indolyl p - D galactoside was obtained from NBL.
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Dissolved in DMF (80 mg/ml) and stored at -20°C.
2.1.4 Plasmids
(1) pFGA, pFGB, pFSCy pVCt pV215
The prototype proviral clones of FeLV-A, FeLV-B and FeLV-C, called pFGA, 
pFGB and pFSC respectively (Elder and Mullins, 1983; Stewart et al, 1986; Riedel 
et al, 1986), were obtained from Dr. M. Rigby (Department of Veterinary 
Pathology, University of Glasgow). pVC and pV215 are two proviral clones of 
chimeric A/C FeLVs created by site directed mutagenesis (Rigby, 1989). They both 
have an FeLV-A backbone but contain a small region near the 5' end of C-specific 
sequence which confers on their resulting, replication competent, viruses many of 
the properties of FeLV-C (Rigby et al, 1992).
(2) pAcLacZ+
The plasmid pAcLacZ+ was obtained from Dr. R. Possee (Institute of Virology, 
Oxford) and is based on the plasmid pAcUW2(B) (Weyer et al, 1990). It is used as 
a transfer vector for the baculovirus expression system and contains the polyhedrin 
promoter and flanking sequences. It also includes the lacZ gene under the control of 
the plO promoter as a selectable marker. The backbone is a pUC8 derivative called 
pUC8/6/8 (Weyer et al, 1990). Unlike the plasmid pAcUW2(B), it does not 
contain the actual polyhedrin gene.
(3) pBluescript SK+
This commercially available plasmid (Stratagene), which usually replicates to a 
high copy number, contains the a  peptide portion of the lacZ gene under the control 
of the T3 promoter. The promoter and the a  peptide segment are separated by a 
multiple cloning site which, if an insert is not present, allows a  complementation 
when transfected into the DS941 host cells. If an insert is present then a  
complementation does not occur. This allows blue / white selection on agar plates 
impregnated with X-Gal. The plasmid also contains an ampicillin resistance gene.
(4) p l-10
This plasmid was obtained from Dr. M. Rigby. It contains the FIV/UK8 env gene in 
a pUC derivative. The 5' terminal 15 base pairs were derived from the Petaluma 
isolate. This produces one amino acid change (a glutamine instead of a glycine) 
from the predicted UK8 sequence. This amino acid change is in a conserved region 
of the protein (Rigby et al, 1993).
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2.1.5 Sera and Antibodies
(1) Rabbit serum #709
This serum was produced by Dr. G. Reid (Department of Veterinary Pathology, 
University of Glasgow) by immunization of a rabbit with FeLV glycoproteins. 
These proteins were prepared by lentil lectin affinity chromatography from 
detergent disrupted FeLV derived from FL74 culture fluid. The serum reacts well 
with native gp70 in Western blots and can also be used in ELISAs both as a 
capturing antibody or as a primary detection antibody.
(2) Rabbit serum #395
This is a serum derived from a specific pathogen free rabbit.
(3) Monoclonal antibodies
(a) 3-1713-17AP ! 6-15
These are anti-FeLV gp70 monoclonal antibodies, kindly donated by Dr. K. Weijer 
(Netherlands Cancer Institute). They all recognise the region covering amino acid 
residues 204 to 208 of FeLV-A (N.Spibey, personal communication), which has 
been shown to be an important neutralising epitope of gp70 (Elder et al., 1987). 
They are neutralising in vitro; their titres are given in Table 2.1. They are of the 
IgGl subclass (Weijer et al., 1986). The 3-17AP MAb has alkaline phosphatase 
covalently linked to its Fc portion and was available as a purified antibody. The 
monoclonal antibodies 3-17 and 6-15 were available in ascites form.
(b) C1G10, HL2 andHLS
These are anti-FeLV gp70 monoclonal antibodies that were obtained from 
Dr.C.Grant (C1G10) and Professor H.Lutz (HL2 and HL5). C1G10 is reported to 
be FeLV/C-Sarma / FeLV/B-ST specific (Grant et al., 1983). It does not neutralise 
several other FeLV/C isolates. It was available in a purified form. HL2 and HL5 are 
reported to be specific for FeLV-A/Glasgow-1 and a range of FeLV/C isolates 
(OJarrett, personal communication). They were available in ascites form.
The neutralising titres of these monoclonal antibodies in vitro are given in Table 
2 .1.
(c) VPG 68 and VPG 71.2
These monoclonal antibodies were prepared by Mr T. Dunsford (Department of 
Veterinary Pathology, University of Glasgow) against whole FIV virus prepared 
from FL4 cells. They both immunoprecipitate native FIV SU, but do not recognise
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Table 2.1 Neutralisation titres of monoclonal antibodies to FeLV 
subgroups
a) FeLV-A, FeLV-B and FeLV-C
Subgroup and 
Strain
FeLV/A-Glasgow-1 FeLV/B-ST FeLV/C-Sarma
C1G10 0 1280 1280
HL2 5120 4 800
HL5 320 20 200
b) FeLV-C (three isolates)
FeLV/C
Sarma FA27C FS246
C1G10 3000 0 0
HL2 10000 20000 5000
HL5 40 5000 1280
The values presented in these tables were derived from separate experiments with 
different preparations of the antibodies.
the protein in western blots or ELISAs. VPG 71.2 also immunoprecipitates 
recombinant FIV / UK8 SU produced in the baculovirus system (A.Mackay, 
personal communication).
(4) Cat PI 1 / P12
These sera are derived from cats which recovered from natural contact infection 
with FeLV-A/Glasgow 1 (Madewell and Jarrett, 1983). The cats were kept in a 
barrier maintained cattery at the Department of Veterinary Pathology, University of 
Glasgow.
Both sera have neutralising antibodies in vitro with titres of 128 and 256 
respectively. They react well with native gp70 on western blots. The serum P12 
reacts specifically with FeLV-A gp70 in ELISAs. The subgroup specificity of 
serum P ll  in ELISAs is unknown.
(5) Cat 31
This was a cat serum derived from the experimental infection of an 8 week old 
kitten with biologically cloned FeLV-C/Sarma. The kitten developed neutralising 
anti-FeLV-C/Sarma specific antibodies. The kitten was then boosted 8 months later 
with concentrated, purified FeLV-C/Sarma. The serum has high titres of anti- 
FeLV-C/ Sarma specific antibodies on testing with an ELISA, but low anti FeLV-A 
titres.
The neutralising antibody titres of this serum were 16 against FeLV-A/Glasgow-1, 
16 againist FeLV-B/ST and 1024 against FeLV-C/Sarma.
(6) Cat Wendy / Q25 / Ruth 2
These are specific pathogen free cat sera, obtained from animals kept in a barrier 
maintained cattery at the Department of Veterinary Pathology, University of 
Glasgow.
(7) Pooled FIV-infected cat serum P2
This serum was obtained by pooling the sera derived from a number of cats infected 
with UK8 isolate of FIV (Rigby et al., 1993). The cats were kept in a barrier 
maintained cattery at University of Glasgow. The serum reacts well with FIV 
proteins on western blot.
(8) Goat serum
Goat serum that was used as a blocking antigen in western blots and ELISAs was 
obtained from Scottish Antibody Production Service. It was stored in 10 ml aliquots
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at -20°C until required.
2.1.6 Viruses
(1) Baculoviruses
The baculovirus used, Autographa californica multiple nuclear polyhedrosis virus 
(AcMNPV) (strain C6), was obtained from Dr. N. Stow (Institute of Virology, 
Glasgow).
(2) Feline Leukaemia Viruses
The FeLV strains used were; FeLV-A/Glasgow 1 (Jarrett et aL, 1973); FeLV- 
B/Snyder-Theilen (ST) (Sarma and Log, 1973); FeLV-C/FA27C (Onions et al., 
1982). They were obtained in either biologically or molecularly cloned form from 
Mr. M. Golder (Feline Virus Unit, University of Glasgow).
2.1.7 Bacterial Strains 
(1) DS941
This is a strain of E.coli which has a partially deleted chromosomal lacZ gene and 
can be used for blue/white selection of recombinant plasmids containing the 
appropriate segment of lacZ. It is also resistant to streptomycin.
DS941 (Flinn et al, 1989) is a derivative of AB1157 (Bachmann, 1972) and was 
obtained from Institute of Genetics, University of Glasgow. The genotype is recF 
laclq lacZMM15.
2.1.8 Eukaryotic Cell Lines
All cells were grown in media supplemented with 2 mM glutamine, 100 IU/ml 
penicillin and 100 pg/ml streptomycin. All the media used were supplied by Gibco 
BRL and kept at 4°C. All mammalian cells were cultured at 37°C and in air 
enriched with 5% C02. When necessary, a humified incubator was used. All 
adherent mammalian cells were subcultured by first washing with PBS-EDTA and 
then with 0.025% trypsin / PBS-EDTA mixture. After a short incubation at 37°C 
the cells were resuspended in fresh medium and replated. Cell were stored in a 10% 
DMSO / 90% FCS mixture in liquid nitrogen.
(1)AH927
This feline fibroblast cell line was derived from the culture of a whole embryo of 
unknown gestational age (Rasheed and Gardner, 1980). It supports the growth of all 
FeLV subgroups. AH927 cells were obtained from Dr. B. Willett (Department of
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Veterinary Pathology, University of Glasgow) and were maintained in DMEM with 
added 10% FCS.
(2) QN10S
This is a feline cell line which was derived from the AH927 fibroblast cell line by 
Professor O. Jarrett. It carries the proviral DNA of the Moloney murine sarcoma 
virus containing the mos oncogene. It is therefore described as a S+ L- cell line. 
The cells are used for routine FeLV isolations in the diagnostic laboratory of the 
Feline Virus Unit, University of Glasgow. QN10S cells were obtained from the 
staff of the Feline Virus Unit and were maintained in DMEM with added 10% FCS 
and 25 mM HEPES. They were used between passages 60 and 90.
(3) F422
This is an FeLV positive feline cell line derived from a thymic lymphosarcoma 
(Rickard et al, 1969). The cells produce FeLV of subgroup A. The F422 cell line 
was maintained in RPMI 1860 with added 10% FCS. The principle use of this cell 
line was as a source of purified FeLV. Large quantities of the cells were grown in 
roller flasks and the viral particles from the culture fluid were concentrated by 
ultrafiltration followed by centrifugation in a sucrose gradient. Preparations of 
virions purified in this manner were obtained from Mr. M. Golder. The virus was 
lysed with 1% Triton XI00 on ice for 30 minutes, diluted with an equal volume of 
TBS, and stored at -20°C until used.
(4) FL74
This is a transformed feline lymphoblastoid cell line which produces FeLV of all 
three (A, B and C) subgroups (Kawakami et al., 1967). The FL74 cell line was 
maintained in RPMI 1860 with added 10% FCS. Concentrated virion preparations 
prepared in a similar fashion to that described above were obtained from Mr. M. 
Golder. Triton lysis was also performed on these preparations.
(5) 3201B
This is a CD4 + / CD8 + feline T cell line derived from a naturally acquired, FeLV 
negative, lymphosarcoma (Snyder et al., 1978). The cell line was obtained from Dr. 
B. Willett, and maintained in RPMI 1860 with added 10% FCS.
This cell line is sometimes also known as FeT (Kristal et al., 1993). It is reported to 
support the growth of FeLV-A and -C but not FeLV-B, albeit at a much lower level 
than that seen with AH927. FeLV-C has been reported to induce apoptosis in these 
cells when infected at a high multiplicity of infection (Rojko et al., 1991).
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(6) MDCK
This is a canine fibroblast cell line derived from the kidney of a normal adult 
cocker spaniel which supports the growth of a wide range of mammalian viruses 
(Madin et al., 1957). MDCK cells were obtained from Dr. N. Spibey (Department 
of Veterinary Pathology, University of Glasgow), and were maintained in DMEM 
with added 10% FCS. The ability of MDCK cells to support the growth of FeLV 
was not known at the start of this project.
(7) H uT 78
This is a human T cell line derived from a cutaneous lymphoma of a patient 
suffering from Sezary Syndrome (Gazdar et al., 1980). The tumour cells were 
induced to proliferate in vitro using the mitogen concanavalin A. They are mature T 
cells of the helper phenotype, expressing the CD4 antigen and constitutively 
producing IL-2. They are susceptible to HIV infection. They are free from HTLV-1 
infection (Mann et al, 1989). Their susceptibility to FeLV infection was unknown 
at the start of this project.
The cell line was obtained from Dr. M. Harris (Department of Veterinary 
Pathology, University of Glasgow), and maintained in RPMI 1860 with added 10% 
FCS.
(8) S/9
The Sf9 cell line, a subclone of Sf21, was derived from the ovarian tissue of the fall 
army leaf worm (Spodoptera frugeriperda) (Vaughn et al, 1977). These cells were 
used throughout the project for the production of recombinant viruses and proteins. 
The cells were obtained from Dr. M. Harris.
Sf9 cells were maintained in TC100 media with added 10% FCS at 28°C without 
CO2 supplementation. For the production of recombinant proteins the cells were 
maintained in SF900 media, a serum-free insect cell medium, after infection with 
the recombinant virus. A much improved version of the SF900 medium, SF900 11, 
was used when it became available. No serum-free medium was found to be able to 
support the growth of insect cells for more than 3 passages.
2.2 Manipulation of DNA
Most DNA manipulations were carried out using standard published protocols 
(Sambrook et al. 1989) with commercially available enzymes and buffers.
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2.2.1 Preparation of Plasmid DNA
To generate sufficient quantities of DNA for use in transfections and enzymic 
manipulations a Triton X100 (TX100) lysis technique was used.
A 500 ml bacterial suspension, cultured overnight, was pelleted using a JA14 rotor 
in a J2-21 centrifuge at 6,000 rpm for 15 minutes. The supernatant was discarded 
and each pellet was resuspended in 2 ml of 12.5% sucrose in 50 mM Tris (pH 8.0). 
The suspensions were pooled in JA20 centrifuge tubes (10 ml per tube) and 1 ml of 
freshly prepared lysozyme solution (10 mg/ml) was added. After 5 minutes 1 ml 0.5 
M EDTA was added rapidly, followed by a solution of 2% TX100 in 50 mM Tris 
(pH 8.0) with 62 mM EDTA (1 ml/ml suspension). The suspension was kept on ice 
for a further 15 minutes.
The lysed bacterial debris was pelleted by centrifugation at 15,000 rpm for 60 
minutes. For every 1 ml of supernatant so formed, 1 g of caesium chloride was 
added, together with ethidium bromide solution (100 pi / 10 ml solution). The 
solution was then pipetted into polypropylene tubes and centrifuged at 55,000 rpm 
overnight using a VTi 65 rotor. The DNA was visualised under UV light and was 
harvested using a hypodermic needle and syringe. The ethidium bromide was 
removed using butanol extraction and the DNA was ethanol precipitated, dried and 
dissolved in sterile water. The quantity of DNA was measured using a Beckman 
DU 64 spectrophotometer in scan mode. The quantity of plasmid DNA was 
estimated using the conversion of OD26o = 1.0 equivalent to 50 pg/ml. The 
preparations routinely had an OD26o/OD28o ratio of approximately 2, indicating that 
they were free from contaminating proteins.
2.2.2 Phenol/Chloroform Extraction of DNA
To remove proteins from DNA solutions an equal volume of phenol was mixed 
with the DNA solution and the two phases allowed to partition. The aqueous phase 
was removed and an equal volume chloroform was added to it. The two phases 
were allowed to separate and the aqueous component was retained. These 
procedures were performed in a fume hood.
2.23 Ethanol Precipitation of DNA
DNA was purified from solutions by adding 2.5 volumes of pure ethanol and 0.1 
volumes of sterile 5 M NaCl. The precipitate was allowed to form for 1 hour at 
-20°C and then pelleted in a benchtop 'Microcentaur’ centrifuge (M.S.E.) at 13,000 
rpm for 15 minutes. The pellet was washed twice in 70% ethanol before drying by 
centrifugation under vacuum in an 'Univap' evaporator (Uniscience Limited).
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2.2.4 Restriction Enzyme Digestion of DNA
Commercially available restriction enzymes were used with their appropriate 
buffers. When double digests required different buffers, the DNA was ethanol 
precipitated between digests. Generally 2 units of enzyme were used to digest 10 
pg of DNA.
2.2.5 Agarose Gel Electrophoresis
Separation of DNA of differing sizes was achieved by electrophoresis through a 1% 
agarose gel made with TBE buffer. The gel was made with a small quantity of 
ethidium bromide (7 pi stock solution / 100 ml gel). The DNA solutions were 
mixed with agarose gel loading buffer prior to loading. During electrophoresis the 
gel was examined periodically under UV light until the desired separation of the 
products was achieved.
The molecular mass markers used with agarose gels were derived from X DNA 
digested with Hind 111 or °PX RF DNA digested with Hae 111 (Gibco).
2.2.6 Purification of DNA from Agarose
A standard method of electroelution was used for most purifications of DNA from 
agarose (Sambrook et al 1989). A slab of agarose containing the DNA was placed 
in a dialysis bag with a small volume of sterile buffer and the bag was placed in the 
electrophoresis chamber. Voltages of 100 V over a period of 3-4 hours were used 
and allowed good recovery. After electroelution the DNA was precipitated with 
ethanol.
For fragments of DNA less than 1 kbp, the slabs of agarose were repeatedly frozen 
and thawed in SPIN-X (Costar) tubes containing 0.22 pm cellulose acetate filters 
and were then centrifuged in a bench top centrifuge at 13,000 rpm for 20 minutes.
2.2.7 Acrylamide Gel Electrophoresis of DNA
To visualise small (less than 0.5 kbp) fragments of DNA, electrophoresis through a 
7.5% acrylamide gel was used. These gels were made with TBE buffer and 
polymerised with TEMED (1.5 pl/ml gel) and 10% ammonium persulphate (6 pl/ml 
gel). After electrophoresis the gels were stained with fresh buffer containing a small 
quantity of ethidium bromide. The DNA solutions were mixed with agarose gel 
loading buffer prior to loading.
The molecular mass markers used with acrylamide gels were derived from 9X RF 
DNA digested with Hae 111 (Gibco).
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2.2.8 Purification of Synthetic Oligonucleotides
Following synthesis in a 381A DNA Synthesizer (Applied Biosystems) the 
oligonucleotide (without a terminal trityl group) was eluted from the column with 
30% ammonia and then deprotected by incubation overnight in a water bath at 
55°C. The following day the solution was cooled, then precipitated with ethanol. 
Aliquots of the oligonucleotides were stored at -20°C. The quantity of 
oligonucleotide was estimated using a spectrophotometer and the conversion of 
OD260 =1.0 equivalent to 35 pg/ml.
2.2.9 Amplification of DNA by PCR
A commercial kit obtained from Boehringer Mannheim was used for all polymerase 
chain reaction (PCR) manipulations. This contained the Taq DNA polymerase as 
well as the reaction buffer and dNTPs. The kit was used according to the 
manufacturer’s instructions. Reaction mixes containing the appropriate 
concentration of buffer, enzyme and 200 nmoles of each dNTP were dispensed in 
aliquots prior to the addition of primers and templates. For each 100 pi of reaction 
mix 1 pg of each primer was added and 1 pi of template stock (approximate 
concentration 1 ng/pl). The reaction mixes had 50 pi of mineral oil placed on top to 
reduce evaporation losses. The reactions were performed in an air cooled Omnigene 
TR3 thermal cycler (HyBaid). Reaction parameters are given in the appropriate 
chapters. Temperature changes were effected as rapidly as possible. Preparative 
yields of product were prepared from several reaction aliquots utilising the original 
template. PCR products were extracted with phenol/chloroform and then ethanol 
precipitated before digestion with restriction enzymes.
2.2.10 Sequencing of DNA
Sequencing of plasmid DNA was carried out using a Sequenase kit (Stratagene) and 
35S dATP (Amersham International) for dideoxy-mediated chain termination 
method (Sanger et al.} 1977)). The manufacturer's instructions for the composition 
of the sequencing reactions were followed and the 6% polyacrylamide gel with 8 M 
urea was prepared in a Sequi-gen nucleic acid sequencing cell (Bio-Rad) as detailed 
elsewhere (Sambrook et al. 1989). After prewarming the gel for 1 hour at 60 W the 
gel was loaded and electrophoresis continued until the either the xylene cyanol or 
bromophenol blue had reached the bottom of the gel. This generally took 2 to 4 
hours and allowed about 300 bp to be sequenced. The glass plates were then 
separated and the gel was removed using a large sheet of Whatman 3M paper. The 
gel was then dried under vacuum in a Model 583 gel dryer (BioRad, California). 
Once the gel was dry to the touch an autoradiograph was prepared. Sequencing was 
performed on both strands of DNA using two sets of reactions, employing different
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primers.
2.3 Manipulation of Proteins
2.3.1 Determination of Total Protein Content
This was performed by a microtitre assay using Bradford's reagent (Dunn, 1989). 
This solution was made by adding 100 mg Coomassie Blue G250 and 30 mg SDS 
to 50 ml 95% ethanol and then adding 100 ml of 85% phosphoric acid. The final 
volume was adjusted to 200 ml and the resulting solution used as a 5 x stock 
(Sambrook et al. 1989).
A volume of 100 pi of the diluted reagent was added to 10 pi of protein solution 
and was incubated at room temperature for 10 minutes. The OD595 was then 
measured in an EL312 Bio-Kinetics Plate Reader (Bio-Tek Instruments). A 
standard curve using bovine albumin was generated with each assay which was 
repeated at least twice for each sample. This test works well for low protein 
concentrations (0.05 mg/ml -1 mg/ml).
23.2 Polyacrylamide Gel Electrophoresis of Proteins
For the routine separation of proteins, electrophoresis through a polyacrylamide gel 
with a discontinuous buffer system containing SDS was used (Laemmli, 1970). 
Normally a 7.5% polyacrylamide separating SDS-PAGE gel was overlaid with a 
4% polyacrylamide stacking gel. Gradient gels were made with a Multiphor 11 
gradient maker (Pharmacia). Gels were made by adding TEMED (1.5 pl/ml gel) 
and 10% ammonium persulphate (6.0 pl/ml gel) to freshly prepared solutions 
containing diluted acrylamide/bis-acrylamide mixture and the appropriate buffer. 
Normally a MiniProtean (Bio-Rad) gel apparatus was used. When larger glass 
plates were used, a very thin film of petroleum jelly was used to coat the spacer 
bars to ensure a good seal. Prior to loading, the samples were boiled with SDS- 
PAGE gel loading buffer. Electrophoresis was continued until adequate resolution 
of the Rainbow Markers (Amersham International) has been achieved.
23.3 Staining SDS-PAGE Gels
(1) Coomassie staining
For routine staining of SDS-PAGE gels a solution of Coomassie brilliant blue R250 
in 50% methanol, 45% water and 5% acetic acid was used followed by destaining 
in 50% methanol, 45% water and 5% acetic acid. Using this technique 0.5 pg of 
protein could be visualised.
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(2) Silver staining
For the sensitive detection of small quantities of proteins a silver staining technique 
similar to that described elsewhere (Sambrook et al. 1989) was employed.
The gels were initially fixed for 4 hours in 30% ethanol, 60% water and 10% acetic 
acid and were then incubated for 1 hour in 30% ethanol in water. Rehydration using 
deionised water for 2 hours was followed by 30 minutes in a 0.1 pg/ml solution of 
DTT in deionised water. The gels were stained with a 0.1% solution of silver 
nitrate (freshly prepared from a 20% stock) for 30 minutes and were then washed 
three times with deionised water. The staining was carefully developed with a 
freshly prepared solution of sodium carbonate in formaldehyde. Once sufficient 
intensity had been achieved the reaction was stopped using 1% acetic acid. The gels 
were then washed thoroughly in deionised water and preserved (see below).
Using this technique 0.05 pg of protein could be visualised.
23 .4  Preserving SDS-Polyacrylamide Gels
Polyacrylamide gels were preserved by enclosing in a moist cellophane sandwich 
which was then baked in an Easi-Breeze gel dryer (Hoefer Scientific Instruments).
2.3.5 Western Blotting
Following SDS-PAGE to separate the polypeptides of a protein mixture, detection 
by immunological reactivity was achieved by western blotting (Towbin et al.,
1979).
Gloves were worn at all times during this procedure to ensure that skin oils did not 
prevent efficient protein binding. A plastic cassette with two foam pads was used to 
hold the membrane and gel together. Two sheets of Whatman 3M filter paper were 
cut to the same size as the foam pads. One sheet of either 0.2 pm nitrocellulose 
Trans-Blot’ membrane (BioRad) or 0.45 pm nylon ’HyBond’ membrane (Amersham 
International) membrane was cut to just a little larger than the polyacrylamide gel. 
The membrane was then soaked in western buffer. After SDS-PAGE to separate the 
polypeptides, one sheet of filter paper was used to transfer the polyacrylamide gel 
off the glass plate and on one to the foam pads on the black side of the opened 
cassette. The membrane was carefully placed on top and the second sheet of filter 
paper (soaked in western buffer) was placed on top. Air bubbles were removed by 
rolling a pipette over the top of the sandwich. The second foam pad was then 
placed on top and the cassette closed and placed in the chamber with the gel (black) 
side of the cassette nearest to the negative terminal of the chamber. Electroblotting 
of the proteins from the gel to the membrane was performed at 120 V for 1 hour
51
(small gels) or 180 V for 1.5 hours (large gels). The apparatus was kept cool using 
an ice block and the western buffer was circulated using a magnetic stirrer.
When electroblotting was complete the membrane was removed from the apparatus 
and placed in a clean container containing the blocking solution (see section 2.1.3) 
and gently rocked for 4-12 hours. If a goat polyclonal anti-antibody preparation was 
to be used then 10% goat serum was added to the blocking solution. The membrane 
was then washed several times using PBS-Tween (see section 2.1.3) over a period 
of 2 hours.
The blocking solution had 0.2%(v/v) 0.5 M EDTA, 0.5%(v/v) Tween 20 and the 
appropriate quantity of serum / monoclonal antibody added. The solution was then 
incubated with the membrane in a plastic bag on a rapidly rotating platform for 2 
hours. Care was taken to exclude any air bubbles from the bag. If a second antibody 
was to be used then the membrane was briefly washed in PBS-Tween before 
incubating with a similarly prepared solution for a further hour. All such antibodies 
were conjugated with alkaline phosphatase.
The membrane was then washed several times using PBS-Tween over a period of 1 
hour. The membrane was finally washed in alkaline phosphatase (AP) buffer. The 
blots were developed by incubating with a substrate solution containing 1.65 pg 
BCIP and 3.3 pg NBT in 10 ml of AP buffer. The reaction was allowed to proceed 
until the purple staining bands could be clearly seen. The reaction was stopped with 
water or Tris-EDTA and the membrane was photographed promptly.
2.3.6 ELISAs
Several different enzyme linked immunoabsorbant assays (ELISAs) (Belanger et 
al., 1973) were performed. The general method that was used is described below. 
Specific details are given in the relevant chapters.
A positive and a negative control were always included. All reactions were 
performed at room temperature with gentle agitation between stages. An ELISA 
plate washer (Ultrawash 11; Dynatech) was sometimes used.
A 96-well, medium binding, flat-bottomed microtitre plate (Greiner) was coated 
with an antibody preparation diluted with coupling buffer (100 pi per well) and left 
overnight. The plate was washed twice with TBS-Tween (see section 2.1.3) and 
was then blocked for 1 hour with blocking solution (200 pi per well). The plate was 
washed twice more with TBS-Tween. The antigens to be tested were diluted using 
1% empigen in TBS and then added to the plate (100 pi per well) for 3 hours. A 
further 2 washes were followed by the addition to each well of 100 pi of the second
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antibody preparation, also diluted in blocking solution with 0.5% Tween 20 added. 
The plate was then incubated for 1 hour, washed twice and an alkaline phosphatase 
linked anti-antibody preparation (diluted in blocking solution with 0.5% Tween 20) 
was added. The plate was then washed at least 6 times with TBS-Tween before 
adding 50 pi of a 1 mg/ml solution of 4-nitrophenyl phosphate in AP buffer to each 
well and incubating for approximately 4 hours.
The reaction was stopped with 50 pi of 0.4 M NaOH and the result was read at 405 
nm using an EL312 Bio-Kinetics Plate Reader (Bio-Tek Instruments).
2.4 Growth and Manipulation of Prokaryotic cells
2.4.1 Growth of Bacteria
Small colonies of bacteria were grown on L agar plates, containing the appropriate 
antibiotic. When necessary these plates were impregnated with X Gal by carefully 
spreading out 100 pi of X Gal stock solution and leaving to dry at 37°C.
Large scale cultures of DS941 bacteria were grown in an orbital shaker at 37°C 
using L broth supplemented with the appropriate antibiotics. This required 25 pg 
streptomycin per millilitre of culture.
2.4.2 Storage of Bacteria
For long term storage of bacteria 0.5 ml of an overnight culture were added to 0.5 
ml filter sterilised 30% glycerol and immediately frozen to -70°C.
2.43  Transformation of Bacteria
Transformations of bacteria were performed by electroporation using competent 
cells.
(1) Preparation o f competent cells
The recipient bacterium for all electroporations was E.coli, strain DS941. These 
cells were initially prepared for electroporation by adding a 10 ml overnight culture 
to 1 litre of L Broth and growing to mid logarithmic phase (at about an OD600 of 
0.6). This took about 2 hours. The cells were then pelleted at 5,000 rpm for 15 
minutes using a JA14 rotor in a J2-21. This washing procedure was repeated several 
times. At each subsequent washing step the cells were resuspended in a smaller 
volume. The final wash used ice-cold 10% glycerol and the cells were then 
resuspended in 2 ml of 10% glycerol and aliquots of 100 pi were frozen to -70°C. 
The cells remained competent for several months using this procedure.
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(2) Electroporation
Prior to electroporation 40 pi of competent bacteria were placed in ice cold, sterile, 
cuvettes with electrodes set 2 mm apart. An aliquot of 2 pi containing 
approximately 40 ng of the DNA to be electroporated was then introduced. Care 
was taken to ensure that the DNA solution was free from salts. This was achieved 
by ethanol precipitating all DNA solutions before electroporation. The DNA was 
left with the bacteria in the cuvettes for about 2 minutes.
To electroporate the bacteria, a Gene Pulsar (Bio-Rad) set at 2.5 kV, 25 pF and 
200 Q was used. These parameters allowed the delivery of a pulse of approximately 
3.9 msec duration. After the pulse the cells were resuspended as rapidly as possible 
in 1 ml of L Broth containing ampicillin (100 pg/ml) and were then incubated for 1 
hour in an orbital incubator set at 37°C. The cells were pelleted and resuspended in 
0.5 ml of fresh L Broth. This suspension was spread out on an agar plate containing 
a selective antibiotic and, if appropriate, X-Gal.
(3) Identification o f recombinants
To screen transformed bacteria for the presence of recombinant plasmids, colonies 
were picked from the agar plates and spread out in small patches on another L agar 
plate impregnated with ampicillin (100 pg/ml) and streptomycin (25 pg/ml). This 
plate was then incubated at 37°C overnight. The patches were scraped off with 
sterile toothpicks and resuspended in 100 pi of STET solution (see Standard 
Solutions above). A 10 pi volume of lysozyme solution (10 mg/ml) was added to 
each and the suspensions were left for 15 minutes at room temperature before being 
plunged into boiling water for exactly 40 seconds. The chromosomal DNA and 
associated protein were pelleted by centrifugation in a benchtop centrifuge at 
15,000 rpm for 15 minutes. The supernatant was removed carefully and 10 pi was 
analysed by agarose gel electrophoresis. The remainder of the supernatant was 
diluted with 3 volumes of water, then ethanol precipitated for restriction enzyme 
digests.
2.5 Growth and Manipulation of Eukaryotic cells
2.5.1 QN10S cells
The cells, which attach firmly to plastic, were subcultured by carefully washing 
once in PBS-EDTA and then once in 0.025% trypsin in PBS-EDTA before adding 
more trypsin / PBS-EDTA (5 ml per 75 cm2 tissue culture flask). They were seeded 
for routine maintenance at 1 x 106 per 75 cm2 flask and were subcultured twice a 
week.
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Infections of QN10S cells with FeLV were performed using 12-well tissue culture 
trays containing 22 mm diameter wells. The cells were subcultured the day 
previously and seeded at a density of 4 x 104 per well. The virus was inoculated 
into 1 ml of cell supernatant enriched with 4 pg/ml polybrene. The cells were 
incubated at 37°C for 2 hours with occasional agitation and the inoculum was then 
replaced with fresh medium. Foci of transformed cells were usually visible 5 days 
post infection. To ensure accurate estimation of foci numbers the foci were counted 
microscopically 6 days post infection. The plates were drained of their medium 7 
days post infection and the cells fixed and stained in 0.5% (w/v) crystal violet in 
4% formaldehyde. The plaques were then visible to the naked eye and were 
recounted. Occasionally this stage was not possible as the plaques were too large to 
be distinguished.
2.5.2 Sf9 cells
These cells, which only loosely adhere to plastic, were subcultured by removing the 
medium and gently scraping the cells into fresh medium with a plastic scraper. For 
general maintenance, 5 x 106 cells were inoculated into a 75 cm2 tissue culture 
flask. The cells were subcultured on the day they became confluent to prevent them 
from becoming overgrown and detaching from the plastic surface. The cells 
required subculturing every 3 days or so using this density.
For transfections and infections the following densities were seeded the previous 
day: 1 x 106 per 25 cm2 flask; 3 x 106 per 75 cm2 flask; 4 x 105 per well of a 6-well 
dish. These densities gave a thin covering of cells that allowed at least 4 days of 
subsequent growth. After overnight incubation the medium was gently removed and 
a small volume of diluted virus (e.g 5 ml in a 75 cm2 flask) was inoculated and 
incubated for 2 hours at 27°C before replacing with fresh medium. For maximal 
virus production 0.1 plaque forming unit per cell was inoculated.
To assay for p galactosidase activity in cells the supernatant was removed and the 
cells were fixed in a solution containing 2% formaldehyde and 0.2% glutaraldehyde 
in PBS for 10 minutes at 4°C. They were then washed twice before staining for 30 
minutes with 50 mM potassium ferricyanide, 50 mM potassium ferrocyanide, 20 
mM MgCl2 and 0.4 mg/ml X-Gal in PBS.
(1) Transfection o f plasmid DNA
A  standard calcium phosphate precipitation technique (Sambrook et al. 1989) was 
found to be effective for all transfections involving Sf9 cells. Approximately 20 pg 
of plasmid DNA and 1 pg of wild type AcMNPV DNA were added to a CaCl2 
solution to make a solution with a final volume of 0.5 ml and a CaCl2 concentration
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of 250 mM. A volume of 0.5 ml of 2 x HEPES buffered saline was then added drop 
by drop. A faint cloudy precipitate normally developed over a period of 30 minutes. 
After this time the suspension was added, with 5 ml of fresh medium, to a 75 cm2 
flask of cells in the mid-logarithmic phase of growth. The cells were incubated for 
2 hours and then were gently washed with medium. The cells were then maintained 
in fresh medium and examined daily for the presence of polyhedrin.
2.6 Growth and Manipulation of Viruses
2.6.1 FeLV
To ease the handling of FeLV, aliquots of high titre FeLV stocks were diluted 1 
part in 10 with fresh medium and stored at -70°C. The diluted stocks were then 
titrated once, using QN10S cells, and then at regular intervals afterwards. No 
decrease in titre was observed in viruses so handled. Once thawed the aliquots of 
the diluted virus were discarded after use.
2.6.2 AcMNPV
Most of the techniques used in course of this work are similar to those described in 
a recently published account of the general laboratory handling of baculoviruses 
(King and Possee, 1992).
To prepare a stock of AcMNPV (either wild type or recombinant) a confluent 225 
cm2 flask of Sf9 cells (which contains about 6 x 107 Sf9 cells) was subcultured into 
8 similar flasks and the cells were grown to approximately 60% confluence, before 
infecting with 0.1 pfu AcMNPV per cell. The flasks were incubated for 5-7 days at 
27°C before harvesting the cells and supernatant into 50 ml polypropylene tubes. 
The supernatant was clarified by centrifugation at 3500 rpm for 10 minutes in a J2- 
21 and was then stored at 4°C. Most virus stocks were not filtered.
All baculoviruses were routinely stored at 4°C. The stocks were then titrated once, 
using Sf9 cells in a 6-well tissue culture flask without an agarose overlay, and then 
at regular intervals afterwards. A decrease in titre of approximately five-fold was 
observed over a period of 6 months with viruses stored in this manner. For long­
term storage, concentrated stocks (see below) of the viruses were frozen at -70°C. 
Storage of unconcentrated stocks in this manner resulted in 1,000-fold decrease in 
titre. The lack of a convenient method of long term storage is a minor disadvantage 
of this system. In general the titres achieved by this route were the same as those 
published (approximately 1 x 107 to 5 x 107) (King and Possee, 1992).
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(1) Manufacture o f concentrated AcMNPV stocks
Concentrated AcMNPV stocks are required for the production of DNA and long­
term storage of the virus. To prepare these stocks the virus was pelleted from 200 
ml of virus stock with a titre of greater than 107 pfu/ml by centrifugation at 20,000 
rpm for 1.5 hours using JA 20 rotor. The pellets were soaked overnight in a small 
volume of TE.
The next day, the virus was resuspended by vigorous pipetting and the resulting 
suspension was layered onto a sucrose gradient formed by pipetting 3 ml of 10% 
sucrose in TE onto a 2 ml cushion of 50% sucrose. The virus was purified by 
centrifugation at 24,000 rpm for 1 hour using a SW40 rotor. The thin translucent 
layer of viral particles at the interface of the sucrose layers was harvested with a 
hypodermic needle and syringe using strong overhead illumination.
The virus was then diluted 1 : 5 with TE and pelleted at 30,000 for 1 hour in a 
SW50 rotor. The viral pellet was then soaked overnight in TE and resuspended the 
next day. The concentrated viral suspensions were stored at 4°C.
(2) Preparation o f AcMNPV DNA
To prepare AcMNPV DNA for transfection about 200 pi of the purified virus was 
incubated with 200 pi TE and 100 pi 20% sarkosyl in TE at 60°C for 30 minutes. 
The reaction mix was then layered on top of a solution of 54% caesium chloride 
with 25 pg/ml ethidium bromide in polycarbonate centrifuge tubes for the SW50 
rotor. The DNA was separated from the viral proteins by centrifugation at 35,000 
rpm overnight at 20°C. 20 pg of AcMNPV transfer vector was used as a control. 
The band of viral DNA was visualised and harvested under UV light. Butanol was 
used to remove the ethidium bromide followed by overnight dialysis to remove the 
caesium chloride. The quantity and quality of DNA was measured by 
spectrophotometry at 280 nm and 260 nm.
To prepare AcMNPV DNA for PCR, 10 pi of concentrated stock was lysed by 
plunging into a bath of boiling water with 90 pi TE for 4 minutes. These 
preparations were used as 10,000 x stocks for use as PCR templates.
Initial difficulties were encountered in the preparation of viral DNA for 
transfection. By allowing the cells to become 60% confluent and infecting with a 
relatively high multiplicity of infection, higher titres were achieved which allowed 
the production of the DNA. From eight 175 cm2 tissue culture flasks approximately 
20 pg of AcMNPV DNA was isolated.
57
(3) Plaque purification
Several methods have been proposed to purify recombinant from wild type 
baculoviruses. Several attempts using a limiting dilution protocol were all 
unsuccessful and the remainder of the purifications were achieved with a 
modification version of the agarose overlay technique (Brown and Faulkner, 1977).
To perform these purification steps the Sf9 cells were seeded at a density of 5 x 105 
cells per well of a 6-well dish and incubated overnight. The following day the cells 
were infected with serial tenfold dilutions of the virus. Whilst the cells were being 
infected, a 1.5% low melting point agarose gel was made by melting 3 g low 
melting point agarose in 100 ml PBS, cooling to 37°C and adding an equal volume 
of prewarmed medium. The virus inoculum was removed after 2 hours and 1.5 ml 
of the gel was added and allowed to cool. Before adding the gel the temperature 
was carefully monitored to ensure that it was less than 32°C. After the gel had 
solidified a further 1.5 ml of fresh medium was added. As the normal X-Gal 
staining technique was not applicable to these assays, after 2 days the liquid 
medium was carefully replaced with fresh medium containing 80 pg/ml of X-Gal. 
For the following 2 days the wells were carefully examined for the development of 
blue plaques which were then examined microscopically. Those which contained 
the least polyhedrin positive cells were picked by removing the medium and 
carefully sucking up a plug of agarose and the underlying medium using a pastette. 
The plug was then introduced into 1 ml of fresh medium and was used as the stock 
for the next round of purification.
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Chapter 3. Production of Recombinant Viruses
3.1 Introduction
The major aim of this project was to produce recombinant baculoviruses which 
expressed SU of FeLV subgroups A, B and C. The optimal expression of a gene in 
the baculovirus system requires the production of a stock of pure recombinant 
virus. This chapter details the generation and analysis of recombinant baculoviruses 
containing sequences coding for these FeLV SUs.
The transfer vector used in this system contained two promoters active in insect 
cells. The plO promoter was employed to generate a selectable marker, p 
galactosidase, and the polyhedrin promoter was used to produce the FeLV SUs. A 
series of preliminary experiments were performed to establish if functional FeLV-A 
SU could be produced in the baculovirus system using this multiple expression 
vector. On the basis of the results, fragments of each SU were generated by PCR 
and then were inserted into a modified transfer vector. The resulting recombinant 
viruses were examined for the presence of the correct SU coding sequence using 
PCR and restriction enzyme analyses.
The production of a recombinant baculovirus which served as a negative control is 
also described. This baculovirus contained the sequences coding for the SU portion 
of the feline immunodeficiency virus (FIV) env gene. As the virus was made using 
the same transfer vector it also contained the lacZ gene for generation of p 
galactosidase.
3.2 Preliminary Experiments
Preliminary experiments were performed to investigate the ability of the 
baculovirus expression system to produce FeLV-A SU. No attempt will be made 
here to detail all the techniques used as they will be discussed at length below. 
Experiments which utilised other expression systems will also be briefly 
mentioned.
3.2.1 Baculovirus Expression System
Initially, all of the FeLV env gene was subcloned as a Pst 1 fragment from pFGA 
(Stewart et al., 1986) into the pBluescript vector by Dr. N. Spibey. The resulting 
plasmid, called pBMAewv (see Figure 3.4), was analysed using restriction enzymes. 
From this plasmid, all of the FeLV-A SU coding sequence and the non-anchoring 
portion of TM was subcloned as a Bam HI / Apa 1 (blunted) fragment into a 
preparation of Bam HI / Sna B1 digested pAcLacZ+ vector. The recombinant 
pAcLacZ+ vector (pAcA9) was co-transfected with wild type baculovirus DNA
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into Sf9 cells. The supernatant was harvested 4 days later. The cells were fixed and 
then were stained with X-Gal, as described in Chapter 2. This demonstrated that 
recombinant viruses had been produced. A sandwich ELISA (described in detail in 
section 3.3.3) demonstrated the presence of recombinant gp70 in the supernatant. 
The recombinant virus was designated AcA9.
Using a limiting dilution technique, many attempts were made to purify AcA9 with 
limited success. These results suggested either that AcA9 was dependent upon a 
wild type, helper virus, or that the purification technique was inefficient. Two 
consecutive plaque purifications using agarose overlays did not produce a helper 
independent stock. Conversations with Dr. R. Possee suggested that the deletion of 
the small segment between the Bam HI and Sna B1 sites was likely to be of 
functional significance.
Despite these problems, a large stock of AcA9 virus was produced and was used to 
infect cells at a high multiplicity. Recombinant FeLV gp70 was demonstrated in the 
supernatant by western blot with the monoclonal 3-17AP. This result prompted 
attempts to generate helper independent, pure, recombinant baculovirus stocks.
3.2.2 Other Expression Systems
Two other expression systems were tried in tandem with the early baculovirus 
system experiments.
The pSVL transient expression vector (Pharmacia) contains the SV40 promoter and 
is reported to work well in COS cells (Templeton and Eckhart, 1984). A Bam HI / 
Tha 1 fragment of FeLV env (which includes all of SU and 15 codons of TM) was 
inserted into the pSVL plasmid to form pT6. However, on transfection of pT6 into 
COS cells no product was detected in the supernatant. No further attempts at 
expression were made using this system.
Attempts were also made to express short fragments of FeLV env using the 
inducible prokaryotic vector, pGEX-2T (Smith and Johnson, 1988). This vector 
generates glutathione-S-transferase fusion proteins. Fragments corresponding to the 
sequences between nucleotide numbers 278 & 532 and 278 & 957 (Stewart et al, 
1986) were amplified by PCR. The fragments were then inserted into pGEX-2T. 
Fusion proteins were expressed, but in preliminary experiments did not appear to 
interfere with viral entry or with the action of neutralising antibodies.
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3.3 Results
3.3.1 M anufacture of Recombinant pAcLacMCS Plasmid
The results from the preliminary experiments were sufficiently encouraging to 
suggest modification of pAcLacZ+ by the insertion of a multiple cloning site 
(MCS) at the Bam HI site. Complimentary synthetic oligonucleotides, 5’ GAT CCC 
TGC AGC CCG GGT CTA GAC CGC GGG GTA CCA 3' and 5' GAT CTG GTA 
CCC CGC GGT CTA GAC CCG GGC TGC AGG 3’ were incubated at 90°C for a 
period of 1 hour in Klenow buffer then allowed to cool to 40°C over a period of 2 
hours. The annealed products were purified by acrylamide gel electrophoresis and 
spin membrane centrifugation (SPIN-X, Costar). The products were ligated into a 
preparation of Bam HI cut pAcLacZ+ which had been purified by agarose gel 
electrophoresis and electroelution. These oligonucleotides introduced Pst 1 and Sma 
1 sites, as well as preserving the Bam HI site. Additional, non-unique, sites were 
introduced for Xba 1, Sst 11 and Kpn 1 to allow easier restriction enzyme analysis of 
the resulting recombinant plasmids. Multiple copies of the MCS were removed by 
Dr. N. Spibey by digestion with Pst 1. The products from this reaction, after 
purification by agarose gel electrophoresis and electroelution, were then religated. 
The restriction enzyme sites of the resulting plasmid, designated pAcLacMCS (see 
Figure 3.1), were checked with an extensive selection of enzymes. A sample of 
these digests is presented in Figure 3.2.
To confirm that pAcLacMCS could produce pure recombinant virus a Bam HI / Apa 
1 (blunted) fragment of FeLV-A env was subcloned from pBMAe/iv (see section 2.1 
above and Figure 3.4), into a preparation of Bam HI / Sma 1 digested pAcLacMCS. 
The resulting recombinant transfer vector, pAcA22, was co-transfected with wild 
type baculovirus DNA into Sf9 insect cells. The recombinant virus, termed AcA22, 
was purified from the supernatant using 5 rounds of a plaque purification technique 
(Brown and Faulkner, 1977) modified as described in Chapter 2. A titrated stock 
was then used to infect 10 large (225 cm2) tissue culture flasks each containing 2 x 
107 cells at about 30% confluence and a multiplicity of infection of 0.15. After 
infection the virus inoculum was removed and replaced with SF900 serum free 
medium. The supernatant was harvested 5 days later and was concentrated by 
ultrafiltration (see Chapter 4). Expression was demonstrated by several of the 
techniques, described in Chapter 4. Early experiments with neutralisation inhibition 
(Chapter 5) and infection interference (Chapter 6) assays were also performed, with 
promising results.
A similar cloning strategy was followed with a Bam HI / Sst 11 fragment of FeLV 
env (which includes all of SU and 15 codons of TM). Several pure recombinant
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Figure 3.2 Restriction enzyme digests of the pAcLacMCS vector
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To confirm the insertion of a multiple cloning site into the vector 
pAcLacZ+ an array of restriction enzyme digests was perform ed. 
Aliquots of 2 pg of each plasmid were incubated with 5 units of each 
enzyme in the appropriate buffer for a period of 2 hours. The products 
were separated by 1% agarose gel electrophoresis. The photograph is of 
the ethidium bromide stained gel.
Key
K = Kpn  1, P = Pst 1, S = Sma 1, X= X ba  1, U = Uncut, m/m2 = 
molecular mass markers
viruses were produced but no secreted SU was ever demonstrated in the 
supernatants of infected cells. No investigation was undertaken to determine the 
reason for this lack of expression.
On the basis of these experiments a stratagem was developed to express all 3 FeLV 
subgroup SUs using the pAcLacMCS transfer vector. It was decided that the SU 
fragments would be generated by PCR as the env gene of subgroups B and C do not 
possess convenient restriction sites. The use of this technique would also facilitate 
the inclusion of sequences conferring specific activity on the recombinant proteins 
and consequently would permit purification by exploitation of that activity. The 
addition of 6 histidine residues would allow the use of a nickel-nitrilotriacetic acid 
adsorbent with bound nickel to affinity purify the proteins from the supernatants of 
infected cells (Hochuli et al., 1987). This adsorbent had previously worked well in 
the purification of recombinant HIV nef produced using the baculovirus system in 
the Department of Veterinary Pathology (Harris and Coates, 1993).
33 .2  Manufacture of Recombinant pAcLacMCS Transfer Vectors
The oligonucleotides that were used in the PCR reactions described below are 
defined in Figure 3.3. The cloning strategy that was used is illustrated in Figure 3.4.
Preparative PCRs were performed with the following parameters; annealing, 55°C, 
1 minute; extending 72°C, 5 minutes; denaturing, 90°C, 1 minute. The reactions 
were introduced into the thermal cycler once the recorded temperature reached 
80°C. This hot start technique is believed to increase the specificity of the reaction 
(Erlich et al, 1991). Each reaction was performed in quadruplicate. At the end of 
the reaction a 10 pi aliquot was analysed by agarose gel electrophoresis and the rest 
of the reactions were pooled, phenol extracted and then ethanol precipitated. The 
PCR products were digested, first with Bam HI, and then with Sma 1. The digested 
products were then purified by agarose gel electrophoresis, followed by 
electroelution.
Using PCR as defined above, fragments of the env genes of the proviral clones 
pFGA, pFSC and two A/C chimeras pV215 and pVC (Rigby, 1989) were generated 
with 6 histidine residues and stop codons at their carboxy termini. These fragments 
included all the SU and the TM sequences as far as the Apa 1 site in FeLV-A env 
(nucleotide number 1838; (Stewart et al., 1986)) which code for the first 147 amino 
acids at the amino terminus. The fragments did not include the anchoring 
transmembrane region and were referred to as AHS, CHS, 215HS and VCHS 
respectively. They were all cloned directly into a preparation of Bam HI / Sma 1 
digested pAcLacMCS which had been purified by agarose gel electrophoresis 
followed by electroelution. The recombinant plasmids, called pAcAHS, pAcCHS,
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pAcVCHS and pAc215HS respectively, were purified on a caesium chloride 
gradient.
On attempting to repeat this cloning procedure using a pFGB template to produce 
the equivalent FeLV-B SU fragment, BHS, the PCR produced two species of 
product. One, as expected, was 1.8 kbp; the other was approximately 500 bp. The 
yields of the larger species could not be improved despite altering a number of 
parameters. Attempts at ligating the digested, gel purified product directly into 
pAcLacMCS failed. The fragment was, however, successfully subcloned into 
pBluescript. The resulting recombinant plasmid, pBMBHS, was analysed using 
multiple restriction enzyme digests, confirming that the insert was of the correct 
size and orientation. The BHS fragment was then subcloned into pAcLacMCS as a 
Bam HI / Sma 1 fragment to generate pAcBHS.
To distinguish between the recombinant transfer vectors, each was digested with 
Eco R1 and Hind 111. The results of these digests are presented in Figure 3.5 (A). 
They show that all of the recombinant plasmids, but not the parent plasmid, have a 
1.8 kbp insert between the two Eco R1 sites either side of the multiple cloning site. 
This result confirmed that the inserts were of the correct size. The Hind 111 digests 
show that pAcLac-AHS, -VCHS and -215HS have a Hind 111 site approximately 0.5 
kbp from their 5' terminus. The vector containing the FeLV-C SU insert, pAcLac 
CHS, produced a different pattern of fragments confirming the existence of the 
Hind 111 site near nucleotide 1100 (Riedel et al.f 1986) of the insert: pAcLacBHS 
has no Hind 111 sites in the insert.
These results are entirely in accordance with predictions based on available 
sequence data. Results with Acc 1, Cla 1, Apa 1, Bgl 11 and Kpn 1, were also in 
agreement with expectations (data not shown).
As the A/C subgroup phenotype is determined by a small region delineated by the 
Hinc 11 and Hind 111 sites (nucleotide numbers 276 and 532) (Rigby, 1989), the 
integrity of this region is vital to any experiments which investigate differences 
between these two subgroups. To demonstrate that the recombinant pAcLacMCS 
clones contained the same size of Hind 111 / Hinc 11 fragments as the proviral clones 
from which they were derived, a double digest was performed and the products 
were analysed on an 8% acrylamide gel (see Figure 3.5(B)). This experiment 
showed that a fragment of approximately 250 bp was absent from pAcLacCHS and 
pFSC and exhibited some size differences between the others. This fragment 
represents the 276-532 nucleotide region. The fragment from pAcAHS is slightly 
larger than that from pAcVCHS, which in turn is slightly larger than that from 
pAc215HS. The differences are also seen in the proviral clones. Analysis of
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Figure 3.5 Restriction enzyme digests of plasmid clones
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A. To distinguish between the 5 recombinant pAcLacMCS clones and the parent 
plasmid 2 pg of each plasmid was digested with 5 units of 2 restriction enzymes 
(jEco Rl and Hind 111) in the appropriate buffer. Undigested controls were also 
included. The products were separated on a 1% agarose gel using 40V overnight. 
The photograph shows the ethidium bromide stained gel.
Lanes: 1 = parent pAcLacMCS, 2 = pAcLacAHS, 3 = pAcLacBHS, 4 = 
pAcLacCHS, 5 = pAcLacVCHS, 6 = pAcLac215HS, m/m2 = molecular mass 
markers.
Figure 3.5(continued) Restriction enzyme digests of plasmid clones
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B.  To distinguish the pAcLacMCS recombinants containing FeLV-A, FeLV-C 
and the two A/C chimeras, a double digest with the restriction enzymes Hinc 
11 and H ind  111 was performed on 5pg of plasmid. The products were 
separated on an 8% acrylamide gel using 50 V for 4 hours. Controls using the 
original proviral clones were performed in tandem. The photograph was then 
taken of the ethidium bromide stained gel.
Lanes: 1 = pAcLac215HS / pV215, 2 = pAcLacV CHS / pVC, 3 = 
pAcLacCHS / pFSC, 4 = pAcLacAHS / pFGA, m = molecular mass marker.
available sequence data suggested that the fragments from pAcLacVCHS and 
pAc215HS should be of the same size. This indicated that the original proviral 
clones might not be of the expected sequence.
DNA sequencing was performed using a commercial kit (Sequenase, Stratagene), as 
described in Chapter 2, to determine the sequences between the Hind 111 and Hinc 11 
sites of the two chimeric proviruses. Each strand of DNA was sequenced 
separately. Sequencing revealed that the sequences were identical to the published 
sequences (Rigby, 1989; Rigby et al„ 1992). It was tentatively concluded that the 
apparent anomalies in fragment size observed on the polyacrylamide gel (Figure 
3.5(B)) were due to the effects of secondary structure.
Using a mixture of multiple restriction enzyme digests and direct sequencing the 
recombinant pAcLacMCS vectors had been confirmed as containing the desired 
inserts in the correct orientation.
3.3.3 Production of Recombinant Viruses
The recombinant pAcLacMCS transfer vectors, pAcAHS, pAcBHS, pAcCHS, 
pAcVCHS and pAc215HS, were co-transfected with wild type baculovirus DNA 
into Sf9 insect cells. Following transfection the Sf9 cells were monitored twice 
daily for the presence of polyhedrin. Once numerous polyhedrin crystals could be 
seen, but before the majority of the cells had become infected, the supernatants 
were harvested by centrifugation at 3500 rpm for 10 minutes in a GPR bench 
centrifuge and then stored at 4°C. The cells were fixed and then stained with X-Gal. 
On microscopic examination approximately 5% of the cells were positive for |3 
galactosidase expression, indicating that recombinant viruses had been produced. 
The transfectant supernatants had average titres of approximately 104 pfu/ml.
The recombinant viruses were purified from the wild type viruses by a plaque 
purification technique (Brown and Faulkner, 1977) modified as described in 
Chapter 2. The p-galactosidase enzyme encoded in the recombinant viruses acted 
upon the colourless substrate X-Gal to produce a blue product allowing convenient 
selection of the recombinant viruses. An illustration of the stained cells is shown in 
Figure 3.6. Several plaques were picked from each round of purification. To 
achieve complete purification of the recombinant viruses 4 to 5 rounds of plaque 
purification were necessary.
During several stages of the purification procedure the stock of semi-purified 
recombinant virus was used to infect a 25 cm2 tissue culture flask containing Sf9 
cells at about 30% confluence. After infection the medium was removed and 
replaced with the serum free medium, SF900 11. The supernatant was harvested 3
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Figure 3.6 Sf9 cells infected with a mixture of recombinant and wild 
type viruses
m
4
The colour photograph shows Sf9 cells that were infected at sub-confluence 
with a mixture of recombinant (lacZ positive) and wild type viruses. The cells 
were left for 4 days post-infection before fixing with 2% formaldehyde and 
0.2% glutaraldehyde and then staining with X-Gal. No agarose overlay was 
used in this experiment.
Some of the cells can be seen to contain small refractile crystals of polyherin, 
other cells are stained blue by the X-Gal. A few cells contain the polyhedrin 
crystals and are stained blue.
days later and concentrated using cellulose acetate miniconcentrators with a 
nominal molecular weight cut off of 30 kDa (Millipore). An aliquot of this 
concentrated supernatant was then used in a sandwich ELISA using the polyclonal 
anti-gp70 rabbit #709 serum and the anti-gp70 monoclonal antibody 3-17AP.
This ELISA was performed using the general method described in Chapter 2. The 
plate was washed with TBS-Tween between stages. A 1 in 1,000 dilution of the 
rabbit #709 serum in coupling buffer was used to coat the wells of a ELISA 
microtitre plate. The wells were incubated with blocking solution (3% Marvel in 
TBS) for a period of 2 hours and the antigens, diluted in 1% empigen in TBS, were 
then added. After a period of 3 hours, the wells were incubated with a 1 in 1,000 
dilution of the alkaline phosphatase conjugated monoclonal antibody, 3-17AP, for a 
further hour. The assay was developed with 4-nitrophenyl phosphate in AP buffer.
The positive control used in this ELISA was a glutathione-S-transferase fusion 
protein (GST-E) which contained the oligopeptide previously defined as a 
neutralising epitope on gp70 (Elder et al, 1987). The negative control used was a 
fusion protein (GST-G) which contained an oligopeptide derived from the VR 1 
region (Rigby, 1989). These controls (obtained from Dr.N.Spibey) were used 
because native gp70 was found to be recognised relatively inefficiently in this 
assay. Control protein preparations derived from uninfected and wild type infected 
Sf9 cells were also included in this ELISA. These controls were designated C5 and 
C6 respectively.
Using this ELISA, recombinant FeLV SU was demonstrated in the supernatants 
from the pAcAHS, pAcCHS, pAcVCHS and pAc215HS / wild type DNA co­
transfections. The positive control fusion protein, GST-E, reacted well: the negative 
control fusion protein, GST-G, did not react. No reaction was demonstrated with 
the control protein preparations C5 and C6 in this ELISA.
The supernatant from the pAcBHS / wild type AcMNPV co-transfection did not 
contain a detectable env product. Despite several attempts with a number of plaque 
purified isolates no recombinant protein could be demonstrated. No further analyses 
were undertaken.
The purified recombinant viruses which were freed of polyhedrin contamination 
were used to generate large volumes of high titre stocks for use in protein 
production work. Typically these stocks had titres in the range 2 x 107 to 8 x 107 
pfu/ml. Concentrated stocks of virus were also made and then were used to prepare 
viral DNA for PCR purposes, as detailed in Chapter 2.
The recombinant viruses were termed AcAHS, AcCHS, AcVCHS and Ac215HS
i
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respectively. The recombinant SU proteins produced were designated Bgp70-A, -C, 
-VC and -215 respectively.
3.3.4 Confirmatory PCR Reactions and Digests
As mutations can occur during recombination and stocks of viruses can become 
contaminated it was decided to confirm that the recombinant viruses contained the 
correct FeLV coding sequences. This was achieved by initially generating 
fragments of FeLV VR1 from the recombinant baculoviruses by PCR. Several 
attempts were made to sequence the PCR products directly, without success. In the 
light of this failure, it was decided to use restriction enzyme digests of similar PCR 
products to partially confirm the identity of the recombinant viruses.
Two sets of PCRs were performed in tandem on each of the original proviral 
plasmids, the recombinant pAcLacMCS clones and the DNA obtained from the 
concentrated stocks of purified recombinant viruses. The reaction conditions for the 
PCRs were; annealing, 55°C, 1 minute; extending 72°C, 1 minute; denaturing, 
90°C, 1 minute. The reactions were allowed to proceed for 30 cycles. Aliquots of 
10 pi from each reaction were analysed by agarose gel electrophoresis. The 
remaining products were purified by phenol extraction followed by ethanol 
precipitation. Restriction enzyme digests were performed on the purified products. 
The first set of reactions used the oligonucleotide primers 18 and MR 14 (see 
Figure 3.3), followed by digestion with Hind 111. the second set used the 
oligonucleotide primers 7 and MR 14, followed by digestion with Bgl 11.
The results of the first set of reactions (18 + MR 14) are shown in Figure 3.7 (A). 
The PCR products showed some differences in size, the AcAHS product being 
noticeably smaller than the AcCHS product, contrary to expectations based on their 
predicted sequence. These differences were also seen in those reactions that used 
the proviral clones or the pAcLacMCS clones as templates. This result suggested 
that secondary sequence structure, which affected the results shown in Figure 3.5 
(B), might also have influenced the outcome of this analysis. Digestion of the 
products of these reactions with Hind 111 is shown in Figure 3.7 (B). Although 
incomplete digestion had occurred, it was clear that AcAHS, AcVCHS and 
Ac215HS had Hind 111 sites whereas AcCHS had not.
The results of the second set of reactions are shown in figure 3.7 (C). Again size 
differences were observed which did not agree with expectations based on sequence 
data. In these reactions the fragments from AcAHS and AcCHS appeared to be of 
the same size, AcVCHS and Ac215HS being smaller. These differences were also 
seen in those reactions that used the proviral clones or the pAcLacMCS clones as 
templates. This suggested that secondary sequence structure might again be
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Figure 3.7 Restriction enzyme digests of PCR products from 
recom binant viruses
kbp m l  2 3 4 m 1 2 3 4 m 1  2 3 4 m N
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A. 1 ng of template was added to a PCR reaction mix containing primers 18 
and MR 14 and the reaction allowed to proceed for 30 cycles under standard 
conditions. An aliquot of 10 pi of each 300 pi reaction was analysed by 8% 
PAGE using 100 V for 4 hours. The photograph is of the ethidium bromide 
stained gel.
B.  Following the above PCR, the remaining products were phenol extracted, 
ethanol precipitated and then resuspended in the appropriate buffer. Each 
was then digested with 5 units of Hind 111. The products were separated as 
above.
Block X represents reactions that used the original proviral clones as 
templates, block Y the recombinant pAcLacMCS vectors and block Z the 
recombinant AcMNPVs.
Lanes: 1 = A (pFGA/ pAcLacAHS/AcAHS) 2 = C (pFSC etc.), 3 = VC 
(pVC etc ) 4 = 215 (pV215 etc.) m = molecular mass markers, N = no 
template added.
influencing the result. Digestion of the products with Bgl 11 is shown in Figure 3.7 
(D). The digest was incomplete. This gel demonstrated that the products derived 
from AcVCHS and AcCHS contained Bgl 11 sites. The products derived from 
AcAHS and Ac 215HS did not.
This pair of reaction sets demonstrated specific differences between the 
recombinant viruses, suggesting that they did contain different FeLV SU coding 
sequences. The variations in the restriction enzyme profiles were in accordance 
with expectations. This partially confirmed the identity of the recombinant viruses. 
To confirm fully that each VR 1 sequence had been preserved intact sequencing of 
the PCR products would be necessary. As direct sequencing failed, in the future it 
would be prudent to clone the products into plasmids and then sequence the 
products.
3.3.5 Production of Control Recombinant Baculovirus
It was decided that an additional control protein preparation would be required in 
cell binding studies which contained (3 galactosidase and an irrelevant recombinant 
retroviral SU protein. The availability of the FIV SU coding sequence of the UK8 
isolate greatly assisted the generation of such a preparation.
The SU coding sequence was subcloned from the plasmid p i-10 as a Bam HI / Eco 
RV fragment. This fragment was purified by agarose gel electrophoresis and 
inserted into a similarly purified Bam HI /  Sma 1 digested preparation of the 
pAcLacMCS vector. The resulting recombinant plasmid, pAcFlO, was analysed 
with a panel of restriction enzymes (see Figure 3.8). The plasmid pAcFlO 
contained a 1.3 kbp Kpn 1 fragment in accordance with predictions based upon 
sequence data.
The plasmid was then cotransfected with wild type AcMNPV DNA and a pure 
stock of the recombinant virus was prepared by plaque purification as described 
above. This stock was named AcFlO. The ability of AcFlO to produce recombinant 
FIV SU was demonstrated by western blot as detailed in Chapter 4. The 
recombinant FTV SU was called BgplOO.
3.4 Discussion
This chapter describes the production by PCR of four recombinant baculoviruses 
containing fragments of FeLV env coding for the SU and part of the TM from 
FeLV-A, FeLV-C/Sarma and two A/C chimeric viruses, FeLV-A/C-Sarma and 
FeLV-A/C-FZ215 (Rigby, 1989). It also details the production of recombinant 
baculovirus which contained the coding sequence of the SU of the UK8 isolate of
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Figure 3.8 Restriction enzyme digests of pAcFlO
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To distinguish between the FIV e/rv-containing pAcLacMCS clone, pAc F10, 
and the parent plasmid 2 pg of each plasmid was digested with 5 units of 2 
restriction enzymes (Eco Rl and Kpn 1) in the appropriate buffer. Undigested 
controls were also included. The products were separated on a 1% agarose gel 
using 40V overnight. The photograph shows the ethidium bromide stained gel.
Lanes: E = Eco Rl cut plasmid, K = Kpn 1 cut plasmid, U = uncut plasmid, m/m2 
= molecular mass markers.
FIV. All the recombinant viruses contained the lacZ gene under the control of the 
plO promoter as a selectable marker.
PCR is a powerful method for generating large numbers of copies of a double 
stranded DNA template using oligonucleotide primers, a thermostable DNA 
polymerase and repetitive cycles of denaturing, annealing and extending. First 
developed as a method used in the diagnosis of sickle cell anaemia (Saiki et al, 
1985) it has since developed into one of the most widely used techniques in 
molecular biology. A recent review of current PCR technology has been published 
(Erlich et al, 1991).
The results from the Hinc 11 / Hind 11 double digest had initially suggested that the 
sequences of one or more of the proviral clones did not agree with published data. 
Direct DNA sequencing of the chimeric proviral clones failed to identify any such 
inconsistency. A mixture of PCR, multiple restriction enzyme digests and 
sequencing were then used to confirm the identity of the recombinant 
baculoviruses. This process was thought to be necessary as an error could have 
been introduced at several stages in the cloning process. The lack of proof reading 
function by Taq DNA polymerase, mutation during recombination and laboratory 
contamination were all potential sources of such errors.
The failure to produce Bgp70-B despite the presence of (3 galactosidase positive 
plaques may have been due to an error in cloning. Sequencing of the vector could 
be performed to identify any defect in the region of the polyhedrin promoter. 
Alternatively, there may be some block in the production of FeLV-B SU in insect 
cells. As the insert had its own leader and start codon, an error introduced by the 
PCR remains the likeliest explanation. This result reinforces the care with which 
this technique should be routinely used in cloning reactions. Another attempt 
should be made to generate Bgp70-B. The availability of such a protein would 
allow the augmentation of the studies reported in later chapters.
No detailed PCR analysis was attempted on the control recombinant virus, AcFlO, 
as the recombinant protein, BgplOO, expressed by it could be visualised on a 
western blot probed with the pooled infected cat serum P2 (data shown in Figure
4.3). The FeLV-A proteins did not react on similar western blots (data not shown). 
Such immunological techniques readily demonstrated that the control virus was 
distinct from the FeLV env containing viruses. The first description of the 
production of recombinant FTV SU using the baculovirus system has recently been 
published (Verschoor et al., 1993).
The AcFlO virus encoded for the SU protein of the UK8 isolate of FIV but, because 
the 5’ terminal 15 base pairs were derived from the Petaluma isolate, one amino
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acid was altered (a glutamine instead of a glycine) from the predicted UK8 
sequence. This amino acid change was in a conserved region of the protein (Rigby 
et al., 1993) and was therefore unlikely to be of significance. This change was 
introduced by the necessity of designing PCR primers based on the original (i.e 
Petaluma) sequence when the molecular cloning of the UK8 isolate was being 
performed. This alteration was subsequently corrected and the intact FTV/UK8 
sequence expressed in the baculovirus system by other workers in the Department 
of Veterinary Pathology (M.Rigby and A.Mackay, personal communication). There 
were no detectable differences in the immunological reactivity of the intact UK8 
recombinant SU protein when compared with the slightly altered UK8 recombinant 
protein (data not shown).
The inclusion of the lacZ gene under the control of the plO promoter allowed 
efficient selection of recombinant viruses. Plaque purification assays normally have 
to be left for 4-5 days before polyhedrin negative plaques can be seen (King and 
Possee, 1992). The use of the selectable marker reduced this time period to 2-3 
days. The use of the lacZ gene with the plO promoter in this manner has been 
reported by others (Vialard et al, 1990). The gene can also be controlled by the 
Drosophila melanogaster heat shock promoter (hsp70) (Zuidema et al, 1990).
During the course of this work the baculovirus expression system was developing 
rapidly. The use of linearised DNA, which is of relatively low infectivity, with a 
transfer vector that permits recircularisation, greatly increases the efficiency of 
recombination (Kitts et al, 1990). This is because the transfer vector allows 
recircularisation of the linear DNA, introducing the desired gene. The number of 
wild type viruses recovered is therefore low. A further development uses linearised 
DNA from a (3 galactosidase positive baculovirus to provide a selectable marker for 
the identification of recircularised, non-recombinant viruses. This development 
reduces the number of plaque purification steps required (Harris and Coates, 1993). 
Such a system has the added advantage of only producing one recombinant protein. 
However, there is no evidence that the production of |3 galactosidase interferes with 
the production of other recombinant proteins. The major disadvantages with this 
technology are the potential complications that would result from cross­
contamination of viruses produced using the two systems. In the above system (3 
galactosidase positive baculoviruses are produced which do not contain the desired 
gene. In the pAcLacMCS system the (3 galactosidase positive baculoviruses do 
contain the desired gene. As such it was considered unwise to use the two systems 
simultaneously.
The very recent introduction of a method for the rapid production of recombinant 
baculovirus DNA in prokaryotic cells may also prove to be a valuable addition to
69
the system (Luckow et al., 1993).
In conclusion, recombinant baculoviruses were produced which expressed 
truncated FeLV env genes from subgroups A and C. Baculoviruses which expressed 
the truncated env genes of two FeLV-A/C chimeras were also produced. The 
baculovirus system was found to be convenient and reliable to use. It was therefore 
decided to further investigate the production of recombinant surface glycoproteins 
in this system.
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Chapter 4. Production of Recombinant Proteins
4.1 Introduction
This chapter describes the production, concentration and purification of one of the 
recombinant proteins, Bgp70-C, using the baculovirus AcCHS. Attempts to 
quantify the amount of recombinant protein produced are also discussed.
Having established a protocol for the production of Bgp70-C, it was possible to 
perform large scale preparations of each of the four recombinant FeLV SUs. The 
manufacture of three control protein preparations is also described.
4.2 Results
4.2.1 Initial Production of Recombinant Bgp70-C
Initially the production and concentration of recombinant protein using the AcCHS 
virus were studied. Once the production of the Bgp70-C protein had been 
optimised, two methods of purification were investigated.
(I) Optimisation o f the production o f  recombinant Bgp70-C
Peak levels of polyhedrin production are usually observed about 54 hours post­
infection. However, the optimum time to harvest recombinant proteins can vary 
from this figure (King and Possee, 1992).
An experiment was performed to determine both the optimum time to harvest the 
supernatant and the most efficient dose of virus to use. Six 25cm2 flasks were 
seeded with 3 x 106 Sf9 cells. The next day the cells were inoculated with dilutions 
of the purified, titrated recombinant virus stock, AcCHS. After inoculation of the 
diluted virus, the flasks of cells were incubated for 2 hours on a tilting platform at 
room temperature. The inoculum was then removed and the cells were washed once 
in SF900 11 serum free medium. The flasks of cells were incubated with 5 ml of 
fresh SF900 11 medium for 6 days. At 28, 43, 56, 66, 76, 90, 103, 120 and 140 
hours post-infection aliquots of 200 pi were removed and were then centrifuged 
briefly at 6,000 rpm in a benchtop centrifuge. The supernatants were removed and 
frozen. The quantity of protein produced was estimated using the rabbit #709 serum 
/ monoclonal antibody 3-17AP sandwich ELISA (described previously in section
3.3.3). Each aliquot was diluted 1 in 2 with TBS / 1% empigen.
The controls used in this ELISA were the glutathione-S-transferase fusion proteins, 
GST-E and GST-G. GST-E contains the oligopeptide previously defined as a 
neutralising epitope on gp70 (Elder et al, 1987). GST-G contains an oligopeptide 
previously defined as the VR 1 region (Rigby, 1989). The control protein
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preparations, C5 and C6 (see section 3.3.3), were not included in this ELISA. The 
results of the assay are presented in Figure 4.1.
Altering the multiplicity of infection from 0.1 to 30 pfu/cell defined a range, 1-3 
pfu/cell, which produced optimum protein levels. All subsequent infections were 
performed using viral inocula within the range.
Above this range, less protein was produced. At the higher multiplicities of 
infection (10 and 30 pfu/cell) the infected cells showed obvious changes in their 
morphology before 67 hours post infection. This result suggested that high doses of 
the virus were killing the cells before the polyhedrin promoter became fully active.
At the lowest multiplicity of infection (0.1 pfu/cell) it was observed that the cells 
became confluent before changes in their morphology were seen. It is known that 
baculoviruses replicate best in actively dividing cells (King and Possee, 1992).
It was found that the optimum length of time to incubate cells infected post­
infection was between 67 and 76 hours. All subsequent infections were harvested 
after this time period.
If the cells were incubated for a longer period (6 days) then it was observed, using 
western blots, that the levels of recombinant protein rose within the cells. This may 
indicate that the active transport mechanisms in infected cells are preferentially 
affected before the protein manufacturing capability.
(2) Concentration o f the recombinant protein
As the protein was secreted into the supernatant, concentration was considered 
essential before any purification steps were undertaken. In a series of experiments 
the most appropriate method of concentration of recombinant Bgp70-C was 
determined. For these experiments the recombinant protein was produced by 
infecting 25 cm2 tissue culture flasks containing 3 x 106 Sf9 cells as described 
previously.
Ammonium sulphate precipitation (Harris, 1989) of the proteins was attempted, 
with little success. This might have been because the very low protein 
concentration in the supernatant prevented precipitation. Freeze drying was found 
to be effective, but suffered from the potential disadvantage of the coincidental 
concentration of salts from the SF90011 medium (Harris, 1989).
In contrast, the use of a Model 8200 stirred ultrafiltration cell (Amicon) proved an 
effective means of concentrating the supernatant with minimal increase in the salt 
concentration. Ultrafiltration was performed by first soaking a cellulose triacetate
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filter with a nominal molecular weight cut-off of 20 kDa (Sartorius) overnight in 
water. The next day the supernatant was harvested and was clarified by 
centrifugation at 5,000 rpm for 15 minutes in a JA14 rotor in a J2-21 centrifuge. 
The supernatant was then introduced into the assembled ultrafiltration cell and a 
pressure of 3.0 kg/cm2 slowly applied using nitrogen. The ultrafiltration cell was 
checked at periodic intervals and refilled when the level of supernatant fell below 
100 ml. When all of the supernatant had been filtered, the concentrate was 
diafiltrated with 400 ml of ice cold, sterile TBS. The supernatant was then finally 
concentrated to approximately 5% of its original volume.
The greatest disadvantage of this technique was the length of time required for 
concentration. Typically a flow rate of 1 ml per minute was achieved for the first 
200 ml but, as the membrane pores became blocked, the flow rate steadily fell. 
Generally 400 ml of supernatants were ultrafiltered then diafiltrated in a single 
session which lasted 1 2 - 2 0  hours. The major determinant of the length of this 
period was the care with which all particulate matter was removed by centrifugation 
prior to ultrafiltration.
(3) Purification o f the concentrated supernatants
Initially, purification of the concentrated supernatant was attempted using a nickel- 
nitrilotriacetic acid adsorbent immobilised on agarose (Hochuli et al., 1987). The 
adsorbent was generously provided by Dr. G. Reid (Department of Veterinary 
Pathology, University of Glasgow). The supernatant and the adsorbent were 
incubated together for 1 hour at room temperature with gentle rotation. They were 
then separated by centrifugation at 2,000 rpm in a GPR bench centrifuge for 2 
minutes. The adsorbent was washed with TBS until the OD28o of the washing was 
reduced to 0.04 or lower. The bound protein was eluted from the nickel- 
nitrilotriacetic acid adsorbent by incubation at room temperature with a solution of 
100 mM EDTA in 100 mM Tris (pH = 8.0). The eluate and the adsorbent were 
separated after 1 hour incubation by centrifugation. The elution was repeated and 
the eluates were pooled. The eluates were dialysed overnight against TBS at 4°C.
The purification of the protein was assessed by western blot using the monoclonal 
antibody 3-17AP. This was performed by incubation of a nylon membrane 
(prepared using the methods outlined in section 2.3.5) with a 1 in 600 dilution of 3- 
17AP in blocking solution. The results with the nickel-nitrilotriacetic acid 
adsorbent were disappointing in that only a fraction of the recombinant protein was 
recovered; the remainder did not appear to bind to the adsorbent. Despite 
investigating the effect of altering the pH of the binding phase, no improvement 
could be elicited. No further investigations into the failure of this system were
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performed.
Experiments were then performed to investigate the efficiency of other methods in 
purifying the protein. In particular, lentil lectin affinity chromatography (Sutton,
1989) was performed by incubating the (20 x) concentrated supernatant with l/10th 
of its volume of lentil lectin immobilised on Sepharose 4B (Pharmacia) for 2 hours 
at room temperature with gentle rotation. Centrifugation at 2,000 rpm for 2 minutes 
separated the lentil lectin from the supernatant. The lentil lectin was then washed 
with TBS until the OD2so of the washing was reduced to 0.04 or lower. The bound 
protein was eluted from the lentil lectin by incubation for 1 hour at room 
temperature with an equal volume of a solution of 0.5 M methyl-a 
mannopyranoside in TBS. The eluate and the lentil lectin were separated by 
centrifugation. The elution was repeated, and the eluates were pooled. The eluates 
were dialysed overnight against TBS at 4°C.
The final volume of the eluate was half that of the concentrated supernatant. The 
overall concentration factor was therefore 40 fold.
The various stages in the production, concentration and purification of the 
supernatant are shown in Figure 4.2. For the experiment shown in this figure the 
protein was prepared using 4 triple layered 225 cm2 flasks with 2 x 107 cells per 
layer infected with 0.8 pfu/cell of the titrated purified stock of the FeLV-A SU 
containing baculovirus, AcAHS. After infection the cells were covered with a total 
volume of 380 ml SF90011 medium and were incubated for 72 hours. The Sf9 cells 
were harvested with the supernatant by tapping the flask to dislodge them. One 
flask was fixed and stained with X-Gal. Although most of the cells had become 
detached, those that remained were strongly p gal positive. The detached cells, 
which were precipitated by centrifugation, were resuspended in 10 ml of TBS and 
then 10 x lysis buffer (5 % NP40 in TBS) was added. The lysed cells were kept on 
ice for 5 minutes, before the lysate was cleared by centrifugation at 3,000 rpm for 
10 minutes. The clarified supernatant was concentrated by ultrafiltration. The 
concentrated supernatant was then purified by lentil lectin affinity chromatography.
Aliquots of 30 pi were taken at various stages of this preparation and were analysed 
by electrophoresis through two 5-20% SDS-polyacrylamide gradient gels followed 
by either western blotting using the monoclonal antibody, 3-17AP, or silver 
staining. Western blotting and silver staining were performed by the general 
techniques outlined in Chapter 2. The western blot was performed by incubating 
the nylon membrane with 3-17AP, diluted 1 in 600 in blocking solution, for 2 hours 
at room temperature. After this time, the membrane was washed in PBS-Tween and 
then AP buffer. The blot was developed with NBT/BCIP in AP buffer.
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The silver stained gel illustrated in Figure 4.2 showed that the unconcentrated 
supernatant contained a single major protein species at 70 kDa as well as several 
minor species. No protein bands were seen in the filtrate suggesting that 
concentration of the supernatant by ultrafiltration was effective. The western blot 
(also Figure 4.2) demonstrated that there was a marked increase in the quantity of 
protein in the concentrated supernatant that reacted with 3-17AP. The silver stained 
gel also demonstrated that most of the proteins in the concentrated supernatant did 
not bind to lentil lectin. In contrast, the western blot showed a marked loss of 
protein in the supernatant, after lentil lectin affinity chromatography, that reacted 
with 3-17AP. Elution removed most of the recombinant protein from the beads and 
the eluate was seen on the western blot to be a single major protein band at 80 kDa 
with two lower bands, one faint and the other, at about 40 kDa, more intense. The 
eluate was seen on the silver stained gel to contain a single major species at about 
70 kDa with a minor species at about 80 kDa. All the preparations also had small 
amounts of high molecular weight species. These may represent aberrantly 
glycosylated proteins or the poor solubility of the proteins in the gel. Poor gel 
solubility causes inconsistent migration of the proteins.
The cells were seen to have contained some protein which reacted with 3-17AP, but 
less than that present in the concentrated supernatant. This difference was ascribed 
to the relatively low multiplicity of infection and the length of time the preparation 
was incubated before harvest. There were no significant differences between the 
major products in the supernatant and the cells. All the recombinant protein 
preparations had large amounts of the 40 kDa species which reacted with 3-17AP. 
It is suggested that this protein represents a breakdown product.
The cells and supernatant both contained large quantities of p galactosidase. It can 
be seen as a 100 kDa band which reacted specifically with a monoclonal antibody 
on western blots (data not shown). The p galactosidase did not bind to the lentil 
lectin and could not be demonstrated in the eluate.
Also shown in Figure 4.2 is a preparation of native SU derived from lysed F422 
supernatant as described in Chapter 2. This preparation was used as a positive 
control. It also has a breakdown product at about 35 kDa. This is common in 
preparations of native FeLV SU (Akerblom et al, 1989).
(4) Quantification o f recombinant Bgp70-A
The total protein in the eluate was measured as described in Chapter 2 and was 
found to be equivalent to 1 pg/106 Sf9 cells.
A mixture of 0.5 M methyl-aglucopyranoside together with 0.5 M methyl-
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amannopyranoside in TBS was used for the rest of the project in an attempt to 
improve the efficacy of elution from the lentil lectin. However, no quantitative 
assessment of any increase in protein content of the eluates resulting from this 
alteration was performed.
The optimised variables outlined above enabled as much as 4 pg of total protein to 
be produced from 106 Sf9 cells in later preparations.
Comparison between the silver stained gel and the western blot of the relative 
positions of the major bands in the F422 preparation and the eluate (Figure 4.2) 
indicated an anomaly. In the silver stained gel the major band in F422 was of a 
larger molecular mass than the major band in the preparation of Bgp70-A. In the 
western blot the major species in Bgp70-A was of a larger molecular mass than that 
in F422. This suggested that the major band in Bgp70-A was not that which reacted 
with 3-17AP in the western blot. It was concluded that the eluate was contaminated 
with a protein of slightly lower molecular weight than gp70.
4.2.2 Large Scale Preparations
To prepare large quantities of each protein for analysis the following procedure was 
used for each preparation. Ten 225 cm2 flasks were seeded with Sf9 cells at a 
density of 2 x 107 cells per flask. The next day the cells were incubated for 2 hours 
with an inoculum containing 2 pfu/cell of one of the recombinant baculoviruses, 
AcAHS, AcCHS, AcVCHS, Ac215HS. The cells were then washed once with 
SF90011 serum free medium and were then maintained in SF900 11 medium for 66 
hours. The supernatant was harvested and then concentrated by ultrafiltration as 
described in section 4.2.1 b) above. Diafiltration was found to be unnecessary for 
lentil lectin binding (data not shown) and was not performed on these preparations. 
The concentrated supernatant was then purified by lentil lectin affinity 
chromatography. A mixture of 0.5 M methyl-aglucopyranoside together with 0.5 M 
methyl-amannopyranoside in TBS was used to elute the recombinant protein. The 
resulting solution was then dialysed extensively against TBS at 4°C. The proteins 
were stored in aliquots at -70°C until used.
4.23 Production of Purified Control Protein Preparations
(7) F IV  SU
To prepare large quantities of the recombinant FIV SU protein, BgplOO, ten 225 
cm2 flasks of Sf9 cells were prepared and infected as outlined above. The protein 
was purified by lentil lectin affinity chromatography from the concentrated 
supernatant as described before. The various stages in the production of
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recombinant FIV SU are illustrated in Figure 4.3. The western blot illustrated that a 
large amount of the protein remains in the cell. This suggested that the recombinant 
FTV SU was not as well exported from the Sf9 cells as the FeLV SUs. The 
purification of the exported protein from the concentrated supernatant, using lentil 
lectin affinity chromatography, is also demonstrated.
A control preparation made from the FL4 cell line was used as a source of native 
FTV SU. The native protein can be seen as a heterogeneous band at approximately 
110 kDa. The recombinant product was substantially smaller than the native 
protein. The apparent molecular mass of the recombinant protein was 
approximately 90 kDa.
(2) Uninfected control
To produce a control solution that contained only Sf9 insect cell proteins a large 
scale preparation was performed, as described above, but no virus was inoculated 
into the flasks. The supernatant was harvested and then concentrated to form a 
preparation that was called C5. This preparation was then purified by lentil lectin 
affinity chromatography and the resulting control preparation was designated C5L.
The total quantity of protein in C5L was larger than that observed with virus- 
infected cells. This was thought to be due to the maintenance of the rapid growth 
rate of the cells in the absence of virus.
(3) Wild type infected control
To produce a control solution that contained baculoviral proteins a large scale 
preparation was performed as described above. The cells were infected with wild 
type AcMNPV (2 pfu/cell) and then were incubated for 66 hours. The supernatant 
was concentrated to form a preparation called C5, which was then purified using 
lentil lectin affinity chromatography. The purified preparation was designated C6L.
The total quantity of protein in this preparation was slightly less than the average 
protein concentration of the recombinant FeLV SU preparations.
4.3 Discussion
This chapter details the analysis of the production of one recombinant protein, 
Bgp70-A, which was then purified from concentrated supernatant by lentil lectin 
affinity chromatography. It also details the large scale manufacture of 4 
recombinant FeLV SU proteins (Bgp70s) and three control protein preparations 
(BgplOO, C5L and C6L).
The eluates of BgplOO and the Bgp70s all contained at least one major impurity, a
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species of 60-69 kDa. This protein was probably the major baculoviral envelope 
glycoprotein, gp64 (Volkman, 1986). As this protein was glycosylated it would be 
expected to co-purify with the recombinant protein when using lentil lectin affinity 
chromatography.
The lack of binding of the recombinant Bgp70s to the nickel-nitrilotriacetic acid 
adsorbent may have been due to several factors. The histidine residues may not 
have been exposed on the surface of the recombinant protein. Alternatively, post- 
translational modification or non-specific proteolysis could have removed them. 
Finally, the charges on the histidine residues could have been masked because the 
isoelectric points of glycoproteins are generally lower than their non-glycosylated 
counterparts. This difference is due to the acidic nature of the carbohydrate side 
chains.
Lectins are a large family of ubiquitous carbohydrate binding proteins that are 
widely used in molecular biology for the purification of glycoproteins (Sutton,
1989). As lentil lectin is known to bind mannose residues well, and insect cell 
glycosylation produces mannose-rich carbohydrate side-chains (Kuroda et aL,
1990), no investigation was undertaken using other lectins. A more detailed 
discussion of insect cell glycosylation is presented in Chapter 5.
The major product which reacted with 3-17AP in the eluate was slightly larger than 
the SU from F422. The difference in size was probably partly due to the presence 
of this non-anchoring portion of TM. This could be confirmed with a monoclonal 
antibody specific for the amino portion of TM. The calculated relative molecular 
mass of this portion was 15 kDa (and of the whole TM protein, 22 kDa). The 
predicted relative molecular mass of the recombinant protein was therefore 85 kDa. 
However, the observed relative molecular mass was approximately 80 kDa. The 
difference was probably due to aberrant glycosylation of the recombinant protein. 
The difference between the size of the recombinant FIV SU product, BgplOO, and 
the native FTV SU was probably also due to the aberrant glycosylation of the insect 
cells. The glycosylation of the recombinant proteins was further investigated using 
enzymatic digestion with endoglycosidase (see section 5.2.4).
It is not possible to state a definitive figure for the quantity of recombinant proteins 
in the preparations. However, it is clear that relatively little protein was produced 
compared with the reported values of some baculovirus expressed proteins. Early 
experiments had relied on Coomassie stained gels of the concentrated impure 
products to estimate quantity. However, the preparations contained several other 
proteins that interfered with this form of analysis. In particular, species at 70 kDa 
were a cause of some initial misplaced optimism. The nature of these species was
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never formally determined, but it is likely that they were serum albumin and, to a 
lesser extent, the baculovirus p74 protein (Rohrmann, 1992).
In attempting to express membrane proteins in the baculovirus system, other 
workers have also found that yields were disappointingly low (King and Possee, 
1992). This may appear to be a limitation of the baculovirus system which will 
have to be considered in the future when selecting a system for recombinant protein 
production. However, the baculovirus expression system does produce some 
proteins well. Up to 50% of the total cellular protein can be of recombinant origin 
(Matsuura et al, 1987). The proteins that are expressed well such as |3 
galactosidase (Pennock et al, 1984), p interferon (Smith et al, 1983b) and 
influenza HA (Kuroda et al., 1986), are often not, or only sparsely, glycosylated. 
The high level of expression of p galactosidase by insect cells was confirmed in 
these experiments. Approximately 30% of the relative molecular mass of FeLV SU 
is composed of carbohydrate. In the case of the FTV SU this figure rises to 50%. It 
is possible that the degree of glycosylation required by the protein influences the 
ability of the insect cell to produce that protein. It is more relevant to compare the 
expression of FeLV SU with other, heavily glycosylated, retroviral SU proteins that 
have been expressed using the baculovirus vector system.
There have been several reports of the expression of entire retroviral env genes in 
insect cells (Wells and Compans, 1990; Thomsen et al., 1992; Arp et al., 1993; 
Verschoor et al, 1993). These reports indicate that the proteins are retained within 
the cells, sometimes in inclusion bodies (Arp et al., 1993). Such inclusion bodies 
assist subsequent purification, though potentially denaturing concentrations of urea 
or guanidinium hydrochloride are required for solubilisation. Thomsen et al. (1992) 
expressed FeLV gag as well as the entire env and found that the immature particles 
produced by the gag containing recombinant virus would incorporate the env gene 
product when an env containing recombinant virus was used as well. Apart from the 
use of these immature particles, no attempt was made to isolate the env protein. It 
would be interesting to discover if the e«v-containing baculovirus did produce 
inclusion bodies. The inclusion bodies may increase protein stability thereby 
increasing the yield. The authors also note that their product was not processed into 
gp70 and pi5(E). There was no evidence of such cleavage in the recombinant 
proteins described in this thesis. Some investigators report cleavage of HIV env 
(Wells and Compans, 1990), while others do not (Rusche et al., 1987; Hu et al, 
1987). The HTLV-1 and FTV env products are not cleaved (Arp et al, 1993; 
Verschoor etal., 1993).
There have also been several reports of the expression of truncated env in insect 
cells. Notebom et al. (1990), expressed only the SU component of ALV in insect
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cells but, unexpectedly, the protein was not transported into the supernatant. They 
suggest that the lack of TM was responsible. The TM of RSV is known to be 
necessary for the stabilisation of an external glycoprotein oligomer which is 
required for efficient extracellular transport (Einfeld and Hunter, 1988). This may 
explain the apparent lack of expression in the supernatant of the preliminary 
experiments using the Bam HI / Sst 11 segment of FeLV env. This segment only 
contained 15 amino acids of TM. In contrast the successful Bam HI / Apa 1 
fragments contain 147 amino acids. This would suggest that the components of TM 
required for oligomerisation reside in this 142 amino acid residue region. The 
advantage of producing a secreted product is that it greatly facilitates subsequent 
purification. The relative lack of export of the recombinant FTV SU may have been 
due to a similar lack of oligomerisation. The production of a recombinant 
baculovirus containing a truncated FTV env lacking the transmembrane domain of 
the anchoring TM protein would enable further analysis of the transport 
mechanisms in insect cells. Such a recombinant protein might also be more 
efficiently exported from the cells, facilitating purification and increasing the yields 
of protein obtained. The relevance of such studies to the transport in higher 
eukaryotic cells has not been ascertained.
One report of HIV env expression (Wells and Compans, 1990) is of particular 
interest as it describes the production of a recombinant baculovirus that expressed a 
truncated version of HIV env which lacked a transmembrane domain and was 
therefore analogous to the work presented here. These authors found that the 
protein was mainly secreted into the supernatant. They also demonstrated that the 
recombinant protein specifically bound to CD4, even in the absence of proteolytic 
cleavage. This encouraged studies, reported in Chapter 6, which examined the 
interaction of the recombinant protein with cell surface proteins.
The quantification of recombinant proteins requires some care. The use of 
immunoreactivity as a measure of recombinant protein (Hu et al., 1987) is highly 
dependent upon the assay used. As recombinant baculoviral proteins are aberrantly 
glycosylated the immunoreactivity may differ markedly from the native protein. 
This is particularly true when a polyclonal serum is used since the great majority of 
antibodies may be directed against the carbohydrate components of the retroviral 
envelope (Elder et al., 1986). This point will be illustrated further in Chapter 5. The 
level of expression quoted by these authors (which assuming 6 x 108 cells/litre of 
culture fluid was equivalent to 2-3 pig/106 cells) could not be confirmed 
independently as neither of the other two reports of HIV env expression in insect 
cells (Rusche et al, 1987; Wells and Compans, 1990) quote a figure. Notebom et 
al. (1990) quote a figure for the production of ALV SU of 1-2 pg/106 Sf9 cells.
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They do not, however, state the method which they used to arrive at this figure. As 
their product had an apparent molecular mass of 65 kDa (due to incomplete 
glycosylation) and was not purified from cell lysates, contamination of the 65 kDa 
species with the baculoviral envelope protein gp64 must be considered a possibility. 
Arp et al. (1993) report a recombinant HTLV-1 env product that is equivalent to 10 
pg/106 cells. This result was obtained from analysis of the purified inclusion 
bodies. However the majority of the protein produced was not glycosylated. The 
component that was glycosylated did not contain a large amount of carbohydrate. 
This may, in part, explain the larger quantities produced. FeLV, FIV, ALV and HIV 
all have much greater quantities of carbohydrate in their SU proteins.
The detailed molecular factors determining the level of expression of the 
polyhedrin gene, or its equivalent following recombination, are not well 
characterised. The 5' non-coding region of the polyhedrin gene is known to be 
required for high levels of expression. The seven 5' nucleotides, TATAAATA, in 
this region are of particular importance (Matsuura et al, 1987). The polyhedrin 
promoter is known to be generally more efficient than the p i0 promoter (Min and 
Bishop, 1991). It is also known that polyhedrin production is not directly 
proportional to viral replication and that all genes that have been expressed at a 
high level have been derived from cDNA or genomic clones that do not contain 
introns (Luckow and Summers, 1988). The lack of detailed information on factors 
which govern the expression of foreign genes is a common disadvantage with 
eukaryotic protein expression systems. In common with other eukaryotic systems, 
the unpredictable nature of recombinant protein production is a major disadvantage 
of the baculovirus expression system. Even in recombinant baculoviruses 
containing the same foreign gene the level of expression seems to vary (Luckow 
and Summers, 1988). Several isolates were made of each recombinant baculovirus 
reported here, though no detailed analysis of the levels of protein production was 
undertaken.
To produce larger quantities of protein would require the development of a specific 
protocol for this purpose. The use of spinner cultures has been advocated (King and 
Possee, 1992). However attempts to adapt Sf9 cells to serum free medium spinner 
cultures failed. As Sf9 cells can tolerate low (2%) serum concentrations (data not 
shown), it may be possible to use small amounts of serum to avoid these adaption 
problems. Concentration of 10% serum-containing medium by ultrafiltration results 
in rapid membrane fouling. The use of spinner cultures is probably best restricted to 
the production of proteins that are retained within the Sf9 cells. A similar problem 
would probably exist with the air-lift fermentation vats that are used for the 
industrial scale production of recombinant baculovirus proteins (Luckow and
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Summers, 1988).
In conclusion, few reports of the expression of retroviral SU proteins record a 
reliable figure for the quantity of protein produced. This may suggest that the 
truncated FeLV SU/TM recombinant proteins described in this thesis may not be 
produced in unusually low quantities for this system. Similarly, the quantities of 
FTV SU cannot be determined, even in relation to the quantity of FeLV SU. It is 
suggested that the degree of glycosylation required by the protein may influence the 
total yield obtained. Further analysis, possibly using mutated SUs with fewer 
glycosylation sites, is required.
82
Chapter 5. Analysis of Recombinant Proteins
5.1 Introduction
This chapter describes detailed analyses of the four recombinant FeLV SU proteins. 
These experiments characterised the interaction of anti-gp70 antibodies, 
particularly virus neutralising antibodies, with the proteins. The experiments also 
examined whether the proteins' expected subgroup phenotypes were identifiable by 
immunological methods.
Western blotting was performed to examine the ability of the antibodies to bind 
linearised polypeptides. Enzyme linked immunoabsorbent assays (ELJSAs) were 
then performed to investigate the ability of the antibodies to bind to the antibody- 
captured proteins. ELISAs are thought to be more representative of the 
antigen/antibody interaction in vivo. Finally the ability of the recombinant proteins 
to block the action of virus neutralising antibodies was investigated. These assays 
were used to examine the ability of the recombinant proteins to function in a similar 
manner to the native SU glycoproteins. The value of any recombinant protein is 
largely determined by its ability to mimic its wild type counterpart. Recombinant 
proteins expressed in the baculoviral system are sometimes immunologically 
distinct from their native counterparts (Luckow and Summers, 1988).
5.2 Results
5.2.1 Western Blotting
Western blots were performed to analyse the binding of five sera to the four 
recombinant proteins, Bgp70-A, -C, -VC and -215. The blots were performed as 
outlined in Chapter 2. The membranes were washed between stages for one hour 
with PBS-Tween. The proteins were separated by 7.5% SDS-PAGE before 
electroblotting onto nitrocellulose membranes. The negative control preparations, 
C5L and C6L, were included in these analyses (see 2.3.2 and 2.3.3). Two positive 
control preparations of FeLV purified from F422 and FL74 cells were also 
included. The antibody preparations used were 3-17AP, rabbit #709 serum, rabbit 
#395 serum, cat P ll  serum and cat 'Wendy' serum, which are defined in Chapter 2. 
A silver stained gel was also prepared of the same proteins. The results of these 
analyses are presented in Figure 5.1
To demonstrate the binding of the monoclonal antibody 3-17AP to the four Bgp70s, 
the antibody was diluted 1 in 600 with blocking solution and was then incubated 
with one of the nitrocellulose membranes for 2 hours. The membrane was 
developed with a solution of NBT and BCIP in alkaline phosphatase buffer.
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To investigate the binding of the rabbit #709 anti-gp70 serum to the recombinant 
proteins, another membrane was incubated for 2 hours with #709 serum, diluted 1 
in 300 with blocking solution. Following this step, a goat anti-rabbit IgG - alkaline 
phosphatase conjugate (BioRad), diluted 1 in 1,000 with blocking solution, was 
incubated with the membrane for 1 hour. The membrane was developed as above. 
A similar blot was prepared using the SPF rabbit #395 serum.
To investigate the binding of recovered cat P ll  serum to the recombinant proteins a 
fourth membrane was incubated for 2 hours with the serum diluted 1 in 100 with 
blocking solution. Following this, a goat anti-cat IgG - alkaline phosphatase 
conjugate (SeraLab), diluted 1 in 500 with blocking solution, was incubated with 
the membrane for 1 hour. The membrane was developed as above. A similar blot 
was performed using the SPF cat 'Wendy* serum.
The pattern of binding to the recombinant proteins observed with the rabbit anti- 
gp70 serum was similar to that observed with the monoclonal antibody 3-17AP. 
Both the rabbit #709 serum and the 3-17AP antibody bound to a lower 65 kDa 
species as well as the major 80 kDa species. This result suggested that the epitope 
recognised predominantly by the hyperimmune serum may have been the same as 
that recognised by 3-17AP. In contrast, the pattern of binding seen with the 
recovered cat serum was different. The PI 1 serum did not bind to the lower 65 kDa 
species and bound only to a component of the broad 80 kDa band. This finding 
suggested that P ll  serum may have predominantly recognised different epitopes. It 
was not obvious why P ll did not bind to the 65 kDa species, as it probably 
represented the small amount of SU portion that was cleaved from the TM during 
production. It is possible that the quantity of protein present was insufficient to 
provide a visible reaction.
Both #709 and P ll  sera bound to a 55 kDa species in FL74 and F422 derived 
virions and a to 50 kDa species in F422 derived virions. These species probably 
represent breakdown products of gp70. As neither were recognised by 3-17AP, it is 
suggested that the portion containing this epitope had been cleaved off. This result 
also demonstrated that #709 serum did have antibodies to epitopes in native FeLV 
SU, other than that recognised by 3-17 AP. The importance of this observation 
becomes apparent when considering the testing of developmental FeLV vaccines in 
species other than the cat. If such animals predominantly respond with neutralising 
antibodies to one epitope, which the cat seems unresponsive to, then the value of 
such experiments is reduced.
It was interesting to compare the relative reactivities of the gp70 derived from F422 
and FL74. The 3-17AP antibody and the #709 serum appeared to bind to more of
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the FL74, suggesting that more FL74 derived gp70 was present. However, the 
recovered cat P ll  serum bound to more of the F422 gp70. The reason for this 
difference was probably due to the relative abundance of FeLV-A in the two 
preparations. P ll  serum was derived from a cat that had recovered from an 
infection with FeLV-A and therefore may mainly recognise this subgroup. Further 
investigations into this observation are presented below.
The silver stained gel showed that the major bands in the two FeLV preparations 
were of different sizes, yet all three of the anti-gp70 antibody preparations 
recognised components in the two preparations that were of the same size. This 
suggested that the major band in the F422 preparation, previously assumed to be 
gp70, might be another protein. A likely candidate is bovine serum albumin, which 
is approximately 70 kDa in size.
The binding of 3-17AP to a 46 kDa protein in the uninfected control preparation, 
C5L, could not be readily explained. Similarly, the binding of #709 to a band at 150 
kDa was probably a spurious reaction to an insect cell component. The SPF rabbit 
#395 serum did not show such binding.
5.2.2 ELISAs
To investigate further the interaction of the recombinant proteins with various sera 
a number of ELISAs were performed. The techniques used are outlined in Chapter 
2. The ELISA microtitre plates were washed 4 times between each stage with TBS / 
0.05% Tween 20.
(1) Rabbit #709 serum / MAb 3-17AP ELISA
To demonstrate that the anti-gp70 monoclonal antibody 3-17AP bound to the 
recombinant proteins a sandwich ELISA was performed. This ELISA was also used 
during the purification of the recombinant baculoviruses and the optimisation of 
protein production (see sections 3.3.3 and 4.2.1).
The controls used in this ELISA were the glutathione-S-transferase fusion proteins 
GST-E and GST-G. GST-E contains the oligopeptide previously defined as a 
neutralising epitope on gp70 (Elder et al, 1987). GST-G contains an oligopeptide 
derived from the VR 1 region. The control preparations, C5L and C6L, were also 
included in this ELISA (see section 4.2.3). The rabbit #709 anti-gp70 serum, 
diluted 1 in 1,000 with coupling buffer, was incubated overnight (100 pi per well). 
The next day the plate was blocked by incubating with 2% Marvel in TBS (200 pi 
per well). Threefold dilutions of the antigens in 1% empigen in TBS were then 
incubated with the plate for 3 hours (100 pi per well). The initial quantities of
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protein were 10 pg (GST-G and -E), 4 pg (C5L, C6L, Bgp70-A and -215) or 1.3 pg 
(Bgp70-C and -VC). The plate was then incubated with a 1 in 1,000 dilution of 3- 
17AP in 2% Marvel in TBS (100 pi per well) for 1 hour. The reaction was 
developed by adding 50 pi of a 1 mg/ml solution of 4-nitrophenyl phosphate in AP 
buffer to each well and incubating for approximately 4 hours. The results of this 
ELISA are presented in Figure 5.2.
The three negative control preparations, (GST-G, C5L and C6L) did not react in 
this experiment. In contrast the positive control, GST-E, reacted well, confirming 
the specificity of the assay. The four recombinant proteins also reacted well. These 
reactions were greater than the F422 derived gp70 (data not shown).
(2) MAb 3-17 / cat serum ELISA
A  set of ELISAs were performed to investigate the ability of two recovered cat sera, 
P ll  and Cat 31, to bind to the recombinant proteins. The ability of Cat 31 serum, 
which is FeLV-C/Sarma specific, and P12, which is FeLV-A specific, to 
discriminate between the various recombinant proteins was also analysed.
The monoclonal antibody 3-17 was obtained as ascites from Dr. K. Weijer. This 
preparation was not alkaline phosphatase linked. It was coupled to an ELISA plate 
by diluting 1 in 1,000 with coupling buffer and incubated in a 96-well plate 
overnight (100 pi per well). The next day the plate was blocked with 2% Marvel 
and 10% goat serum in TBS (200 pi per well). Five-fold dilutions of the antigens in 
1% empigen in TBS were then incubated with the plate for 3 hours (100 pi per 
well). The quantities of the recombinant proteins used were 4 pg (C5L, C6L, 
Bgp70-A and -215) or 1.3 pg (Bgp70-C and -VC). The plate was then incubated 
with a 1 in 200 dilution of serum for 2 hours followed by a 1 in 600 dilution of a 
goat anti-cat IgG - alkaline phosphate conjugate. 2% Marvel in TBS (100 pi per 
well) for 1 hour. The reaction was developed by adding 50 pi of a 1 mg/ml solution 
of 4-nitrophenyl phosphate in AP buffer to each well and incubating for 
approximately 4 hours. Equal volumes of C5L and C6L were mixed together and 
used as a negative control. FL74 derived gp70 was used as a source of FeLV- 
C/Sarma and FeLV-A gp70, and F422 derived gp70 as a source of FeLV-A gp70 
alone. The results of this experiment are presented in Figure 5.3.
The reaction of Cat 31 serum with FL74 was much greater than with F422. In 
contrast, the reaction of PI 2 with F422 was greater than with FL74 (reflecting the 
relative abundance of FeLV-A gp70 in the two preparations). This partially 
confirms the reported subgroup specificities of these sera (OJarrett, personal 
communication). To confirm these observations fully would require isolated FeLV- 
C/Sarma gp70.
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The reaction of Cat 31 serum was much greater with Bgp70-C than with the other 
three Bgp70s. The reaction of PI 2 with Bgp70-C was much less than with the other 
Bgp70s. This suggested that the majority of the antibodies in both sera were 
directed against regions other than that which determines subgroup specificity.
(3) Subgroup-specific MAb ELISA
A third ELISA was performed with the subgroup specific monoclonal antibodies 
C1G10, HL2 and HL5. These antibodies are all neutralising in vitro, but differ in 
their titres against the three FeLV subgroups (see Table 2.1). Two monoclonal 
antibodies were used as controls in this experiment; 6-15, which is similar to the 
broadly neutralising 3-17 monoclonal antibody, and VPG 68, which can function as 
a capture antibody for native FIV SU in ELISAs. Only three of the Bgp70 
preparations (Bgp70-A, -C and -215) were used in this experiment.
This ELISA was performed by incubating overnight several aliquots of each 
recombinant protein diluted with coupling buffer (100 pi per well). The quantities 
of the recombinant proteins used were 4 pg (BgplOO, Bgp70-A and -215) or 1.3 pg 
(Bgp70-C). The next day the plate was blocked with 2% Marvel and 10% goat 
serum in TBS (200 pi per well). Those antibodies that were only available in 
ascites form (6-15, HL2 and HL5) were diluted 1 in 200 with 2% Marvel and 10% 
goat serum in TBS. The purified antibodies (VPG 68 and C1G10) were diluted 1 in 
100 from 1 mg/ml stocks. The diluted monoclonal antibodies were then added to 
the wells in a chequerboard fashion and the plate was incubated for 2 hours. The 
plate was then incubated with a 1 in 1,000 dilution (in 2% Marvel and 10% goat 
serum in TBS) of a goat anti-mouse IgG - alkaline phosphate conjugate (BioRad) 
for 1 hour. The reaction was developed by adding 50 pi of a 1 mg/ml solution of 4- 
nitrophenyl phosphate in AP buffer to each well and incubating for approximately 4 
hours.
The results of this experiment are presented in Figure 5.4. The monoclonal 
antibody C1G10 reacted well with Bgp70-C but did not react with the other 
Bgp70s. The monoclonal antibodies HL2 and HL5 did not react with Bgp70-C but 
reacted well with the other Bgp70s. The monoclonal antibody 6-15 reacted with all 
three Bgp70s, but the reaction with Bgp70-C was weak.
5.2.3 Neutralisation Inhibition Assays
To investigate the ability of neutralising antibodies to bind to the recombinant 
proteins a series of experiments was performed which were referred to as 
neutralisation inhibition assays (NIAs). These assays measured the ability of the 
recombinant proteins to increase the apparent titre of virus in the presence of virus
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neutralising antibodies. The ability of a recombinant protein to block the action of 
virus neutralising antibodies was taken to indicate that the neutralising antibody 
was binding to the protein. As these assays were potentially susceptible to a wide 
range of non-specific or spurious reactions, a number of controls were included. 
The assays were performed using QN10S cells seeded the previous day in 12-well 
tissue culture trays at a density of 4 x 104 cells per well in 1 ml of medium 
containing 4 pg/ml of polybrene. Each assay was performed at least twice on 
separate days to reduce the likelihood of spurious reactions.
Initially, the amount of Bgp70-A required to block the action of neutralising 
antibodies was titrated. Aliquots of 50 pi of dilutions of Bgp70-A and P ll serum 
were mixed in a chequerboard fashion in a sterile, round bottomed 96-well 
microtitre tray. An aliquot of FeLV-A/Glasgow-1 was diluted with medium until a 
titre of 2.4 x 103 pfu/ml was obtained. From this diluted stock further aliquots of 50 
pi containing 120 pfu were added to the reactions. The reactions were then 
incubated for 2 hours at 37°C in a humidified incubator. Three aliquots of 25 pi 
were taken from each reaction and were used to infect 3 wells of QN10S cells. The 
reaction inocula were incubated with the cells for a further 90 minutes. After this 
interval, the overlying medium was replaced with fresh medium and the cells were 
incubated for a further 6 days before the number of plaques were counted 
microscopically.
To control for direct interaction of the virus and the antigen, some reactions were 
performed without serum. To demonstrate that the P ll  cat serum contained virus 
neutralising antibodies, other reactions were performed without recombinant 
protein. To establish that the recombinant proteins were not acting with non­
specific components of the cat P ll serum to enhance viral entry, some reactions 
were performed with SPF cat serum. To control for non-specific cytotoxicity of the 
antigen, some wells had only the proteins added. Non-specific inhibition of 
neutralising activity by baculoviral or insect cell proteins was controlled by 
inclusion of reactions with a mixture of the two negative controls (C5L and C6L) in 
place of the recombinant protein. When one component of the reaction was omitted 
fresh medium was used in its place.
The results of this experiment are presented in Figure 5.5. A significant, specific 
inhibition of neutralising activity was demonstrated. The degree of variability in the 
average number of plaques in the absence of serum and protein (+/- 20%) was a 
common, though not universal, finding in these experiments. No reason was 
determined for this variability. The decrease in the average number of plaques 
observed with the SPF serum was taken as the lower limit of this variability. The 
negative protein control (C5L/C6L) did not block the action of neutralising
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antibodies. Neutralising activity was not observed in the SPF serum (even at 
dilutions as low as 1 in 4 - data not shown). The cells did not undergo any changes 
in morphology in the presence of the protein alone.
In the absence of serum, increasing quantities of recombinant protein appeared to 
cause a decrease in the number of plaques. This suggested that, to a slight extent, 
the protein might have directly inhibited the replication of the virus. However, this 
particular result was not obtained in subsequent experiments. Moreover the number 
of plaques obtained with the SPF serum was always lower, indicating that normal 
experimental error was probably responsible for this apparent decrease.
The second neutralisation inhibition assay investigated the ability of the other 
Bgp70s to block the action of neutralising antibodies. The assay was performed in 
the same manner as that described above with the sole exception of the inclusion of 
different recombinant protein preparations in the place of the dilutions of Bgp70-A. 
The results are presented in Figure 5.6 (A). Inhibition of neutralising activity was 
observed with Bgp70-A, Bgp70-VC and Bgp70-215. No inhibition was observed 
with Bgp70-C, the negative controls or the controls without protein. This result 
suggested that most of the neutralising activity of P ll  serum was directed at regions 
other than that which determined subgroup phenotype. This assay was repeated 
with the PI 2 serum that is known to be specific for FeLV-A. The result was similar 
(see Figure 5.6 (B)). This result implied that the P I2 serum was not unusual in its 
FeLV-A specificity.
5.2.4 Deglycosylation of Bgp70-A
Insect cell glycosylation differs both qualitatively and quantitatively from that of its 
mammalian counterparts (Luckow and Summers, 1988). To investigate the nature 
of the recombinant proteins' glycosylation, an endoglycosidase was used to remove 
all the N-linked carbohydrate side chains which were attached to the specific 
recognition sequence Asn-X-Ser/Thr. The recombinant protein was denatured 
before incubation with the enzyme as this raises the susceptibility of the protein to 
deglycosylation.
An aliquot of 160 pi of Bgp70-A containing 16 pg total protein was added to 12.5 
pi (3 mercaptoethanol, 50 pi E2 buffer (Oxford Glycosystems) and 12.5 pi 10% 
SDS. The solution was boiled for 2 minutes, then centrifuged at 6,000 rpm for 30 
seconds in a benchtop centrifuge. An aliquot of 40 pi of 20% Triton X100 was 
added and the solution was incubated at room temperature for 5 minutes. A 30 pi 
sample was taken and frozen with 15 pi of SDS gel loading buffer. Then 2 units (10 
pi) of the enzyme peptide-N-glycosidase-F (PNGaseF) (Oxford Glycosystems) was 
added to the solution together with 10 pi of E2 buffer and 0.1 pg of pepstatin. The
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reaction was incubated for 24 hours at 25°C. Aliquots of 30 pi were taken 10, 20, 
40, 70, 140, 240 minutes and 24 hours later. Each aliquot was immediately placed 
in 15 1^ of SDS gel loading buffer and then frozen.
A similar procedure was performed with concentrated, purified FeLV from F422 
supernatant. All the samples were boiled before loading on a 7.5% SDS- 
polyacrylamide gel. Electrophoresis was continued for 4 hours at 200 V. The 
proteins were then electroblotted onto a nylon membrane and probed with a 1 in 
600 dilution of 3-17AP. The western blot was then developed with NBT/BCIP in 
AP buffer.
The results of this experiment are presented in Figure 5.7. It could be seen that the 
F422 derived gp70 was effectively deglycosylated with several intermediates. The 
final product was approximately 50 kDa in size, which is close to the predicted 
non-glycosylated size of 45 kDa. The difference was probably due to the small 
quantity of carbohydrate attached to serine or threonine residues (O-linked) which 
are not cleaved by the enzyme. Such O-linked carbohydrate side chains comprise 
approximately 10% of the total carbohydrate content of native FeLV SU (Pinter and 
Honnen, 1988). In contrast the final product of the deglycosylation of Bgp70-A was 
approximately 65 kDa in size, which again is slightly more than the predicted size 
of 60 kDa. It is known that insect cells can perform O-linked glycosylation (King 
and Possee, 1992). Unfortunately, the intermediates in the deglycosylation of 
Bgp70-A were not readily distinguishable. Therefore it was not possible to confirm 
that all the glycosylation sites used in native FeLV SU were also used in Bgp70-A. 
The high molecular mass forms of Bgp70-A were not affected by deglycosylation, 
suggesting that their presence was not due to aberrant glycosylation.
5.3 Discussion
The experiments in this chapter examined the similarities and differences exhibited 
by the four recombinant FeLV SU proteins, Bgp70s. It was found that the 
baculovirus expression system had produced Bgp70s that were immunologically 
similar to the native proteins. Furthermore, using subgroup-specific antibodies, one 
of the recombinant proteins could be distinguished. The two chimeric proteins 
were, however, indistinguishable from Bgp70-A.
The results obtained from the western blots demonstrated that the monoclonal 
antibody 3-17AP bound to all four recombinant proteins as did the rabbit anti-gp70 
serum, #709. The P ll  cat serum also bound to all four recombinant proteins, 
indicating that it possessed antibodies that recognised linear epitopes on all the 
Bgp70s.
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Figure 5.7. Deglycosylation of Bgp70-A and native gp70
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Aliquots of Bgp70-A and F422 virus were boiled with 0.1% b 
mercaptoethanol and 1% SDS for 2 minutes. Triton X 100 was added to 
the denatured proteins which were then incubated for an extended period 
with PNGase F, the appropriate buffer and the protease inhibitor, 
pepstatin. Aliquots were taken at various time points (0, 10, 20, 40, 70, 
140, 240 minutes and 24 hours) and immediately frozen. The samples 
were separated by SDS-PAGE and then were transferred onto a nylon 
membrane. The blot was probed with 3.17AP and each side was 
developed separately with NBT and FOP.
The relatively poor ability of the #709 / 3-17AP sandwich ELISA to react with 
native gp70 was not investigated. The ability of the recombinant Bgp70s to react 
well in the same assay was the only difference that was observed in immunological 
reactivity between the native and recombinant proteins. Immunoreactivity has been 
used in the quantification of recombinant protein (Hu et al., 1987). However, the 
difference in reactivity between the native SU and Bgp70s in this assay illustrates 
the care with which this technique should be used. In the second set of ELISAs the 
quantity of recombinant antigen required to elicit the same response as 1 pg of 
native gp70 was many times greater than in the #709 / 3-17AP ELISA.
The 3-17 capture / cat serum sandwich ELISA results (Figure 5.3), when examined 
as a group, suggested that the majority of the anti-gp70 antibodies were directed at 
regions other than that which determines subgroup phenotype. Unlike western 
blots, ELISAs preserve the structural integrity of antigens and so represent a better 
approximation to the ’natural’ interaction. The ability of the cat 31 serum to 
distinguish Bgp70-C from Bgp70-A suggested that the predominant epitope it 
recognised may be subgroup specific. However, the A/C-Sarma chimera Bgp70-VC 
was not recognised by the cat 31 serum. As this is derived from a chimeric virus 
which in superinfection interference assays is classified as belonging to subgroup C 
(Rigby, 1989) it therefore follows that the cat 31 serum recognises a component of 
FeLV-C/Sarma SU which is unique to FeLV-C/Sarma, but is not the subgroup- 
determining VR1 region. The reciprocal experiment with the FeLV-A specific P12 
cat serum demonstrated that cats which recover naturally from FeLV infection do 
not generate antibodies that recognise the subgroup-determining VR1 region. This 
result was repeated with P ll  cat serum to demonstrate that P12 serum was not an 
unusual variant.
The neutralisation inhibition assay results extended these observations by 
demonstrating that the majority of the neutralising antibodies were directed at 
regions other than those which determined subgroup phenotype. It was not possible 
to perform a NIA with cat 31 serum as only very limited supplies were available. 
Using Bgp70-C it might be possible to generate a serum similar to that of cat 31. 
The differences in reactivity of cat 31 serum and P12 serum are of importance 
when attempting to identify neutralising epitopes on FeLV SU.
These results are all in accordance with previously published work on the 
specificity of neutralising antibodies in relation to subgroup phenotype (Russell and 
Jarred, 1978a; Russell and Jarrett, 1978b). The present work, in utilising subgroup 
chimeras and isolated recombinant SUs, has confirmed that the regions of SU that 
are responsible for subgroup specification are distinct from the regions that are 
recognised by neutralising antibodies. It has also confirmed that the SU proteins
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can be separately classified according to their ability to bind different neutralising 
sera. There is a lack of correlation between subgroup phenotype based on 
superinfection interference and neutralisation assays (Russell and Jarrett, 1978b). 
The ability to produce recombinant FeLV SU which will block the neutralising 
activity of serum from cats that have recovered from a natural challenge represents 
a useful tool for further studies directed at identifying those epitopes that are 
recognised by such virus neutralising antibodies. As the majority of neutralising 
antibodies are specific to a neutralisation subgroup the epitope recognised by 3-17 
is unlikely to be one of the epitopes that the cat mounts a neutralising response 
against.
Glycosylation is important for protein solubility and, sometimes, antigenicity. The 
most significant disadvantage of the baculovirus expression system is that insect 
cell protein glycosylation differs, both quantitatively and qualitatively, from that of 
mammalian counterparts. The nature of glycosylation in insect cells has only been 
examined indirectly; by the incorporation of radiolabelled sugars, by the 
examination of the effect of endoglycosidases and by the addition of glycosylation 
inhibitors such as tunicamycin. The glycosylation of recombinant proteins 
manufactured in the baculovirus expression system has been best studied in the 
production of fowl plague haemagglutinin (Kuroda et al., 1990). These studies 
involved cleavage of radiolabelled carbohydrate side chains with specific 
endoglycosidases. In mammalian cells, carbohydrates are attached to proteins by 
means of a precursor consisting of glucose, mannose and n-acetyl glucosamine 
residues on a dolichol pyrophosphate carrier. This is then trimmed and elongated in 
a series of species and site-specific steps. Insect cells are believed to synthesize 
similar precursors and trim them back to an oligomannosidic core but appear not to 
elongate the trimmed precursor (Kuroda et al, 1990). However, they are able to 
introduce fucose residues onto some of their truncated carbohydrate side chains 
(Kuroda et al, 1990).
There have been few studies on the glycosylation patterns of recombinant retroviral 
proteins produced in the baculovirus expression system. Recombinant ALV gp85, 
in contrast to wild type ALV gp85, is digestible with endoglycosidase H (Notebom 
et al, 1990). This result indicates that full maturation to the complex 
oligosaccharide structure of wild type ALV gp85 is not achieved. This may have 
had functional implications as inoculation of chickens with crude lysates of the 
gp85-expressing Sf9 cells failed to elicited neutralising antibodies although 
specific, non-neutralising, antibodies were produced. In studies of the glycosylation 
of recombinant HTLV-1 env it was demonstrated that only some of the product was 
glycosylated as treatment with tunicamycin did not affect the size of the major
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product (Arp et al, 1993).
Incomplete glycosylation does not necessarily produce a reduction in the ability to 
elicit neutralising antibodies. The F glycoprotein of human parainfluenza virus type 
3, when produced as a recombinant protein in the baculovirus expression system, is 
incompletely glycosylated, yet still elicits a neutralising antibody response in cotton 
rats (Hall et al, 1991). However in other studies carbohydrate side chains have 
been shown to shield antigenic determinants and prevent receptor binding (Deom et 
al., 1986; Robertson et al., 1985).
The high molecular mass species in Bgp70 preparations, seen particularly after 
denaturation prior to deglycosylation, may represent insoluble fractions. This could 
be confirmed by preparing gels containing 6 M urea which increases protein 
solubility. The requirement for urea to solubilise recombinant retroviral proteins for 
SDS-PAGE analysis has already been noted (Arp et al., 1993). Further 
deglycosylation experiments, using more specific endoglycosidases, should be 
performed to assess the specific differences between native and recombinant 
retroviral proteins. The role of the carbohydrate side chains of FeLV SU in 
shielding important epitopes and in cell surface receptor binding could be 
investigated using the products of such experiments. In particular, PNGaseF treated 
Bgp70-A could be used in neutralisation inhibition assays. Other forms of 
denaturation, such as heat treatment, could also be used to assess the contribution 
of higher orders of structure on the binding of neutralisation antibodies to the 
recombinant SUs.
In conclusion, the recombinant surface glycoproteins of FeLV were found to be 
immunologically similar to their native counterparts. They inhibited the action of 
neutralising antibodies and did so in a subgroup specific fashion. These data 
suggested that the proteins may be able to act as ligands for FeLV cell surface 
receptors. They also suggested that the Bgp70-A protein could serve as an FeLV 
vaccine. These possibilities were investigated in experiments detailed in the next 
two chapters.
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Chapter 6. Receptor Binding Studies
6.1 Introduction
This chapter describes the use of recombinant FeLV surface glycoproteins as 
ligands in binding studies aimed at identifying FeLV cellular receptors. The 
identification of the FeLV cellular receptors may help to unravel some of the 
mechanisms underlying the pathogenesis of retrovirus-induced disease. In 
particular, the unique disease specificity of FeLV-C may be due to a specific 
interaction of FeLV-C surface glycoprotein with early erythropoietic progenitor 
cells. An analogous situation has been described in the pathogenesis of murine 
erythroleukaemia induced by Friend spleen focus forming virus (Li et al., 1990).
Recently a protein of approximately 70 kDa has been suggested as a putative 
receptor for FeLV-A (Ghosh et al, 1992). These workers used native FeLV SU in 
several assays in an attempt to define the receptor. The protein was prepared by 
immunoaffinity chromatography of large quantities of detergent disrupted virions 
derived from the concentrated culture fluid of AH927 cells (Rasheed and Gardner, 
1980) infected with FeLV-A. Initially the ability of the protein to bind to the feline 
T cell line, 3201B, was demonstrated. Binding studies were also performed with 
the human T cell line, HuT 78 (Gazdar et al, 1980). The values obtained with this 
cell line were taken as the non-specific background level. No attempt was made to 
block virus infection directly with this preparation of FeLV SU. Subsequently, the 
radiolabelled FeLV gp70 was used to co-immunoprecipitate a cell surface protein 
with an apparent molecular mass of 70 kDa. The converse of this experiment was 
also performed; using 125I surface labelled 3201B cells or cell membranes, a protein 
of similar size was co-immunoprecipitated. Control experiments were also 
performed with HuT 78 cells. No protein was co-immunoprecipitated in these 
cases.
In this chapter, an infection interference assay is described. This assay was 
performed to investigate the ability of one of the proteins, Bgp70-A, to block 
directly the infection by FeLV of a susceptible cell line. The assay was then 
repeated with a wider range of the recombinant proteins to analyse the specificity 
of the reactions.
On the basis of the results obtained from the infection interference assays, cell 
binding experiments were performed with detergent lysates made from 125I surface 
labelled cells. The complexes which formed between the labelled and recombinant 
proteins were cross-linked and then co-immunoprecipitated with an anti-gp70 
monoclonal antibody immobilised on protein G beads. As the recombinant protein
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preparations contained large quantities of a protein, which was presumed to be 
baculoviral gp64, it was decided that radiolabelling of these preparations to detect 
binding of the recombinant surface glycoprotein to cell receptors would result in an 
high background of non-specific activity.
6.2 Results
6.2.1 Infection Interference Assays
Infection interference assays were performed to investigate the ability of the 
recombinant proteins to block FeLV infection of susceptible cells. The ability of 
detergent disrupted FeLV particles to interfere with infection of susceptible cells 
had previously been demonstrated by others (OJarrett, personal communication).
Several preliminary experiments were used to establish a reliable method for this 
assay. These experiments demonstrated that optimum interference by the 
recombinant FeLV-A surface glycoprotein, Bgp70-A, of FeLV-A infection was 
achieved when the recombinant protein was present both during and after the virus 
adsorption phase of infection. No detailed analysis was undertaken into effect of 
the length of time that the protein was incubated with the cells after virus 
absorption. Incubating the cells with the protein before, but not after, virus 
absorption was found to be a poor method of demonstrating infection interference. 
The lack of availability of the relatively large quantities of recombinant proteins 
required for these experiments precluded systematic optimisation of the assays.
Prior to performing the infection interference assays, the effect of amphotericin B 
(Fungizone, Gibco) on the QN10S assay was investigated. It was found that plaque 
formation was not impaired by the inclusion of this antifungal agent at a 
concentration of 2.5 pg/ml.
An infection interference assay was undertaken with Bgp70-A and isolates of all 
three FeLV subgroups. The recombinant FTV surface glycoprotein, BgplOO, was 
used as control in this experiment. To perform this experiment, QN10S cells were 
seeded in 12-well tissue culture plates at a density of 4 x 104 cells per well. The 
next day various aliquots of the recombinant proteins were added to 1 ml aliquots 
of fresh medium, which contained approximately 80 pfu of FeLV-A/Glasgow-1, 
FeLV-B/ST or FeLV-C/FA27C and polybrene at a concentration of 4 pg/ml. An 
additional control which contained no recombinant protein was included. The 
culture fluid was removed from the QN10S cells and replaced with 0.5 ml aliquots 
of the virus-protein-medium mixtures. Each assay was performed in duplicate. The 
cells were incubated for 2 hours, after which time the mixtures were removed and 
replaced with 0.5 ml aliquots of protein-medium mixtures prepared in a similar
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fashion as above, but without virus. The cells were incubated for a further 2 days 
and a further 1 ml aliquot of fresh medium containing amphotericin B (Fungizone, 
Gibco) at a concentration of 2.5 pg/ml was added. The cells were maintained for a 
further 4 days before the number of plaques were counted. The results are shown in 
Table 6.1 and are compared using a graph in Figure 6.1.
A reduction in the number of plaques was observed when Bgp70-A was included in 
the culture fluid during and after FeLV-A infection of QN10S cells. This result 
suggested that Bgp70-A interfered with FeLV-A infection. The recombinant FTV 
SU protein, BgplOO, did not interfere with FeLV-A, FeLV-B or FeLV-C infections. 
Furthermore, Bgp70-A did not interfere with FeLV-B or FeLV-C infections. This 
result suggested that the interference observed between Bgp70-A and FeLV-A was 
subgroup specific. The failure to completely inhibit the infection of the cells was 
believed to be a dose-dependant phenomenon, though an absolute inability of the 
protein to completely inhibit the infection could not be discounted.
In the control reactions a slight rise in the number of plaques was observed with 
increasing volume of recombinant protein added. The rise was constant between the 
various controls and was not dependent on the FeLV subgroup used. A non-specific 
interaction between FeLV and baculoviral proteins may account for this 
observation. Alternatively, the slight decrease in serum protein concentration, 
caused by adding the recombinant protein solution to a maximum volume of 50 pi 
to the original 0.5 ml aliquot of viral inoculum, might be responsible.
To extend the above observations, another infection interference assay was 
performed with a larger range of proteins. The assay was similar to that described 
above. The culture fluid of QN10S cells was replaced with 0.5 ml aliquots of 
FeLV-A inocula to which had been added polybrene and various concentrations of 
one of the recombinant proteins, Bgp70-A, Bgp70-C, Bgp70-215 or BgplOO. A 
control mixture without added protein was included. The control protein 
preparation C5L, which was prepared from the culture fluid of uninfected Sf9 cells 
(see section 4.2.3), was also incorporated into this assay. The cells were incubated 
with the virus-protein-medium mixtures for 2 hours and then the mixtures were 
removed and replaced with 0.5 ml aliquots of medium containing the recombinant 
proteins, but without virus. The cells were incubated for a further 2 days and a 
further 1 ml aliquot of fresh medium containing amphotericin B was added. The 
cells were maintained for a further 4 days before the number of plaques were 
counted. The results are shown in Table 6.2 and are compared using a graph in 
Figure 6.2 (A).
The specific interference of FeLV-A infection by Bgp70-A, previously observed in
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Table 6.1 Infection interference assay 1: titration of protein
1. Bgp70-A Virus
Amount of protein 
(Hg)
FeLV-A/Glasgow-1 FeLV-B/ST FeLV -C/FA27C
None 71.25 61.25 54.5
0.62 65.5 56 59.5
1.88 57.5 63 58.5
6.25 43 69.5 69
2. BgplOO Virus
Amount of protein 
(ng)
FeLV-A/Glasgow-1 FeLV-B/ST FeLV-C/FA27C
None 71.25 61.25 54.5
0.62 79 63.5 57.5
1.88 79.5 63 61.5
6.25 81.5 71.5 60.5
The above tables show the results obtained from an infection interference assay, 
which was performed by incubating QN10S cells with a 0.5 ml aliquot of either 
diluted virus alone, or virus with recombinant protein added. After 2 hours, the 
inocula were removed and replaced with either medium alone or medium with 
recombinant protein added. Two days later, a further 1 ml volume of medium was 
added. Each assay was performed in duplicate. The average number of plaques 
from the 2 wells is shown (4 wells were used for the controls without added 
recombinant protein). The values produced were further expressed as a fraction of 
the values obtained from the controls without protein, the results are presented in 
this manner in Figure 6.1.
Figure 6.1 Infection interference assay Is titration of protein
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The following experiment was performed to determine whether Bgp70-A could 
interfere with viral infection of susceptible cells and if such interference was 
subgroup-specific. QN10S cells were infected for 2 hours with a 0.5 ml aliquot 
either of virus alone, or of virus with recombinant protein added. The inoculum 
was removed and replaced with a 0.5 ml aliquot either of medium alone, or of 
medium with recombinant protein added. Two days later a further 1 ml of medium 
was added. Each assay was performed in duplicate. The plaques were counted 6 
days post-infection. The average number of plaques was expressed as a 
percentage of the average of number of plaques counted in controls with no 
protein.
Table 6.2 Infection interference assay 2: inhibition of FeLV-A
Experiment A
Quantity of 
protein
(wd
Protein
Bgp70-A Bgp70-C Bgp70-215 C5L BgplOO
None 17 17 17 17 17
0.5 22 16 12.5 18 14.5
1.5 11 16.5 17 16 18.5
5 8.5 15 16.5 17 18.5
15 0 15 15.5 23 20
Experiment B
Quantity of 
protein
(Mg)
Protein
Bgp70-A Bgp70-C Bgp70-VC Bgp70-215 C5IVC6L
None 46.6 46.6 46.6 46.6 46.6
0.5 NR 45.5 48 51 53.5
1.5 50.5 47 56.5 64 53.5
5 20.5 61.5 66 62 42
15 0 64 64.5 71.5 60
These tables show the results obtained from infection interference assays 
performed with a range of the recombinant proteins and FeLV-A. These assays 
were performed by incubating QN10S cells with a 0.5 ml aliquot of either the 
diluted virus alone, or virus with recombinant protein added. After 2 hours, the 
inocula were removed and replaced with either medium alone or medium with 
recombinant protein added. Two days later, a further 1 ml volume of medium was 
added. Each assay was performed in duplicate. The average number of plaques 
from the 2 wells is shown (8 wells were used for the controls without added 
recombinant protein). The values produced were further expressed as a fraction of 
the values obtained from the controls without protein, the results are presented in 
this manner in Figure 6.2 (A) and (B).
NR = No result (fungal contamination)
Figure 6.2 (A) Infection interference assay 2: inhibition of FeLV-A
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The following experiment was performed to investigate the ability of the 
recombinant proteins to interfere with the infection of susceptible cells by 
FeLV-A/Glasgow-1. QN10S cells, seeded in a 12-well tray the previous day, 
were incubated with a 0.5 ml viral inoculum containing a diluted recombinant 
protein for 2 hours. After this period the inoculum was removed and replaced 
with 0.5 ml of fresh medium containing only the protein. After 2 days a further 1 
ml of fresh medium was added and the cells were incubated for a further 5 days. 
Each assay was performed in duplicate. The plaques were counted 7 days 
post-infection. The average number of plaques was expressed as a percentage of 
the average of number of plaques counted in controls with no protein.
t n
Figure 6.2 (B) Infection interference assay 2: inhibition of FeLV-A
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The following experiment was performed to investigate the ability of the 
recombinant proteins to interfere with the infection of susceptible cells by 
FeLV-A/Glasgow-1. QN10S cells, seeded in a 12-well tray the previous day, 
were incubated with a 0.5 ml viral inoculum containing a diluted recombinant 
protein for 2 hours. After this period the inoculum was removed and replaced 
with 0.5 ml of fresh medium containing only the protein. After 2 days a further 1 
ml of fresh medium was added and the cells were incubated for a further 5 days. 
Each assay was performed in duplicate. The plaques were counted 7 days 
post-infection. The average number of plaques was expressed as a percentage of 
the average of number of plaques counted in controls with no protein.
Figure 6.1, is again demonstrated in Figure 6.2. Neither BgplOO nor C5L interfered 
with the infection of susceptible cells. Significantly, Bgp70-C and Bgp70-215 
failed to inhibit the infection of the cells by FeLV-A. This result confirmed the 
subgroup-specific nature of the infection interference caused by the recombinant 
proteins.
The infection of the cells was completely inhibited at the highest dose of Bgp70-A. 
The wide range in the number of plaques counted in some of the wells that 
contained control protein preparations was probably due to normal experimental 
variation. The assay was repeated with different batches of protein with similar 
results. See Table 6.2 and Figure 6.2 (B).
To determine if FeLV-C could be inhibited by the recombinant chimeric FeLV-A/C 
protein, Bgp70-215, an infection interference assay was performed with FeLV- 
C/FA27C and the same range of recombinant proteins used previously. The assay 
differed slightly from those described previously. Instead of adding different 
volumes of the recombinant proteins to 0.5 ml of the viral inoculum, the volume 
added to the FeLV-C inoculum was kept constant with the addition of sterile TBS. 
A control mixture without protein was included. A 50:50 mixture of C5L and C6L 
(see section 4.2.3) was also used in this assay. The cells were incubated with the 
virus-protein-medium mixtures and then the protein-medium mixtures as before. 
The results are presented in Table 6.3 and Figure 6.3.
Inhibition of plaque formation was observed in those wells that contained either 
Bgp70-C or the FeLV A/C chimeric protein, Bgp70-215. This result extended 
previous observations on the ability of Bgp70-A to interfere with FeLV-A infection 
by demonstrating that Bgp70-C interfered specifically with FeLV-C. The ability of 
Bgp70-215 to interfere with FeLV-C, but not FeLV-A, demonstrates the functional 
similarity between the A/C subgroup-determining VR1 region of the recombinant 
proteins and native FeLVs (Rigby, 1989).
It was noted that, by keeping the volume of viral inoculum constant, the increase in 
plaque formation noted in Figures 6.1 and 6.2 was no longer observed. This result 
suggested that slight decreases in serum protein concentration slightly increase the 
titre of the virus. It is known that larger reductions in serum protein concentration 
result in decreases in viral titre in neutralisation assays (Russell, 1977). A reduction 
in the number of spurious variations in plaque numbers was also noted. In 
retrospect it would have been preferable to keep the volume of inoculum constant 
in these experiments. Time constraints and the lack of large quantities of 
recombinant proteins prevented the experiments presented in Figures 6.1 and 6.2 
from being repeated with this modification.
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Table 6.3 Infection interference assay 3: inhibition of FeLV-C
Quantity of 
protein
(ng)
Protein
Bgp70-A Bgp70-C Bgp70-215 C5L/C6L BgplOO
None 57.75 57.75 57.75 57.75 57.75
0.5 63.5 37.5 21 57 55
1.5 59 7 2 59 59
5 59 0 0 57 57.5
15 55 0 0 54 61.5
This table shows the results obtained from infection interference assays performed 
with a range of the recombinant proteins and FeLV-C/FA27C. The assay was 
performed by incubating QN10S cells with a 0.5 ml aliquot of either the diluted 
virus alone, or virus with recombinant protein added. After 2 hours, the inocula 
were removed and replaced with either medium alone or medium with recombinant 
protein added. Two days later, a further 1 ml volume of medium was added. Each 
assay was performed in duplicate. The average number of plaques from the 2 wells 
is shown (8 wells were used for the controls without added recombinant protein). 
The values produced were further expressed as a fraction of the values obtained 
from the controls without protein, the results are presented in this manner in Figure 
6.3.
Figure 6.3 Infection interference assay 3: inhibition of FeLV-C
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The following experiment was performed to investigate the ability of the 
recombinant proteins to interfere with the infection of susceptible cells by 
FeLV-C/FA27C. QN10S cells, seeded in a 12-well tray the previous day, were 
incubated with a 0.5 ml viral inoculum containing a diluted recombinant 
protein for 2 hours. After this period the inoculum was removed and replaced 
with 0.5 ml of fresh medium containing only the protein. After 2 days a further 
1 ml of fresh medium was added and the cells were incubated for a further 5 
days. Each assay was performed in duplicate. The plaques were counted 7 days 
post-infection. The average number of plaques was expressed as a percentage 
of the average of number of plaques counted in controls with no protein.
6.2.2 Co-immunoprecipitation Studies
The ability of the recombinant proteins to mimic the subgroup phenotype of the 
native gp70 and to block infection of susceptible cells was used in an attempt to 
identify the FeLV cellular receptors.
Initially the monoclonal antibody 3-17 was attached to protein G immobilised on 
sepharose (Sigma) and then the preparation was used to co-immunoprecipitate the 
putative receptor from a mixture containing the recombinant protein and an 125I 
surface labelled cell lysate.
(1) Coupling 3-17 to Protein G
The method used to couple the monoclonal antibody 3-17 to protein G-sepharose 
beads was similar to a published protocol for attaching antibodies to protein A 
(Harlow and Lane, 1988). An aliquot of 450 pi of 3-17 ascites was mixed with 290 
pi of protein G-sepharose beads and 290 pi of TBS. After 1 hour the beads were 
washed twice with 0.2 M sodium borate (pH 9.0) and then were resuspended in 2.9 
ml 0.2 M sodium borate. Dimethyl suberimidate dihydrochloride (Aldrich) was 
added to a final concentration of 20 mM (=0.2 mg/ml) and the cross-linking 
reaction was allowed to proceed for 1 hour. The reaction was stopped by washing 
the beads for 2 hours in 0.2 M ethanolamine. Finally, the beads were washed twice 
in TBS and were stored at 4°C.
(2) Iodination o f Cells
The cell lines used in these experiments were AH927, 3201 B, MDCK and HuT 78. 
The materials and methods used in the culturing of these cell lines have been 
described previously (section 2.5). For all iodination reactions the cells were 
harvested at 90% confluence from 225cm2 tissue culture flasks. The two adherent 
cell lines, MDCK and AH927, were harvested by incubation with a 0.025% trypsin 
/ PBS-EDTA mixture. The cells were washed twice in PBS before being 
resuspended at a density of 2 x 107 cells/ml of PBS. Trypan blue was used to assess 
the viability of the cells. In all cases more than 98% cells were found to be viable.
Cell surface iodination was carried out using a commercial reagent (1, 3, 4, 6- 
tetrachloro-3a, 6a-diphenylglycoluril: Iodo-gen, Pierce Chemical Company) that 
performs a chemical oxidation reaction which labels surface tyrosine residues. 
Some histidine residues are also labelled using this technique (Harlow and Lane,
1988). A 100 pi aliquot of a 1 mg/ml chloroform solution of Iodo-gen was added to 
a 5 ml glass scintillation vial, which had been previously rinsed with chloroform. 
The solution was left to evaporate until a thin film of reagent could be seen coating
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the glass. The vials were then stored upright in a moisture-free environment at 4°C 
until required.
Immediately prior to use the vials were rinsed carefully with PBS to remove any 
large flakes of reagent. Aliquots of 0.5 ml of PBS and 1 mCi of Na125I were added, 
followed by a 0.5 ml aliquot of PBS containing 107 cells. The reaction was mixed 
gently before being allowed to proceed for approximately 20 minutes. The cell 
suspension was transferred from the vial to a 1.5 ml eppendorf tube. The cells were 
then precipitated by centrifugation at 6500 rpm for 1 minute in a benchtop benchtop 
centrifuge. The supernatant, which contained most of the unbound iodine, was 
carefully discarded. The cells were washed 3 times with 1 ml of PBS. Finally the 
cells were precipitated by centrifugation as before.
(3) Co-immunoprecipitation reactions
Experiments which investigated the interactions of Bgp70 with the cell surface 
proteins were performed with either cell lysates or whole cells.
(a) Cell lysates
The 125I surface labelled cells were lysed by the addition of 1.2 ml of 0.5% NP40 in 
TBS to the precipitated cells. The lysis reaction was allowed to proceed for 5 
minutes before being centrifuged at 6500 rpm in a benchtop benchtop centrifuge for 
5 minutes. The protease inhibitors, leupepsin and pepstatin, were added to the 
supernatant to produce a final concentration of 0.5 pg/ml of each. The supernatant 
was frozen at -70°C until required.
To reduce the level of non-specific binding, the lysates were pre-absorbed with a 
100 pi aliquot of Sephadex G25 (Pharmacia) for 1 hour. The Sephadex G25 was 
removed by centrifugation at 6500 rpm for 1 minute. Aliquots of 250 pi of the 
lysate were incubated at room temperature for 90 minutes with 50 pi aliquots of 
Bgp70-A, Bgp70-C, Bgp70-215, BgplOO which contained 25 pg of total protein. 
Chemical cross-linking was performed in a similar manner to that described 
elsewhere (Brenner et al., 1985; Ghosh et al., 1992). Aliquots of 3 pi from a 100 
mM stock of MgCl2 and 5 pi from a 10 mg/ml DMSO solution of a reducible 
bifunctional cross-linker, dithiobissuccinimidyl propionate (DSP), were added. The 
reaction was allowed to proceed for 30 minutes, then a 15 pi aliquot of 3-17-linked 
protein G-sepharose beads was added for 1 hour. A control reaction was performed 
without protein. The sepharose beads were sedimented by centrifugation at 6500 
rpm for 1 minute and were then washed 3 times in PBS.
Samples were prepared for SDS-PAGE analysis by boiling the protein G-sepharose
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beads in 30 pi of SDS gel loading buffer and then centrifugation at 6500 rpm for 5 
minutes. Aliquots of 10 pi of the resulting supernatants were loaded onto a 10% 
SDS-PAGE gel together with 0.5 pi 14C Rainbow markers (Amersham 
International) + 1.5 pi Rainbow markers. The gel was run at 50 V for 2.5 hours 
and then fixed in de-staining solution (see section 2.3.3) for 20 minutes and 
enlightening solution (Du Pont) for 5 minutes. The gel was dried on Whatman 3M 
paper under vacuum in a heated gel dryer (Model 583, Bio-Rad) and then exposed 
for 7 days at -70°C. Photographs of the autoradiographs are shown in Figure 6.4.
Figure 6.4 demonstrates that a number of protein species were co- 
immunoprecipitated from all four cell lines by this technique. No proteins were co- 
immunoprecipitated in the absence of recombinant protein or in the presence of a 
solution of BgplOO. This solution contains the same background of baculoviral 
proteins as those solutions containing the recombinant FeLV glycoproteins. These 
results suggested that no proteins were co-immunoprecipitated directly by 3-17- 
linked protein G-sepharose beads or in association with baculoviral proteins. This 
indicates that the proteins that were co-immunoprecipitated represented the results 
of interactions between the recombinant FeLV surface glycoproteins and the 
(labelled) cell surface proteins. No difference was observed between those proteins 
co-immunoprecipitated with Bgp70-A, Bgp70-C or Bgp70-215. A common species 
was observed in all the cell lines at 100 kDa. A species that was 70 kDa in size was 
noted in lysates prepared from HuT 78 cells but not in lysates prepared from other 
cell lines. This result contrasts markedly with those of other workers (Ghosh et al, 
1992). The differences in intensity that were observed in the various tracks were 
assumed to be due to normal experimental variation. As different species of protein 
were co-immunoprecipitated from all four cell lines the possibility that free 125I or 
the iodination reaction mix had resulted in the labelling of the recombinant proteins 
was not addressed.
In a separate control experiment the ability of the BgplOO protein to co- 
immunoprecipitate proteins from the labelled lysates was investigated. To perform 
the precipitations the monoclonal antibody VPG 71.2 was first coupled to protein 
G-sepharose beads as described above. Aliquots of 125 pi of the labelled cell 
lysates were incubated with 12.5 pg aliquots of Bgp70-A and BgplOO for 90 
minutes. After this time the mixtures were cross-linked and then co- 
immunoprecipitated with 10 pi of VPG 71.2-linked protein G-sepharose beads as 
before. The beads were analysed by SDS-PAGE and then an autoradiograph was 
prepared from the gel as described above over a period of 21 days. A photograph of 
the autoradiograph is shown in Figure 6.5.
Figure 6.5 demonstrates that no proteins were specifically co-immunoprecipitated
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1 x 107 cells were surface labelled and then lysed with 0.5% NP40 in TBS. 
N on-specific  binding was rem oved by incubation w ith Sepharose G25 
(Pharmacia). Volumes of 250 pi of the supernatant were then incubated at room 
temperature for 90 minutes with 50 pi of the recombinant proteins. Chemical 
c ro ss - lin k in g  w as pe rfo rm ed  w ith  the red u c ib le  c ro ss lin k e r, DSP.
Co-immunoprecipitation was performed with 3-17-linked protein G-sepharose 
beads. The beads were sedimented by centrifugation, washed 3 times with PBS
and then were boiled in 30 pi of SDS gel loading buffer. After centrifugation,
aliquots (10 pi) of the supernatants were loaded onto a 10% SDS-polyacrylamide
gel and electrophoresis performed at 50 V for 2.5 hours. The gel was then fixed,
dried and autoradiographed. The markers used were 14-C Rainbow markers
(Amersham International).
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Aliquots of the radiolabelled lysate supernatants were 
incubated with BgplOO or Bgp70-A as before. Chemical 
cross-linking was perform ed, then the pro teins were 
im m unoprecipitated with the anti-FIV SU m onoclonal 
antibody VPG 71.2, linked to protein G-sepharose beads. 
The beads were sedimented by centrifugation and washed 3 
times with PBS. The beads were then boiled in 30pl of SDS 
gel loading buffer and then briefly centrifuged. Aliquots 
(lO pl) of the supernatan ts were loaded onto a 10% 
SDS-polyacrylamide gel; electrophoresis was performed at 
50 V for 3 hours. The gel was then fixed, dried and 
autoradiographed. The markers used were 14-C Rainbow 
markers (Amersham International).
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with BgplOO or Bgp70-A using the monoclonal antibody VPG 71.2. This result 
suggests a confirmation of the specificity of the co-immunoprecipitations shown in 
Figure 6.4.
(b) Whole cells
In an assay similar to that previously described for identifying FeLV cellular 
receptors (Ghosh et al., 1992), surface iodinated HuT 78 and 3201 cells were 
prepared as detailed above and, after the final PBS wash, were resuspended in 1 ml 
of PBS with 50 mM glucose and 1 mM CaCl2. The suspension was split into 
aliquots of 300 pi and incubated for 30 minutes with 50 pi aliquots of Bgp70-A, 
Bgp70-C Bgp70-215 or BgplOO on a rotating platform. Chemical cross-linking was 
performed by adding MgCl2 and DSP as described previously. The reactions were 
then incubated for a further 30 minutes before the cells were precipitated by 
centrifugation and resuspended in 0.9 ml of TBS. The cells were then lysed with 
the addition of 100 pi of 5% NP40 in TBS and incubated for 5 minutes at room 
temperature. Supernatants were prepared from these reactions by centrifugation at 
6500 rpm for 5 minutes. Non-specific binding was reduced by incubating the 
supernatants with Sephadex G25. Co-immunoprecipitation was then performed 
with 10 pi of 3-17-linked protein G-sepharose beads as described above. The beads 
were analysed by SDS-PAGE and then an autoradiograph was prepared from the 
gel over a period of 10 days as described above. A photograph of the 
autoradiograph is shown in Figure 6.6.
Figure 6.6 demonstrates that few protein species could be detected by this 
technique. The species that were detectable in the Hut 78 cell line were similar in 
size to those co-immunoprecipitated from the cell lysates. This suggested that this 
technique was less efficient than using cell lysates. From the result obtained with 
the control without protein in Figure 6.4, it was decided not to include a similar 
control for this experiment.
6.3 Discussion
This chapter describes the use of the recombinant FeLV surface glycoproteins to 
block the infection by FeLV of susceptible cells. The results from these 
experiments suggested that the proteins could be used as ligands with which to 
define the viral cell surface receptors (VCSRs) for FeLV.
The recombinant proteins interfered with the infection of susceptible cells in a 
subgroup specific manner. A chimeric protein containing the VR 1 region of FeLV- 
C in an FeLV-A backbone (Bgp70-215) blocked the infection of FeLV-C but not 
FeLV-A. This result corroborated data demonstrating that the VR 1 region of FeLV
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1 x 107 cells were surface labelled as before and were then incubated with the 
recombinant proteins for 30 minutes. Chemical cross-linking was performed with 
DSP and then the cells were lysed with 0.5% NP40 in TBS. The lysates were 
cleared by centrifugation and non-specific binding was removed by incubation of 
the su p e rn a ta n t fo r 1 hour w ith  S ep h a ro se  G25 (P h a rm a c ia ) . To 
co-immunoprecipitate putative receptor / ligand complexes an aliquot of 10 pi of
3-17-linked protein G-sepharose beads was added for 1 hour. The beads were
then sedimented by centrifugation and washed 3 times with PBS. The beads were 
boiled in 30 pi of SDS gel loading buffer and then briefly centrifuged. Aliquots
(10 pi) of the supernatants were loaded onto a 10% SDS-polyacrylamide gel and
electrophoresis performed at 50 V for 2.5 hours. The gel was then fixed, dried and
autoradiographed.
The markers used were 14-C Rainbow markers (Amersham).
determines the A/C subgroup phenotype (Rigby, 1989). As the existence of three 
FeLV subgroups has been taken as evidence of three FeLV receptors (Sarma and 
Log, 1973; Riedel et al., 1986; Rigby et al, 1992; Brojatsch et al., 1992), it follows 
that the VR1 region represents at least part of a putative receptor binding site (RBS) 
for FeLV. The recombinant proteins therefore contain a receptor binding site (RBS) 
which functions in a similar fashion to the native RBS.
The chimeric Bgp70-215 protein functioned in a similar fashion to Bgp70-A in 
neutralisation inhibition assays (see section 5.2.3). These results demonstrated that, 
in the recombinant chimeric protein, the major neutralisation epitopes were separate 
from the subgroup determining region. This demonstration mirrored observations 
made from studies on native FeLVs (Russell and Jarrett, 1978b; Rigby, 1989) and 
served to emphasise the functional similarity of the recombinant and wild type 
proteins.
FeLV infection could be completely inhibited by increasing the quantity of the 
recombinant proteins. This result demonstrates that exogenous blockade can be as 
effective as the endogenous blockage observed during superinfection interference 
assays. Further work defining the precise qualities of this blockade may help to 
determine whether the phenomenon of superinfection interference is mediated 
entirely at the cell surface or partly post-binding. It has been suggested that FeLV 
receptors are expressed, albeit at a lower level, in infected cells (Ghosh et al., 
1992).
The subgroup specific interference that was observed is best explained in terms of 
receptor blockade. However, no conclusive evidence is presented that this is indeed 
the case. Confirmation of receptor blockade would require competitive binding 
studies involving preparations of highly purified recombinant and native proteins, 
one of which had been specifically labelled. Interaction could occur between the 
recombinant proteins and the native, virion-associated, surface glycoprotein, such 
that the virus was inactivated. However, it is suggested that any such process is 
unlikely to be subgroup specific. For example, the formation of hetero-oligomers 
composed of the recombinant and native proteins could result in inactivation. 
However, it is known that the formation of native SU oligomers is dependent on a 
portion of the amino terminus of the transmembrane protein, TM (Einfeld and 
Hunter, 1988). In FeLV the predicted amino acid sequences of this segment are 
constant between the three subgroups. Therefore, the formation of such hetero­
oligomers would be, almost certainly, subgroup independent.
The ability of recombinant, RBS-containing, proteins to block the infection of a 
susceptible cell line has previously been reported for Epstein-Barr virus (Tanner et
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ah, 1988). The infection of susceptible cell lines has also been blocked by synthetic 
peptides corresponding to putative RBSs. For example, the cellular receptor of 
vaccinia virus was identified as the epidermal growth factor receptor by the ability 
of a synthetic peptide, corresponding to a region of the envelope glycoprotein that 
was homologous with epidermal growth factor, to block plaque formation (Eppstein 
et ah, 1985). These workers also demonstrated that an additional decrease in the 
number of plaques was obtained when the peptide was included after, as well as 
during, the virus adsorption phase. A similar observation was made in the 
preliminary experiments used to define the conditions for the infection interference 
assays. Further experiments should be performed to optimise the assay and 
investigate this phenomenon.
It would be interesting to repeat the FeLV-C infection interference experiment in 
the presence of FeLV-A neutralising serum and Bgp70-215. This would determine 
if FeLV-A neutralising antibodies acted by interfering with receptor binding. Such 
antibodies would not have an effect on FeLV-C, but if they induced conformational 
changes or steric hindrance of the receptor binding properties of Bgp70-215 then 
the infection interference properties of this recombinant protein would be reduced. 
It would not be possible to use Bgp70-A for this experiment as it does not interfere 
with FeLV-C. Similarly, it would not be possible to use FeLV-A in this experiment 
as the neutralising antibodies would also act on the virus. Such studies would help 
to define the action of neutralising antibodies in the FeLV system. It has been 
demonstrated that the antibody class can influence the mechanism of action (Taylor 
and Dimmock, 1985). In that study secretory IgA was found to block receptor 
binding, but neutralising IgG and monomeric IgA molecules did not prevent 
receptor binding. It would probably be technically simpler to perform the above 
experiment than to measure directly the binding of the chimeric virus in the 
presence of FeLV-A neutralising serum.
This is the first report of recombinant proteins that are capable of directly 
interfering with FeLV infection. The availability of such reagents may facilitate the 
identification of the FeLV cellular receptors. The ability of the recombinant 
proteins to accurately mimic the subgroup phenotype of the native gp70 was crucial 
to the relevance of the subsequent co-immunoprecipitation experiments. These 
studies were performed with AH927 and 3201 B cells, which are susceptible to 
FeLV-A (Rasheed and Gardner, 1980; Rojko et ah, 1991) together with MDCK and 
HuT 78 cells, which are not thought to be susceptible to FeLV-A (Jarrett et ah, 
1972; Sarma et ah, 1975). AH927 and 3201 B cells are also susceptible to FeLV-C 
(Rasheed and Gardner, 1980; Rojko et ah, 1991). The ability of MDCK and HuT 
78 cells to support the growth of FeLV-C is unknown and was not investigated.
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The co-immunoprecipitation studies demonstrated that a number of cell surface 
proteins on both susceptible and non-susceptible cell lines interact with 
recombinant FeLV surface glycoproteins. The lack of subgroup specificity in the 
co-immunoprecipitation reactions contrasted markedly with the subgroup 
specificity of the infection interference assays. The number of proteins that were 
co-immunoprecipitated strongly suggests that the recombinant FeLV surface 
glycoproteins cannot be used in this manner to directly identify FeLV cellular 
receptors. These results are at variance with the results of Ghosh et al> (1992), 
which indicated that isolated native gp70 co-immunoprecipitated one protein 
species from 320IB cells and none from HuT 78 cells. A major drawback of that 
study was the failure to demonstrate that the preparation of SU was capable of 
specifically blocking virus entry.
Co-immunoprecipitation of cross-linked protein complexes is, notwithstanding the 
above caveats, a specific method of identifying stable interactions between proteins 
(Brenner et al., 1985). From the negative results of the co-immunoprecipitation 
studies with VPG 71.2 it is probable that the cell surface proteins co- 
immunoprecipitated in the set of reactions illustrated in Figure 6.4 do represent the 
results of non-random interactions with the recombinant baculoviral proteins. 
However, the efficiency of the protein G coupling was not assessed for either 3-17 
or VPG 71.2 and the relative binding abilities of the immobilised monoclonal 
antibodies were not compared. Furthermore, a conformational change of BgplOO 
could be induced by binding to a cell surface protein such that VPG 71.2 could no 
longer immunoprecipitate BgplOO. Therefore, it is possible that this control 
experiment does not permit an assessment to be made of the specificity of the main 
set of reactions. This indicates that there is a slight possibility that some or all of 
these cell surface proteins are the results of random interactions and are not 
involved in virus binding or entry. Repeating this experiment with an FTV 
susceptible cell line with a preparation of recombinant FTV SU that was known to 
block infection would help to unravel this conundrum. Another modification that 
could be made in future experiments is to alter both the concentration and the 
composition of the lysis buffer in which the reactions were carried out. This could 
help to increase further the specificity of the reactions.
It is possible that the actual initial attachment of the virus to the cell is not mediated 
by the VCSR/RBS interaction, but rather by other, less specific, transient, protein- 
protein interactions. Such interactions, though not random, need not be specific to 
susceptible cells and could involve several proteins; unless the RBS subsequently 
recruits a VCSR, the virus will still fail to penetrate the cell. Therefore, another 
interpretation of the results could be that the experiments had identified several cell
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surface proteins involved in this initial phase. This explanation accounts for the 
large number of protein species that were specifically co-immunoprecipitated.
The cell surface proteins involved in these transient non-specific protein-protein 
interactions might also interact in a similar fashion with other viral proteins. The 
use of BgplOO in this chapter was an attempt to control for this variable. As it was 
not possible to prove that BgplOO did not bind to any of the cell lines, the 
interpretation of the results as suggesting that the Bgp70 proteins bound to cell 
surface proteins that were involved in the initial transient phase is still valid. If the 
results of these experiments are interpreted in either of the above fashions, then 
they would suggest that to use co-immunoprecipitation with recombinant viral 
proteins to identify that specific entity which serves as the VCSR is fraught with 
the potential for non-specific interaction. By implication, experiments involving 
preparations of native glycoprotein, especially those which have not been 
demonstrated to block viral infection (Ghosh et al, 1992), are also open to over­
interpretation. It should be noted that the conditions used in the co- 
immunoprecipitation experiments described in this chapter resemble those used by 
Ghosh et al. to identify a 70 kDa protein as a putative FeLV receptor.
It is interesting that, prior to the identification of the ecotropic MuLV receptor as 
the basic amino acid transporter, y + (Albritton et al, 1989; Kim et al., 1991; Wang 
et al., 1991), several attempts had been made to identify the receptor using co- 
immunoprecipitation techniques with 125I surface labelled cells (Robinson et al, 
1980; Schaffar-Deshayes et al, 1981). The earlier study demonstrated a 14 kDa 
protein on the surface of leucocytes that bound to MuLV gp85 complexes. The later 
study demonstrated a 190 kDa protein on the surface of thymus cells that bound to 
MuLV gp71. The predicted molecular mass of the MuLV receptor is 67 kDa 
(Albritton et al., 1989). These results also suggest that using co-
immunoprecipitation to identify viral cellular receptors may be an unreliable 
technique.
The experiments described in this chapter and elsewhere (Reinhart et al., 1993) do 
suggest that superinfection interference and virus binding may be more complicated 
than previously assumed. Superinfection interference may be due to blockade of 
(subgroup specific) cell proteins that are required for virus entry, but not for 
primary virus binding (Reinhart et al., 1993). Further studies on the ability of non- 
susceptible and susceptible cells to bind FeLV, or its recombinant surface 
glycoprotein, are required.
Many other viral cellular receptors have been identified using monoclonal 
antibodies which block virus infection (Fingeroth et al, 1984; Dalgleish et a l,
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1984; Greve et al, 1989; Staunton et al, 1989; Bergelson et al, 1992). These 
monoclonal antibodies are usually raised against susceptible cells. As a result of the 
large number of proteins in these preparations, many hybridomas may have to be 
screened before such a monoclonal antibody is identified. As it is likely that the 
recombinant proteins do bind to the FeLV receptors (as well as other proteins), it 
may be possible by affinity purification using the recombinant proteins to decrease 
the number of contaminating proteins in the susceptible cell preparation used to 
immunise the mice. This might decrease the number of hybridomas that 
subsequently have to be screened.
The receptors for gibbon ape leukaemia virus and ecotropic murine leukaemia virus 
were identified by transfection of cDNA into non-permissive cells, followed by 
probing with recombinant retroviruses expressing drug resistance genes (Albritton 
et al., 1989; O'Hara et al., 1990). It is suggested that the identification of the 
receptors for FeLV may require this type of approach.
Chapter 7. Vaccination Studies
7.1 Introduction
This chapter describes a trial of the recombinant FeLV-A surface glycoprotein, 
Bgp70-A, as a candidate FeLV vaccine. In previous chapters it has been 
demonstrated that this protein is recognised by the sera of cats which have 
recovered from FeLV infection (see sections 5.2.1 and 5.2.2). The protein also 
inhibits the action of neutralising antibodies in vitro (see section 5.2.3). These 
results suggested that the protein might be able to generate neutralising antibodies 
in vivo and thereby induce protection against FeLV challenge.
No commercially available FeLV vaccine has been demonstrated to elicit 
neutralising antibodies prior to challenge with FeLV. One experimental vaccine 
containing native gp70 incorporated into ISCOMs has been demonstrated to elicit 
pre-challenge neutralising antibodies (Osterhaus et al, 1985; Osterhaus et al,
1989). The development of a vaccine that was commercially viable and induced 
prechallenge neutralising antibodies would be of considerable clinical benefit. The 
presence of neutralising antibodies, even at very low titres, is thought to confer 
protection against subsequent viral challenge (Jarrett et al, 1977; Russell and 
Jarrett, 1978b; deNoronha et al, 1978). A vaccine was prepared from the 
recombinant protein and included as part of a larger trial of several other 
experimental FeLV vaccines.
Recombinant soluble proteins are often weak immunogens (Byars and Allison, 
1988; Reid, 1992; Gupta et al, 1993). It was decided that a potent adjuvant should 
be used in the vaccine trail. Quil A is purified by aqueous extraction from saponin, 
which is a mixture of glycosides obtained from the bark of a South American tree, 
Quilaja saponaria Molina. It has been demonstrated to have adjuvanting properties 
and is used in the formation of ISCOMs (Smith et al, 1981; Morein et al, 1984; 
Bomford et al, 1992). QS-21 is a component of Quil A, purified by reverse phase 
chromatography, which has been demonstrated to have minimal toxicity, whilst 
retaining the adjuvant properties of Quil A (Kensil et al, 1991). QS-21 is used as 
an adjuvant in Leucogen (Virbac), which is one of the FeLV vaccines that are 
commercially available in the UK. Quil A is used as an adjuvant in the other 
commercially available FeLV vaccine, Leukocell 2 (SmithKline Beecham Animal 
Health).
107
7.2 Results
7.2.1 Experimental Animals
The specific pathogen free (SPF) cats used in this experiment were obtained from a 
commercial source when they were 7 weeks old and were kept in a barrier 
maintained cattery at Glasgow University. The cats were fed on a diet of Whiskas 
(Pedigree Petfoods) and heat sterilised milk.
Throughout the experiment the welfare of the animals was carefully monitored by 
trained technical staff under the supervision of veterinary surgeons. Experimental 
procedures were carried out within the terms of the Animals (Scientific Procedures) 
Act, 1986. At the end of the experiment (week 19 - see below) all the cats were 
killed using pentobarbitone, which was administered intravenously.
On arrival at the cattery each cat was injected subcutaneously with 0.2 ml of a long 
acting preparation of amoxycillin (Clamoxyl LA, Smithkline Beecham Animal 
Health) and assigned, at random, into one of three groups. Antibiotic cover was 
provided as previous experience had indicated that mild outbreaks of bacterial 
respiratory disease often accompanied transportation and rehousing of the cats. 
Group 1 contained five cats that were subsequently vaccinated with the 
experimental vaccine and were numbered 171 to 175. Group 2 contained five cats 
that were subsequently vaccinated with a commercial FeLV vaccine (Leucogen; 
Virbac) and were numbered 181 to 185. Group 3 contained five cats that were not 
vaccinated and therefore served as the control group. These cats were numbered 
186 to 190.
7.2.2 Preparation of Experimental Vaccine
The recombinant protein vaccine was prepared using a stock of Bgp70-A protein 
that contained 0.3 mg/ml of total protein. A 4.0 ml volume of the recombinant 
protein was formulated into a vaccine with the addition of 0.3 ml of TBS, 0.9 ml of 
a 3% suspension of aluminium hydroxide (Superfos) and 265 pi of a 1 mg/ml 
preparation of Quil A (Superfos; batch number 01046, expiry date February 2003). 
The vaccine was prepared on the day of use and stored on ice.
7.2.3 Vaccination Regime
A subcutaneous injection of 1 ml of the experimental vaccine was given to each cat 
in Group 1 on two occasions, with an interval of 3 weeks. The cats in Group 2 were 
vaccinated at the same time with Leucogen (batch number, 809857/2 K075: expiry 
date, January 1995). The cats in Group 3 were not vaccinated. After each 
vaccination the cats were closely monitored for signs of illness. The first
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vaccinations were given when the cats were 8 weeks old; this time point was taken 
as week 0 of the experiment. For a period of 24 hours after the initial vaccination 
all the cats in Groups 1 and 2 were lethargic. All the cats recovered without 
treatment. No adverse reactions were seen after the second vaccine dose.
Five weeks after the first vaccination all the cats were challenged by oronasal 
inoculation of 1 ml of culture medium containing 1 x 106 pfu of FeLV-A/Glasgow- 
1. This was performed by Professor O. Jarrett by introducing a 0.5 ml aliquot into 
the cat's oropharynx and 0.25 ml aliquots into each nasal chamber.
Heparinised blood samples were obtained from the cats by jugular venepuncture at 
weeks 0, 2, 5, 8, 11, 14 and 19 of the experiment. The plasma was prepared from 
the blood samples by centrifugation at 2000 rpm for 5 minutes in a GPR centrifuge 
and was then frozen in aliquots at -70°C until required.
7.2.4 Analysis of Responses to Vaccination
(1) FeLV assays
Viraemia was assessed by the staff of the Feline Virus Unit using a p27 
competition ELISA and by virus isolation. The p27 ELISA was performed using 
p27 antigen coated wells (Inochem). An 80 pi aliquot of an anti-p27 monoclonal 
antibody-horseradish peroxidase conjugate was added to each well, followed by a 
15 pi aliquot of the test serum. Positive and negative control sera were included in 
each set of reactions. The wells were incubated for 1 hour at room temperature and 
then were washed with a 150 mM NaCl, 0.05% Tween 20 solution. During this 
time the substrate solution was prepared using a commercial kit (TMB microwell 
peroxidase substrate system; Kirkegaard and Perry Laboratories) by mixing equal 
volumes of 3,3',5,5' tetramethylbenzidine (TMB) at a concentration of 0.4 g/1 in an 
organic solvent and 0.02% H2C>2 in a citric acid buffer. After washing the wells 
were blotted dry and then a 100 pi aliquot of the freshly prepared TMB substrate 
solution was added to each well. The reactions were incubated for a further 15 
minutes. The results were read at 650nm using an EL312 Bio-Kinetics ELISA plate 
reader (Bio-Tek Instruments).
Viral isolation was performed by seeding QN10S cells in 12-well tissue culture 
plates at a density of 4 x 104 cells per well with 1.0 ml culture fluid containing 4 
pg/ml of polybrene. The next day 200 pi of the plasma was inoculated into the 
culture fluid and the cells incubated for 2 hours. The inoculum was then removed 
and the cells were incubated for a further 6 days with fresh culture fluid. After this 
time the cells were examined for foci of transformation. The cells in those wells 
without evidence of transformation were routinely subcultured for a further 4 days
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before final scoring.
(2) Anti-gp70 antibody assays
The presence of anti-gp70 antibodies in the plasma of the cats was assessed by 
virus neutralisation and western blotting assays.
The presence of neutralising antibodies was assessed by the staff of the Feline 
Virus Unit using a method similar to that described previously for the neutralisation 
inhibition assay (see section 5.2.3). To perform these assays, QN10S cells were 
seeded in 12-well tissue culture plates at a density of 4 x 104 cells per well with 1.0 
ml culture fluid containing 4 pg/ml of polybrene. The next day twofold dilutions of 
50 pi of the heat inactivated plasma were made in 96-well round bottomed 
microtitre trays. A stock of FeLV-A was diluted to 4 x 102 pfu/ml and then 50 pi 
aliquots were added to the plasma dilutions. The microtitre tray was incubated in a 
humidified incubator for 6 hours. Samples of 25 pi were then added to the culture 
fluid of the QN10S cells. After 2 hours the culture fluid was removed and the cells 
were incubated with fresh medium for a further 6 days. After this time the cells 
were examined for foci of transformation. The end point of assay was taken as that 
dilution of plasma which produced a 75% reduction in the number of plaques 
compared to SPF control serum. Recovered cat serum P ll  was used as a positive 
control in these assays.
The western blot analyses of plasma derived from the cats were performed by Dr. J. 
Christie and Mr. M. Golder (Feline Virus Unit). A nitrocellulose membrane was 
prepared from a 15% SDS-PAGE gel using FeLV derived from F422 culture fluid. 
An aliquot of 100 pi of the vaccine protein and 30 pi of concentrated F422 culture 
fluid were electrophoresed at 100 V until the sample dye reached the bottom of the 
gel. The proteins were then transferred to the membranes. The membranes were 
incubated overnight with blocking solution (see section 2.1.3) supplemented with 
20% goat serum. The next day they were washed 3 times with PBS-Tween (see 
section 2.1.3). The membranes were stored in a moisture free environment in an 
airtight plastic bag at -20°C until required.
The plasmas were preincubated overnight with blocking solution to which had been 
added 20% goat serum, 0.2 % (v/v) 0.5 M EDTA and 0.5% (v/v) Tween 20 
('modified blocking solution'). Supernatants were prepared by centrifugation in a 
benchtop benchtop centrifuge at 6000 rpm for 5 minutes. The nitrocellulose 
membranes were sliced into 2 mm wide strips which were then placed in multiwell 
trays. The blots were incubated with the supernatants for 2 hours. After washing 
with PBS-Tween, the blots were incubated with biotinylated protein A, diluted 1 in 
500 with modified blocking solution, and then, after washing with PBS-Tween,
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with streptavidin-alkaline phosphatase conjugate, which was also diluted 1 in 500 
with modified blocking solution. The western blot strips were developed with 
BCIP/NBT (as described in section 2.3.5). The blots were scored empirically by 
comparison with controls performed with recovered cat serum P ll. A slight 
variation in sensitivity was noted between the different blots that were prepared for 
each set of samples.
The results of these tests are given in Tables 7.1 and 7.2. None of the cats were • 
viraemic or p27 antigenaemic prior to challenge. No cat prior to challenge 
developed virus neutralising antibodies. Only the cats vaccinated with Leucogen 
developed anti-gp70 antibodies on western blot analysis prior to challenge. 
Following challenge with FeLV all the unvaccinated cats became viraemic and 
antigenaemic. One cat, F187, later developed neutralising antibodies and became 
aviraemic, though it was still p27 antigenaemic at the end of the trial. It is probable 
that, had the experiment been continued, this cat would have fully recovered from 
the infection. In this group therefore four of the cats became persistently viraemic 
and the other cat became transiently viraemic. Small quantities of anti-gp70 
antibodies were detectable in some of the other control cats by the end of the trial. 
This is common in persistently viraemic cats (Lutz et al, 1980).
Four of the cats vaccinated with Leucogen became persistently viraemic. The 
remaining cat in Group 2, FI 83, was positive on the p27 ELISA during week 8, but 
no infectious virus was ever isolated and the p27 antigenaemia regressed in 
subsequent samples. This result suggested that a low level of FeLV replication had 
occurred in this cat. This cat developed neutralising antibodies by the end of the 
trial.
In the group of cats vaccinated with the recombinant protein preparation (Group 1) 
two out of the five cats were p27 and virus negative during week 8, but 
subsequently one of these (number 175) became persistently viraemic. Cat number 
173 never became antigenaemic or viraemic. Only cat number 173 produced anti- 
gp70 antibodies that were readily detectable using western blot analysis: it also 
developed virus neutralising antibodies 9 weeks after challenge. The other cats in 
this group produced anti-gp70 antibodies that were only barely detectable on 
western blot.
These results suggest that neither of the vaccines were effective at preventing the 
development of persistent viraemia in the cats.
(23 Analysis o f  response to vaccine protein
A series of western blots were performed to further analyse the antibody responses
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of the experimental cats which were vaccinated with Bgp70-A. The cats' plasma 
samples were used to probe nitrocellulose membranes onto which had been blotted 
either the Bgp70-A vaccine protein, or FeLV proteins derived from F422 cell 
culture fluid. The membranes were prepared from two single well 5-20% gradient 
SDS-polyacrylamide gels. An aliquot of 100 pi of the vaccine protein and 30 pi of 
concentrated F422 culture fluid were electrophoresed at 100 V until the sample dye 
reached the bottom of the gel. The proteins were then transferred to the membranes. 
The membranes were incubated overnight with blocking solution (see section 2.1.3) 
supplemented with 20% goat serum. The next day they were washed 3 times with 
PBS-Tween (see section 2.1.3). The membranes were stored in a moisture free 
environment in an airtight plastic bag at -20°C until required.
To reduce non-specific activity, a preincubation solution was prepared by mixing 
equal volumes of concentrated supernatants harvested from wild type baculovirus 
infected, and mock infected, Sf9 cells (preparations C6 and C5 - see section 4.2.3). 
Aliquots of 10 pi of each cat's plasma from the 0, 5 and 11 week samples were 
incubated overnight at 4°C with 100 pi volumes of the preincubation solution. The 
next day each reaction was added to a 100 pi aliquot of blocking solution to which 
had been added 20% goat serum, 0.2 % (v/v) 0.5 M EDTA and 0.5% (v/v) Tween 
20 ('modified blocking solution'). Each reaction was then centrifuged at 6000 rpm 
in a bench top benchtop centrifuge for 3 minutes and the supernatants were 
retained. The final concentration of the plasma was therefore 1 in 20.
The two nitrocellulose membranes were sliced into 2 mm wide strips which were 
then placed in multiwell trays. The strips were orientated by placing a diagonal cut 
at the top of each. The strips were washed twice with PBS-Tween and were then 
incubated with the preincubated supernatants. After 2 hours, the strips were washed 
with PBS-Tween (see section 2.1.3) for 30 minutes. Goat anti-cat IgG-alkaline 
phosphatase conjugate (Sera Lab), diluted 1 in 300 with modified blocking solution, 
was added to the strips in 100 pi aliquots for 1 hour.
Control sera from a recovered cat (Pll), a SPF cat (Wendy) and a pooled 
preparation of recovered cat sera (PRCS) were prepared by adding 10 pi samples to 
100 pi aliquots of the preincubation solution. To these preparations were added 100 
pi volumes of modified blocking solution. The preparations were left for 15 
minutes at room temperature and then centrifuged at 6000 rpm in a bench top 
benchtop centrifuge for 3 minutes. The nitrocellulose strips were incubated with 
100 pi aliquots of the supernatants. After 2 hours, the strips were washed with 
PBS-Tween and then incubated with the conjugate preparation as above.
An ascites preparation of an anti-FeLV gp70 monoclonal antibody, 6-15, was
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diluted 1 in 100 with modified blocking solution and used to probe a nitrocellulose 
strip from each of the membranes. In the wells containing these strips a goat anti­
mouse IgG-alkaline phophatase conjugate (BioRad) was used as the second 
antibody. This conjugate was diluted 1 in 500 with modified blocking solution.
After incubation with the antibody conjugates, all the strips were washed three 
times with PBS-Tween for 1 hour, then with AP buffer for 5 minutes. The western 
blot strips were developed with BCIP and NBT in AP buffer (as described in 
section 2.3.5). Photographs of the western blots are shown in Figure 7.1. In this 
figure, the sera obtained at 0, 5 and 11 weeks are referred to as the prevaccination, 
prechallenge and 6 weeks post challenge (6 w.p.c.) samples respectively.
Photographs of some of the western blot analyses, performed by Dr. J. Christie and 
Mr. M. Golder (Feline Virus Unit), of samples derived from the cats vaccinated 
with Leucogen are shown for comparative purposes in Figure 7.2. The method is 
given above in section 8.2.4. The samples shown were derived from weeks 0, 5 and 
14 of the experiment and are referred to as the prevaccination, prechallenge and 9 
weeks post challenge (9 w.p.c.) respectively.
These photographs show that all of the Leucogen vaccinated cats developed anti- 
gp70 antibodies prior to challenge. In contrast, none of the cats vaccinated with the 
recombinant baculovirus derived material developed anti-gp70 antibodies prior to 
challenge. In accordance with the results obtained from the Feline Virus Unit, one 
cat (number 173) from Group 1 did develop anti-gp70 antibodies 6 weeks post 
infection. This was the same cat that did not develop viraemia. All of the cats in 
Group 1 developed specific responses to species of protein in the vaccine 
preparation, but did not develop responses to the species recognised by the 6-15 
monoclonal antibody. No response was apparent to the presumed baculoviral gp64 
protein. This indicated that the preincubation had removed non-specific activity. 
The results therefore suggest that the cats preferentially and specifically recognised 
a higher molecular weight species of the recombinant protein. These higher 
molecular weight forms were also apparent in western blots shown previously in 
Figure 5.1. None of the control cats developed titres of anti-gp70 antibodies as high 
as those of the Leucogen vaccinated cats.
7.3 Discussion
This chapter describes a vaccine trial involving the FeLV-A recombinant 
glycoprotein preparation, Bgp70-A. Only the FeLV-A recombinant glycoprotein 
was included in the experimental vaccine as it is this subgroup that is thought to be 
transmitted between cats in the natural situation (Jarrett et al., 1978; Donahue et
113
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al, 1988). Experimental cats were vaccinated with either the recombinant protein 
vaccine or a commercially available vaccine (Leucogen; Virbac) and then 
challenged by oronasal inoculation of FeLV-A. This route of inoculation was used 
as it mimics the natural route of infection (Rojko et al., 1979b). In all three groups 
the challenge resulted in four out of the five cats becoming persistently viraemic. In 
the unvaccinated control group the remaining cat became transiently viraemic. In 
the group vaccinated with Leucogen the remaining cat became transiently p27 
antigenaemic. In the group vaccinated with the experimental vaccine there was no 
evidence of FeLV replication in the remaining cat.
There are several precedents for using baculovirus derived recombinant proteins in 
vaccine studies. Recombinant glycoprotein D of herpes simplex virus (HSV) type 2 
has been reported to elicit both humoral and cellular responses that protect mice 
against a subsequent lethal HSV challenge (Landolfi et al., 1993). Similar 
responses were also observed against HSV type 1 proteins suggesting that cross­
protection may be possible. However, not all recombinant proteins produced using 
baculoviruses are so effective. Vaccination against parainfluenza type 3 (PI-3) virus 
with either recombinant fusion (F) or haemagglutinin-neuraminidase (HN) proteins 
was only partially protective (van Wyke Coelingh et al., 1987; Hall et al., 1991). A 
chimeric FHN protein expressed in the baculovirus system induced higher levels of 
anti-PI-3 antibodies and better protection against experimental challenge compared 
with vaccination with either the F or HN proteins alone (Brideau et al, 1993). 
Recombinant HTLV-1 env, when produced in insect cells, does not induce 
neutralising antibodies, though it does induce specific antibodies against synthetic 
peptides corresponding to important epitopes (Arp et al., 1993).
A recombinant HIV env product, rgpl60, has become the most intensively studied 
baculovirus-derived vaccine. This protein was extracted from the insect cells using 
sodium deoxycholate and then purified using gel filtration followed by lentil lectin 
affinity chromatography (Cochran et al. 1987; Dolin et al., 1991). The vaccine 
preparation was adjuvanted with aluminium phosphate gel. This preparation was 
shown to be both safe and effective at inducing specific anti-gpl20 antibodies in 
healthy humans (Dolin et al., 1991). Neutralising antibodies were elicited in some 
subjects after several vaccinations. Antigen-specific lymphocyte proliferative 
responses were also elicited in humans and rhesus macaques vaccinated with this 
preparation (Keefer et al., 1991; Newman et al., 1992). Phase 1 clinical trials were 
also carried out with asymptomatic HIV positive individuals; the results were 
moderately encouraging (Redfield et al, 1991). Antibodies appear to be directed at 
the carboxy terminus of the SU component rather than the putative neutralising V3 
epitope (Newman et al, 1992). This study also demonstrated the superior
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adjuvanting properties of the purified Quil A derivative, QS-21. Incorporation of 
recombinant HIV gpl20 into ISCOMS may improve the vaccine's immunogenicity 
further (Browning et al, 1992). These results had suggested that the lentil lectin 
purified Bgp70-A protein when adjuvanted with Quil-A might serve as a vaccine 
against FeLV.
Leucogen, in contrast to the above vaccines, is an FeLV vaccine that contains a 
recombinant protein produced using a bacterial expression system (Marciani et al, 
1991). These authors reported the initial development of the vaccine from a 
truncated FeLV env gene which had been inserted into a temperature sensitive 
bacterial expression plasmid. The protein was initially solubilised with 6 M 
guanidine hydrochloride and then purified by gel filtration. The product was then 
redissolved in 8 M urea and a QS 21 adjuvanted preparation was used as an FeLV 
vaccine. Neutralising antibodies were induced in two out of seven cats prior to 
challenge and none of the vaccinated cats became either transiently or persistently 
viraemic. In contrast, three out of the four control cats became persistently 
viraemic, the remaining cat only became transiently viraemic. Clark et al. (1991) 
reported a more extensive trial which demonstrated that cats vaccinated with 
Leucogen only very occasionally produce virus neutralising antibodies. In this trial 
all the twenty control cats developed viraemia (six transiently) following challenge. 
Nine out of the twenty cats vaccinated with Leucogen did not develop viraemia; a 
further eight developed a transient viraemia. Others (Lehmann et al., 1991) have 
shown that pre-existing FIV infection does not affect the response to this 
vaccination.
The results obtained from the vaccine trial reported in this chapter suggested that 
neither vaccine was effective at preventing FeLV infection. There was no evidence 
in any of the vaccinated cats of virus neutralising antibodies prior to challenge. 
There were high titres of anti-gp70 antibodies on western blots in the Leucogen 
vaccinated cats; however, four out of the five cats vaccinated with Leucogen 
became persistently viraemic and the remaining cat was initially antigenaemic. 
Antigenaemia, in the absence of viraemia, may indicate a low level of FeLV 
replication in this cat. It is therefore suggested that none of the cats vaccinated with 
Leucogen were fully protected against FeLV infection. The results of the western 
blotting suggested that the level of anti-gp70 antibodies determined by this 
technique is a poor indicator of the efficacy of the vaccine. The cats vaccinated 
with the baculovirus protein did not possess anti-gp70 antibodies prior to challenge 
and yet the same final result was achieved with this vaccine as with Leucogen.
No antigenaemia was demonstrated in the one cat that did not become viraemic in 
Group 1. It is therefore possible that this cat may have been protected by the
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vaccination with Bgp70-A. However, as no markers of such protection were present 
prior to challenge this cat may have naturally recovered from the infection, the 
vaccine playing no part in the process.
The failure of both vaccines was unexpected. In particular, the failure of Leucogen 
was surprising considering previously reported vaccine trials (Marciani et al, 1991; 
Lehmann et al, 1991; Clark et al, 1991). In the natural situation, even in high risk 
multiple cat households, only a proportion of cats become persistently viraemic. In 
experimental situations it is possible to induce persistent viraemia in every exposed 
cat using immunosuppression with corticosteroids or by infecting kittens at an early 
age (Hoover et al, 1976; Rojko et al, 1979a). It is therefore possible that the dose 
of challenge virus used in this experiment was too large and that the protection 
afforded by Leucogen was unable to eliminate the virus. This would suggest that 
the protection afforded cats by Leucogen in previously reported trials could be 
overcome by high viral doses. As it is not known what viral doses cats are exposed 
to in the natural situation it therefore follows that Leucogen may not provide any 
protection in certain situations. The number of cats becoming persistently viraemic 
following an experimental challenge can be used as a guide to the dose of virus 
used. A further trial should be conducted with a larger number of cats and a dose of 
virus such that 60%-80% of the controls become persistently viraemic.
The failure of the cats vaccinated with the recombinant glycoprotein may also be 
due to an excessive challenge. It is also possible that insufficient antigen was 
present. Possible improvements in the production of the protein have been 
discussed in Chapter 4. A third explanation could be a failure of the adjuvant. Quil 
A contains a mixture of glycosides extracted from saponin which is isolated from 
bark. As such, a certain heterogeneity in composition is to be expected. Other 
adjuvants which could be considered in future trials include muramyl dipeptide 
derivatives (Byars and Allison, 1988) and ISCOMs (Morein et al, 1984; Osterhaus 
et a l, 1985; Osterhaus et al, 1989)
The second adjuvant that was included in the vaccine was aluminium hydroxide. 
Aluminium salts have been widely used in both medical and veterinary vaccines 
(Gupta et al, 1993). They are thought to be mild adjuvants which may therefore be 
inadequate for recombinant soluble protein vaccines. Recently it has been 
demonstrated that a failure of proteins to adhere to the aluminium salts may be the 
cause of this problem (Skea and Barber, 1993). To correct this deficit, antibody 
mediated adhesion of the proteins to the aluminium was attempted with 
encouraging results. It would be sensible to measure the decrease in detectable 
protein following preparation of any aluminium salt adjuvanted vaccine.
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In conclusion, this vaccine trial demonstrated that the protection afforded to cats by 
vaccination with Leucogen is, at best, only partial. Leucogen did induce antibodies 
that detected gp70 in western blotting experiments. Such antibodies did not confer 
protection against the development of viraemia. In contrast the baculovirus derived 
recombinant protein preparation did not induce anti-gp70 antibodies that were 
detectable on western blots. However, this vaccine may have prevented the 
development of viraemia in one cat, though the cat may have recovered naturally. 
Further vaccine studies should be performed with this protein. Investigations into 
the role of cytotoxic T cells in the protection of vaccinated cats are of particular 
importance. Despite the many reports of FeLV vaccines that have been produced 
over the years, there is still a need for an effective, commercially viable, FeLV 
vaccine.
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Chapter 8. General Discussion
This chapter contains a general discussion on the nature and significance of the 
studies presented in this thesis. Suggestions for future work are made in the relevant 
parts of the chapter. A selection of recent innovations that I consider may be of 
value in the study of FeLV pathogenesis and vaccination are also presented.
8.1 The Production of the Recombinant Surface Glycoproteins
This thesis describes the production, purification and analysis of recombinant FeLV 
surface glycoproteins. The proteins were produced in the baculovirus expression 
system from truncated env genes of FeLV-A and FeLV-C/Sarma and two chimeric 
FeLV-A/C chimeras produced by Rigby (1989). The recombinant proteins were 
termed Bgp70-A, Bgp70-C, Bgp70-VC and Bgp70-215, respectively. Truncated 
env genes were used so that the resulting protein would be secreted. It is known that 
retrovirus surface glycoproteins are only secreted in quantity if the transmembrane 
portion of the TM protein is deleted and the amino terminus of TM is left intact 
(Einfeld and Hunter, 1988). The identity of the putative transmembrane portion of 
the FeLV TM protein is known (Stewart et al, 1986), but the minimal requirement 
for the amino terminus sequences is not. During the course of the project the 
production of an FeLV surface glycoprotein product in the baculovirus system was 
reported (Thomsen et al, 1992). These authors expressed a full length env gene in 
Sf9 cells and found that the protein was retained within the cells.
The recombinant proteins were efficiently exported and could be detected in the 
culture fluid of infected cells. This result was consistent with those of similar 
experiments using HIV env (Wells and Compans, 1990). The production of 
secreted surface glycoprotein was useful as it simplified subsequent purification 
procedures. Thus disruption of infected insect cells by detergent to obtain 
recombinant protein (Rusche et al, 1987), which may affect the functional integrity 
of that protein, was avoided. Prior to purification, the supernatants were 
concentrated by ultrafiltration. An attempt to purify the proteins using a nickel 
nitrilotriacetic acid-agarose adsorbent (Hochuli et al, 1987) was unsuccessful. 
Immunoaffinity purification was not attempted due to the lack of a suitable 
quantities of the necessary antibody reagents. However, lentil lectin affinity 
chromatography was found to be an effective method of purifying the recombinant 
proteins. The only major contaminant in the preparations purified in this way was 
believed to be the major baculoviral envelope protein, gp64 (Volkman, 1986). An 
anti-gp64 monoclonal antibody could be used in western blot assays to examine 
this hypothesis; several such antibodies are available (Roberts and Manning, 1993).
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Having established a protocol for the production of the proteins, several large 
batches of supernatants were concentrated and purified using lentil lectin affinity 
chromatography. These stocks were used for a number of experiments which 
examined the biological properties of the proteins. The recombinant proteins were 
found to be approximately 80 kDa in size and they were not cleaved. The quantity 
of protein produced was initially believed to be low in comparison to reported 
values for other retrovirus surface glycoproteins expressed in this system (Rusche 
et al., 1987; Hu et al, 1987; Wells and Compans, 1990; Thomsen et al, 1992; Arp 
et al, 1993). However, it was suggested in Chapter 4 that the difference may be 
apparent rather than real. As the recombinant protein preparations were 
contaminated with the major baculoviral envelope protein, the exact quantity of 
recombinant protein was never determined. Further truncation of the amino 
terminus of the TM gene could be performed to define the minimal requirement for 
SU secretion. This could assist the production of SU as the shorter transcripts may 
allow the production of larger quantities of protein.
Recombinant proteins expressed in the baculovirus system are often incompletely 
glycosylated (King and Possee, 1992) and FeLV SU is no exception. 
Deglycosylation of the recombinant protein with PNGaseF demonstrated that the 
proteins were glycosylated, but not to the same extent as their native counterparts. 
The difference between the predicted deglycosylated size of the recombinant 
protein and the value observed by deglycosylation with PNGaseF was thought to be 
due to the presence of small quantities of O-linked carbohydrate entities. As 
reported by others, this difference was also observed in the native protein (Pinter 
and Honnen, 1988). Formal proof would require the use of a neuramidase prior to 
deglycosylation.
The lentil lectin affinity purified preparations were analysed by western blotting 
and ELISAs. The results of these experiments indicated that the recombinant 
proteins were immunologically similar to their native counterparts. It was also 
demonstrated that subgroup-specific monoclonal and polyclonal antibodies could 
be used to differentiate between Bgp70-C and Bgp70-A in ELISAs. The two 
chimeric proteins, Bgp70-VC and Bgp70-215, were indistinguishable from Bgp70-
A. These results suggested that the proteins could be used to investigate the nature 
of some aspects of the initial virus / host interaction.
8.2 Towards the Identification of a Neutralising Epitope for 
FeLV
It has been demonstrated that the neutralising antibodies produced by cats are, at 
least partially, subgroup-specific (Russell and Jarrett, 1978b). If the FeLV-A/C
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phenotype is mostly determined by VR 1 (Rigby et al., 1992) then it is logical to 
suggest that VR 1 may be involved in the binding of neutralising antibodies. The 
neutralisation inhibition assays described in Chapter 5 demonstrated that the 
recombinant protein Bgp70-A was able to block the action of neutralising 
antibodies. Furthermore, it was shown that Bgp70-C was unable to block the action 
of neutralising antibodies found in sera derived from cats that had been naturally 
infected with FeLV-A. However, the two FeLV-A/C chimeric proteins, Bgp70-VC 
and Bgp70-215, were also able to block the neutralising activities of these sera. 
This provided the conformation that the subgroup determining and neutralising 
antibody binding sites of FeLV are distinct (Russell and Jarrett, 1978b). The 
subgroup-determining VR 1 region appears to play little or no part in the binding of 
neutralising antibodies.
The nature of neutralising epitopes is known only for some viruses. Examples 
include the V3 loop of HIV (Skinner et al., 1988; Javaherian et al., 1989) and the 
loop of influenza virus haemagglutinin (Wiley et al., 1981). In so far as 
generalisations can be made from these examples, it would appear that neutralising 
epitopes are composed of contiguous amino acids, albeit often arranged in a 
particular conformation. Other regions of the molecule may play a peripheral role 
in binding. It may be possible therefore to identify a region or regions that are 
altered in Bgp70-C which may serve as binding sites for neutralising antibodies.
Figure 8.1 correlates data derived from two sources. The surface probability and 
hydrophilicity plots of FeLV-A SU were derived from the output of the 
PLOTSTRUCTURE program which is part of the GCG package for the VAX 
network (Devereux et al, 1984; Jameson and Wolf, 1988). These plots give an 
indication of the properties of a given segment of a protein based in the primary 
amino acid sequence. The hydrophilicity plot indicates the degree of expected 
hydrophilicity in a 6 to 10 amino acid window and can therefore be used as an 
indication that the particular sequence is located on the surface of the protein. 
Highly charged clusters of amino acids are frequently found to be exposed to the 
aqueous environment, whereas strongly hydrophobic clusters are often incarcerated 
in the centre of the protein (Jameson and Wolf, 1988). The surface probability plot 
is a similar measure derived from the side chain solvent accessibility values of the 
individual amino acids. Under the two plots is a line corresponding to the FeLV-A 
sequence. Above and below the lines are boxes which represent variable regions 
(VRs), as defined by Rigby (1989). Horizontal lines separate sequences that are 
dissimilar, diagonal lines separate sequences that are the same. When sequences are 
homologous to A they are not represented. Therefore, in variable region 5 (VR 5) 
FeLV-C/Sarma and FeLV-B/Snyder-Theilen differ from FeLV-A, but FeLV-
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B/Gamer Amstein is the same as FeLV-A.
Predictions of higher orders of structure based on the primary peptide sequence are 
frequently misleading. However, the diagram does correctly identify the 
neutralising epitope recognised by the monoclonal antibody C11D8 (Grant et al, 
1983; Nunberg et al., 1984a; Elder et al, 1987) as having a high surface 
probability. The monoclonal antibody 3-17 (Weijer et al, 1986) described 
throughout this thesis also binds to this region, though it does not interfere with the 
binding of C11D8 (N.Spibey, personal communication). This prediction is to be 
expected as several such antibodies have been produced (Weijer et al, 1986; Elder 
et al, 1987). These antibodies neutralise the virus in vitro in a subgroup 
independent fashion. As cats produce subgroup-dependent neutralising antibodies, 
it is suggested that this epitope is not recognised in the cat.
If VR 1 is not directly involved in the binding of neutralising antibodies, and yet 
the neutralising antibody binding site(s) do vary between isolates, then the diagram 
presented in Figure 8.1 may help to decide which other regions of FeLV SU are 
likely to be involved in the binding of neutralising antibodies. It is suggested that 
the neutralisation epitopes are likely to be those regions of the SU protein which 
differ between FeLV-A and FeLV-C/Sarma. It is possible, however, that changes in 
the tertiary protein structure of other regions of SU may be caused by mutations in 
FeLV-C. Notwithstanding this caveat, by comparison of the sequence data and 
predicted surface probabilities, it is possible to suggest that the most likely sites for 
neutralising epitopes are VR 4 and VR 5. They are both heterologous between 
FeLV-A and FeLV-C/Sarma. They also are hydrophilic and possess moderately 
high surface probabilities.
FeLV-B/Gardner-Amstein (FeLV-B/GA) is homologous to FeLV-A in VR 5; but, 
the ability of FeLV-A sera to recognise FeLV-B/GA appears to be unknown. 
Therefore, it is not possible to discriminate further which region may be involved. 
The production of FeLV-B/GA SU in the baculovirus expression system and 
subsequent use in the neutralisation inhibition assay could help to solve this 
problem. However, it would be simpler to obtain FeLV-B/GA and perform a 
neutralisation assay. As FeLV-B/GA differs in several other regions from FeLV-A, 
formal proof will require the generation of VR4 and VR5 chimeras.
Using site directed mutagenesis to alter the nucleotide sequence of the env gene, 
convenient restriction enzyme sites could be introduced upstream of VR 4 and also 
between VR 4 and VR5. This would allow the generation of VR 4 or VR 5 
chimeric recombinant proteins. VR 4 plus VR 5 chimeric proteins would also be 
created in the process. Such proteins could then be used in neutralisation inhibition
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assays to define further the regions that are involved in neutralising antibody 
binding. Specifically, by mutation of nucleotide residues 811 and 812 (cytidine to 
thymidine and cytidine to adenosine) (Stewart et al., 1986) an Xba 1 site can be 
introduced. Similarly, site directed mutagenesis of nucleotide residue 1019 
(cytidine to guanosine) introduces an Xho 1 site, without affecting the resulting 
amino acid sequence. These restriction enzyme sites could also be introduced into 
FeLV-C/Sarma using the same oligonucleotide primers. The introduction of the 
Xba 1 site into FeLV-B/GA could also be performed with this primer, but a slightly 
different oligonucleotide primer would preserve the guanine residue at nucleotide 
residue 813.
Although it would appear the either or both of VR4 and VR5 are part of the 
neutralising epitope the involvement of other, constant, regions cannot be 
discounted from these experiments and observations.
8.3 FeLV Cell Surface Receptors
The ability of the recombinant proteins to block FeLV infection in a subgroup 
specific manner was employed in an attempt to define cellular receptors for FeLV. 
The attempt failed. However, the experiments demonstrated that co- 
immunoprecipitation may not be the most appropriate way to identify as specific 
cell surface receptor. Recent experiments defining the receptors for two retroviruses 
used recombinant retroviruses (Albritton et al., 1989; O'Hara et al, 1990). This 
may be a more sophisticated and reliable method for performing such studies, 
though the time and financial resource commitments should not be underestimated.
On the basis of superinfection interference studies with retroviral pseudotypes, it 
has been suggested that groups of retroviruses share common receptors on human 
cells (Sommerfelt and Weiss, 1989). Gibbon ape leukaemia virus (GALV) and 
FeLV-B are members of one such group. With the discovery of the gibbon ape 
leukaemia virus receptor (GLVR1) it was possible to confirm that FeLV-B does 
indeed use the same phosphate transporter protein (Takeuchi et al., 1993). 
However, the fine binding specificities of the two viruses differ. Mutation of three 
amino acids within a critical nine amino acid region of GLVR1 induces resistance 
to FeLV-B but not GALV (Tailor et al, 1993). A similar situation has been 
demonstrated in the MuLV system (Eiden et al., 1993). These authors reported that 
subtle differences in the ecotropic murine leukaemia virus (E-MuLV) receptor 
protein could effectively block the entry of the Moloney strain of E-MuLV into a 
murine fibroblast cell line. In contrast, two other E-MuLVs, Friend MuLV and 
Rauscher MuLV, were able to infect the cells. It seems likely that such subtle 
differences account for the ability of FeLV-C, but not FeLV-A, to infect guinea pig
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cells. It has not yet been demonstrated that FeLV-B uses the same receptor on 
feline cells as on human cells. This study should be performed to assess the 
significance of the findings made with human cells. It would be useful to generate a 
recombinant FeLV-B SU in the baculovirus system and to define a method by 
which it could be used to identify GLVR1 on human cells. Success would greatly 
encourage further cell surface receptor studies using the proteins detailed in this 
thesis. Unfortunately, no other retroviruses appear to use the same receptor as 
FeLV-C on human cells (Sommerfelt and Weiss, 1989) and FeLV-A does not infect 
non-feline cells, so it is unlikely that the receptors for either subgroup will be 
identified in the same, co-incidental, manner as the FeLV-B receptor.
The specificities of retroviruses for their receptors may explain the existence of 
endogenous retroviruses. It is possible that xenotropic retroviruses, such as RD 114, 
arose from ecotropic viruses which infected the germ line of a host and 
subsequently suffered from a mutation in the relevant VCSR gene. This would 
imprison the virus, albeit in the host germ line, unable to spread horizontally, 
except in experimental studies to certain heterologous species.
With the identification of several VCSRs as common, important host cell proteins 
the current interest in VCSRs will continue. However, the original interest in 
VCSRs as targets for anti-viral therapy seems to become less relevant with each 
new VCSR that is identified. The biology of the virus should be taken into account 
before strenuous efforts are made to identify its VCSR. FeLV-A replicates in many 
of the tissues of its natural host. It is neutralised by naturally produced antibodies. 
It is suggested that, in attempting to control FeLV infection, the importance of 
identifying the VCSR is less than that of generating an effective vaccine.
8.4 FeLV Vaccination
The results presented in this thesis illustrate some of the difficulties involved in 
FeLV vaccine trials and demonstrate that a commercially available FeLV vaccine is 
of questionable efficacy. The failure of the experimental vaccine should not 
discourage the further investigation of Bgp70-A as an immunogen. Greater 
quantities of protein or more frequent administration should be used in future trials.
The aim of FeLV vaccination should be to prevent FeLV infection entirely. A cat 
that has recovered from FeLV infection usually possesses virus neutralising 
antibodies, which protect it against subsequent challenge (Jarrett et al., 1977; 
Hoover et al., 1977; deNoronha et al, 1978; Salerno et al., 1978). There are no 
other characterised markers for the immune cat. Until there are, the induction of 
prechallenge virus neutralising antibodies must be regarded as the ideal that FeLV
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vaccine researchers should strive to attain. Since the first report of an FeLV vaccine 
trial, many attempts have been made to demonstrate an effective FeLV vaccine. 
Only one experimental vaccine has been shown to consistently induce virus 
neutralising antibodies against FeLV (Osterhaus et al, 1985; Osterhaus et al, 
1989).
Unfortunately, there has been no consensus between these trials as to the challenge 
protocols used, the presentation of results, interpretation of data or the inferences 
drawn. Some investigators, in an attempt to overcome the age-related susceptibility 
of cats to FeLV, have challenged cats by intraperitoneal injection (Marciani et al, 
1991; Clark et al, 1991). Others have supplemented challenge with 
immunosuppressive therapy (Sebring et al, 1991). FeLV is not thought to normally 
enter the cat by direct inoculation (Rojko et al, 1979b) and the use of 
intraperitoneal inoculations may by-pass important mucosal immune systems. It is 
suggested that the use of intraperitoneal inoculation as a challenge protocol is less 
relevant than oronasal administration of the virus, without corticosteriod treatment 
to 12-16 week old SPF cats (Osterhaus et al, 1985; Tartaglia et al, 1993). If kittens 
of this age are used, the practice of administering immunosuppressive therapy post­
challenge (Lewis et al, 1981; Mastro et al, 1986; Haffer et al, 1987; Tizard and 
Bass, 1991; Hines et al, 1991) is unnecessary. In any case, such cats represent the 
major at-risk group and so vaccination studies should be focussed on them. In the 
natural situation young cats will probably be exposed several times to low doses of 
FeLV. A challenge system which effectively mimics this feature would be an 
improvement on conventional challenges. However, the sole experiment performed 
with repeated low dose challenge over a short period of time (Pedersen et al, 1986) 
only induced persistent viraemia in six out of seventeen controls.
An in-contact challenge system using persistently viraemic cats has been used by 
several groups with varying success (Pedersen et al, 1979). Such trials require the 
use of many cats and the effects on the controls are less predictable than in other 
challenge systems. The use of naturally infected cats from a rural environment in 
conjunction with SPF cats (Legendre et al, 1990) would be unacceptable in the 
UK. The subsequent development of respiratory diseases as well as deaths from 
feline infectious peritonitis could have been avoided by using SPF cats that had 
been experimentally infected with FeLV. The use of uninfected outbred cats as 
indicators in multicat households containing FeLV excreting cats has been reported 
by others (Pollock and Scarlett, 1990; York and York, 1991). The results of these 
trials are valid only if the indicator cats have no evidence of previous infection with 
FeLV. The presence of anti-FOCMA antibodies is thought to be a good indicator of 
such exposure (Jarrett, 1984; Pollock and Scarlett, 1990). It is suggested that
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assaying the indicator cats only for virus neutralising antibodies is insufficient 
(York and York, 1991).
There are also inconsistencies in the interpretation of the results of vaccination 
experiments. Some investigators regard transiently infected cats as being protected 
(Pedersen et al., 1986). However, if a vaccinated cat develops a transient viraemia 
following experimental infection then the vaccine has not prevented viral 
replication. At a recent FeLV vaccination conference, the report of the panel was in 
favour of regarding experimentally vaccinated cats which become transiently 
viraemic following challenge as being vaccine failures (Anonymous, 1991).
The small number of cats in most trials has precluded the use of meaningful 
measures of statistical significance. The concept of the ’preventable fraction1 (PF) 
has become popular in recent years (Pollock and Haffer, 1991; Sebring et al., 1991; 
Clark et al, 1991). This value is obtained by expressing the difference between the 
number of vaccinates and controls that become viraemic as a fraction of the number 
of viraemic controls. This means that if a low number of the controls become 
viraemic then the significance of any drop amongst the vaccinates is greatly 
magnified. In fact, the reverse is more likely to be the case. It is suggested that 
analyses using the PF should only be applied when more than 80% of the controls 
become viraemic.
The task of vaccine researchers should be to express the neutralisation epitope of 
FeLV SU in its native conformation and present it to the immune system of the cat 
in an immunogenic form. Identification of the epitope may assist this process. The 
work detailed in this thesis suggests a method by which this could be accomplished. 
Though identification of the neutralisation epitopes of a virus is not a prerequisite 
for successful vaccine manufacture, when traditional approaches have failed, or are 
considered too risky, such knowledge is invaluable in the rational design of subunit 
vaccines. In the future, research into the T cell mediated responses to FeLV may 
demonstrate other regions of FeLV SU which are of importance in preventing the 
development of persistent viraemia. Such regions will also be included in subunit 
FeLV vaccines of the future.
Subunit vaccines may not represent the optimum method of vaccinating against 
FeLV. Recently, a live SIV vaccine, attenuated by a deletion in the nef gene, has 
been shown to be effective at preventing infection (Daniel et al, 1992). A 
disadvantage of this approach is the potential for the attenuated virus to recombine 
with endogenous retroviral elements to produce a fully infectious, pathogenic 
variant. Retroviral recombination is known to be both frequent and ordered (Hu and 
Temin, 1990). Further investigation into the mechanism of retroviral recombination
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may reveal methods by which the process can be prevented. Another problem is the 
potential for transduction of cellular oncogenes by the attenuated virus, which must 
integrate into the host genome to be able to replicate. Transduction of cellular 
oncogenes is thought to be due to the formation of read-through transcripts 
resulting from inefficient viral polyadenylation signals (Swain and Coffin, 1992). 
Definition and alteration of these signals may reduce the incidence of such 
transcripts. This type of approach to vaccination, despite these potential problems, 
should not necessarily be discounted. The use of an attenuated virus as an 
inactivated virus vaccine could reduce the harm caused by, though not the risk of, 
inadequate inactivation. This approach can only be effective in virus systems, such 
as FTV and SIV, that have non-essential, potentiating genes. No such genes are 
known for FeLV. However, by creating a VR 1 mutant that could not replicate in 
cat cells, but could replicate in another species cells, such an attenuated vaccine 
could be generated. The attenuated virus could also be used for the production of an 
inactivated FeLV vaccine. Inactivated FeLV vaccines are known to be efficacious 
(Hoover et al., 1991; Tizard and Bass, 1991), however they must be shown to be 
completely inactivated (Shibley et al, 1991). An inactivated, attenuated virus 
would introduce an extra element of safety into such preparations.
Another recent development is the use of plasmid DNA to induce protective 
immunity (Tang et al, 1992; Robinson et al, 1993). The rationale underlying this 
innovation states that DNA introduced into host cells by whatever means can, 
potentially, stimulate immunity. Plasmid DNA cannot produce infectious progeny 
and so is inherently safer than live virus vectors. If sufficient cells could be 
transfected in vivo with such a plasmid containing the foreign gene then the need 
for viruses as vectors is obviated. An additional advantage is the induction of 
heterologous protection due to cytotoxic T cell activation (Ulmer et al., 1993). This 
technique may yield useful results in the FeLV system. However, a number of 
problems will need to be solved before an effective, commercially viable, DNA 
vaccine against FeLV is available. For example, developing an effective carrier, 
that is easily administered in practice, for the DNA will require much careful 
thought. Recombinant viruses, when used as vaccine vectors, are effective means of 
introducing relevant DNA into cells. Such vectors are capable of replication and 
recombination in the host and so there are concerns regarding their safety. The use 
of non-replicating viral vectors represents an improvement in the development of 
such vaccines (Tartaglia et al., 1993).
This thesis also reports the production of recombinant FIV SU in the baculovirus 
system. Recently, the expression of the entire FIV env gene and subsequent use of 
the product for immunodiagnosis has been reported (Verschoor et al, 1993). The
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use of the recombinant surface glycoprotein of FIV, BgplOO, as a FIV vaccine 
deserves further study. A better yield of recombinant protein may be obtained by 
including the sequences coding for the amino terminus of the FTV TM protein in the 
transfer vector. Progress towards the identification of a linear neutralising epitope 
within FIV SU has recently been reported (Lombardi et al., 1993).
8.5 Conclusion
It is suggested that the principal use of Bgp70's will be in the analysis of the 
immune response to FeLV infection. Future studies involving manipulation of the 
envelope gene and subsequent expression in the baculovirus system should be able 
to rapidly produce recombinant chimeric proteins, free of infectious virus, for the 
localisation of the major neutralising epitopes of FeLV. Also, the products of 
envelope genes which do not produce helper-independent progeny could be 
examined in isolation from their helper virus.
A secondary use of the Bgp70s may be to identify, albeit probably indirectly, FeLV 
cell surface receptors. The production of anti-receptor antibodies may be facilitated 
by using cell membrane proteins, purified by Bgp70 affinity chromatography, as 
immunogens. The recombinant proteins might also be used to screen cDNA 
libraries containing cat genomic DNA.
This thesis demonstrates the potential for the further analysis of several aspects of 
retrovirus pathogenesis using recombinant surface glycoproteins. The effect of 
manipulations of the env gene can be rapidly assessed using this system. In 
particular, site directed mutagenesis of other regions of the env gene could be 
undertaken in an attempt to further define the neutralising epitopes of FeLV. The 
identification of these epitopes will greatly assist the design of an truly effective 
FeLV vaccine.
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